

# AR-V7 and Resistance to Enzalutamide and Abiraterone

New England Journal of Medicine

371, 1028-1038

DOI: [10.1056/nejmoa1315815](https://doi.org/10.1056/nejmoa1315815)

Citation Report

#	ARTICLE	IF	CITATIONS
1	ecancermedalscience. Ecancermedalscience, 2014, 8, 472.	0.6	2
2	Resistance to Androgen-Pathway Drugs in Prostate Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 2233-2234.	13.9	24
5	Emerging role of circulating tumor cells in cancer management. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2014, 35, 237-238.	0.1	5
6	GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 18261-18266.	3.3	114
8	The Evolution of Prostate Cancer Therapy: Targeting the Androgen Receptor. <i>Frontiers in Oncology</i> , 2014, 4, 295.	1.3	28
9	Overcoming tumor heterogeneity in the molecular diagnosis of urological cancers. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 1023-1031.	1.5	2
10	Precision medicine for prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1305-1315.	1.1	11
11	Real-world experience with abiraterone. <i>Lancet Oncology</i> , The, 2014, 15, 1188-1190.	5.1	0
12	Targeting the Androgen Receptor in Prostate Cancer – A Resilient Foe. <i>New England Journal of Medicine</i> , 2014, 371, 1067-1069.	13.9	38
13	Predicting resistance – AR-V7 is a potential biomarker. <i>Nature Reviews Urology</i> , 2014, 11, 606-606.	1.9	2
14	Bevacizumab beyond progression in breast cancer. <i>Lancet Oncology</i> , The, 2014, 15, 1190-1191.	5.1	2
15	Novel anti-androgen receptor signaling agents: Understanding the mechanisms of resistance. <i>Asian Journal of Urology</i> , 2014, 1, 30-39.	0.5	1
16	Reply to Kevin Lu's Letter to the Editor re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. <i>Eur Urol</i> 2015;68:147-53. <i>European Urology</i> , 2015, 68, e132-e133.	0.9	1
18	The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7. <i>Scientific Reports</i> , 2015, 5, 13426.	1.6	55
19	Present, Emerging and Possible Future Biomarkers in Castration Resistant Prostate Cancer (CRPC). <i>Current Cancer Drug Targets</i> , 2015, 15, 243-255.	0.8	15
20	Androgen receptor profiling predicts prostate cancer outcome. <i>EMBO Molecular Medicine</i> , 2015, 7, 1450-1464.	3.3	67
21	Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy. <i>Experimental Hematology and Oncology</i> , 2015, 5, 15.	2.0	10
22	Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization. <i>Journal of Circulating Biomarkers</i> , 2015, 4, 3.	0.8	103

#	ARTICLE	IF	CITATIONS
23	Detection and Characterization of Circulating Tumour Cells from Frozen Peripheral Blood Mononuclear Cells. <i>Journal of Circulating Biomarkers</i> , 2015, 4, 4.	0.8	9
24	Navigating Treatment of Metastatic Castration- Resistant Prostate Cancer: Nursing Perspectives. <i>Clinical Journal of Oncology Nursing</i> , 2015, 19, 723-732.	0.3	6
25	Prognostic Significance and Functional Role of CEP57 in Prostate Cancer. <i>Translational Oncology</i> , 2015, 8, 487-496.	1.7	9
27	Circulating tumor cells in prostate cancer: Does (nuclear) size matter?. <i>Cancer</i> , 2015, 121, 3190-3192.	2.0	0
28	Metformin represses androgenâ€dependent and androgenâ€independent prostate cancers by targeting androgen receptor. <i>Prostate</i> , 2015, 75, 1187-1196.	1.2	51
31	Targeting molecular resistance in castration-resistant prostate cancer. <i>BMC Medicine</i> , 2015, 13, 206.	2.3	52
32	Persistent androgen receptor addiction in castration-resistant prostate cancer. <i>Journal of Hematology and Oncology</i> , 2015, 8, 128.	6.9	59
33	Liquid biopsy. <i>Current Opinion in Oncology</i> , 2015, 27, 560-567.	1.1	35
34	Methylselenocysteine preventing castration-resistant progression of prostate cancer. <i>Prostate</i> , 2015, 75, 1001-1008.	1.2	6
35	Rapid changes in circulating tumor cells following anti-angiogenic therapy. <i>Convergent Science Physical Oncology</i> , 2015, 1, 015002.	2.6	4
36	Androgen receptor targeting drugs in castrationâ€resistant prostate cancer and mechanisms of resistance. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 582-589.	2.3	57
37	New generations of targeted therapies fighting the resistance in solid tumors. <i>Current Opinion in Oncology</i> , 2015, 27, 243-249.	1.1	4
38	Optimal sequencing of docetaxel and abiraterone in men with metastatic castrationâ€resistant prostate cancer. <i>Prostate</i> , 2015, 75, 1814-1820.	1.2	14
39	Sequences and combinations of multifaceted therapy in advanced prostate cancer. <i>Current Opinion in Oncology</i> , 2015, 27, 201-208.	1.1	7
40	Clinical Research in Metastatic Prostate Cancer: A Focus on Impact and Value. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 17-21.	1.8	4
41	Radium-223 dichloride: illustrating the benefits of a multidisciplinary approach for patients with metastatic castration-resistant prostate cancer. <i>Journal of Multidisciplinary Healthcare</i> , 2015, 8, 279.	1.1	15
42	Insights into Chemoresistance of Prostate Cancer. <i>International Journal of Biological Sciences</i> , 2015, 11, 1160-1170.	2.6	73
43	Biomarkers for determination prostate cancer: implication for diagnosis and prognosis. <i>Neoplasma</i> , 2015, 62, 683-691.	0.7	18

#	ARTICLE	IF	CITATIONS
44	TNF signaling mediates an enzalutamide-induced metastatic phenotype of prostate cancer and microenvironment cell co-cultures. <i>Oncotarget</i> , 2015, 6, 25726-25740.	0.8	13
45	Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in&nbsp;castration-resistant prostate cancer. <i>OncoTargets and Therapy</i> , 2015, 8, 1915.	1.0	4
46	Enzalutamide for the treatment of metastatic castration-resistant prostate cancer. <i>Drug Design, Development and Therapy</i> , 2015, 9, 3325.	2.0	44
47	Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer. <i>Oncotarget</i> , 2015, 6, 41825-41836.	0.8	29
48	From bench to bedside: bipolar androgen therapy in a pilot clinical study. <i>Asian Journal of Andrology</i> , 2015, 17, 767.	0.8	3
49	When Prostate Cancer Circulates in the Bloodstream. <i>Diagnostics</i> , 2015, 5, 428-474.	1.3	13
50	Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy. <i>Korean Journal of Urology</i> , 2015, 56, 580.	1.2	1
51	Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model. <i>PLoS ONE</i> , 2015, 10, e0131232.	1.1	8
52	Characterization of RNA from Exosomes and Other Extracellular Vesicles Isolated by a Novel Spin Column-Based Method. <i>PLoS ONE</i> , 2015, 10, e0136133.	1.1	300
53	Mutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide Therapy. <i>PLoS ONE</i> , 2015, 10, e0145176.	1.1	26
54	Characterization of DNA Methylation in Circulating Tumor Cells. <i>Genes</i> , 2015, 6, 1053-1075.	1.0	46
55	Diagnostic associations of gene expression signatures in prostate cancer tissue. <i>Current Opinion in Urology</i> , 2015, 25, 65-70.	0.9	38
56	Integrative molecular profiling of routine clinical prostate cancer specimens. <i>Annals of Oncology</i> , 2015, 26, 1110-1118.	0.6	34
57	Integrative Clinical Genomics of Advanced Prostate Cancer. <i>Cell</i> , 2015, 161, 1215-1228.	13.5	2,660
58	Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2015, 1, 582.	3.4	552
59	MYC Drives <i>Pten/Trp53</i> -Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2. <i>Cancer Discovery</i> , 2015, 5, 636-651.	7.7	65
60	Targeting the androgen receptor in prostate and breast cancer: several new agents in development. <i>Endocrine-Related Cancer</i> , 2015, 22, R87-R106.	1.6	76
62	AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies. <i>Investigational New Drugs</i> , 2015, 33, 679-690.	1.2	43

#	ARTICLE	IF	CITATIONS
63	Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer. <i>Advances in Cancer Research</i> , 2015, 127, 123-158.	1.9	34
64	Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC). <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015, 153, 105-113.	1.2	41
65	The development of abiraterone acetate for castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 289-294.	0.8	14
66	RNA biomarkers to facilitate the identification of aggressive prostate cancer. <i>Molecular Aspects of Medicine</i> , 2015, 45, 37-46.	2.7	16
67	Sequencing of agents in castration-resistant prostate cancer. <i>Lancet Oncology</i> , The, 2015, 16, e279-e292.	5.1	141
68	Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 649-666.	1.1	6
69	Present and future of personalized medicine in adult genitourinary tumors. <i>Future Oncology</i> , 2015, 11, 1381-1388.	1.1	10
70	Treatment of metastatic prostate cancer. <i>Trends in Urology &amp; Men's Health</i> , 2015, 6, 7-12.	0.2	5
71	Advanced neuroendocrine prostate tumors regress to stemness. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14406-14407.	3.3	12
72	Systemic Medical Treatment in Men with Metastatic Castration-Resistant Prostate Cancer: Recommendations for Daily Routine. <i>Oncology Research and Treatment</i> , 2015, 38, 654-668.	0.8	4
73	Advances in the Treatment of Metastatic Prostate Cancer. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1719-1733.	1.4	21
74	Metastasis: Resistance fighters. <i>Nature</i> , 2015, 528, S128-S129.	13.7	5
75	Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 701-711.	12.8	1,044
76	AR splice variant dimerization—clinical implications. <i>Nature Reviews Urology</i> , 2015, 12, 431-433.	1.9	10
77	The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells. <i>Journal of Biological Chemistry</i> , 2015, 290, 20865-20879.	1.6	28
78	Role of STAT3 pathway in genitourinary tumors. <i>Future Science OA</i> , 2015, 1, FSO15.	0.9	58
79	Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 473-485.	0.9	24
80	Beyond immune checkpoint blockade: New approaches to targeting host-tumor interactions in prostate cancer: Report from the 2014 Coffey-Holden prostate cancer Academy meeting. <i>Prostate</i> , 2015, 75, 337-347.	1.2	12

#	ARTICLE	IF	CITATIONS
81	Abiraterone's efficacy confirmed; time to aim higher. <i>Lancet Oncology</i> , The, 2015, 16, 119-121.	5.1	1
82	The year chemotherapy finally gets some respect!. <i>Nature Reviews Urology</i> , 2015, 12, 71-72.	1.9	4
83	Are androgen receptor variants a substitute for the full-length receptor?. <i>Nature Reviews Urology</i> , 2015, 12, 137-144.	1.9	102
84	Leading causes of castration-resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 425-432.	1.1	0
85	Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. <i>EMBO Reports</i> , 2015, 16, 280-296.	2.0	200
86	Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. <i>Prostate Cancer and Prostatic Diseases</i> , 2015, 18, 122-127.	2.0	78
87	Enzalutamide: A new prostate cancer targeted therapy against the androgen receptor. <i>Cancer Treatment Reviews</i> , 2015, 41, 247-253.	3.4	4
88	Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 392-399.	0.9	36
89	Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 152-160.	5.1	1,100
90	Enzalutamide for treatment of CRPC: Rationale for sequencing and potential clinical biomarker for resistance. <i>Cancer Biology and Therapy</i> , 2015, 16, 201-203.	1.5	0
91	Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key?. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 143-145.	1.1	22
92	Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents. <i>British Journal of Cancer</i> , 2015, 112, 1166-1174.	2.9	59
93	Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 749-754.	0.9	11
94	Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 310-321.	0.8	27
95	Translational Implications of Tumor Heterogeneity. <i>Clinical Cancer Research</i> , 2015, 21, 1258-1266.	3.2	424
96	Sequencing current therapies in the treatment of metastatic prostate cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 332-340.	3.4	38
97	Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes. <i>Cancer Research</i> , 2015, 75, 3663-3671.	0.4	158
98	Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 439-445.	1.1	6

#	ARTICLE	IF	CITATIONS
99	Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. <i>Journal of Urology</i> , 2015, 194, 1537-1547.	0.2	179
100	Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer. <i>European Journal of Cancer</i> , 2015, 51, 1946-1952.	1.3	63
101	Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer: A Clinical Commentary. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 407-409.	0.9	4
102	Molecular landscape of prostate cancer: Implications for current clinical trials. <i>Cancer Treatment Reviews</i> , 2015, 41, 761-766.	3.4	53
103	Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms. <i>Endocrine-Related Cancer</i> , 2015, 22, 805-818.	1.6	24
104	New advances in genitourinary cancer: evidence gathered in 2014. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 443-464.	2.7	4
105	Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells. <i>European Urology</i> , 2015, 68, 939-945.	0.9	223
106	Chemotherapy in Prostate Cancer. <i>Current Oncology Reports</i> , 2015, 17, 44.	1.8	25
107	Has the Time Arrived for Biomarker-Directed Therapy in Castration-Resistant Prostate Cancer?. <i>JAMA Oncology</i> , 2015, 1, 577.	3.4	5
108	Determinants of Receptor- and Tissue-Specific Actions in Androgen Signaling. <i>Endocrine Reviews</i> , 2015, 36, 357-384.	8.9	93
110	Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. <i>Annals of Oncology</i> , 2015, 26, 2044-2056.	0.6	89
111	Androgen pathway resistance in prostate cancer and therapeutic implications. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1521-1537.	0.9	50
112	Using circulating tumor cells to inform on prostate cancer biology and clinical utility. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2015, 52, 191-210.	2.7	20
113	Prognostic and Predictive Biomarkers for Castration Resistant Prostate Cancer. <i>Biomarkers in Disease</i> , 2015, , 447-480.	0.0	1
114	Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer?. <i>European Urology</i> , 2015, 68, 802-804.	0.9	0
115	Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid Tumors. <i>Neoplasia</i> , 2015, 17, 385-399.	2.3	212
116	Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1037-1048.	1.1	5
117	Anticancer Drugs That Modulate Hormone Action. , 2015, , 81-131.		4

#	ARTICLE	IF	CITATIONS
118	The androgen receptor for the radiation oncologist. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2015, 19, 220-227.	0.6	4
119	Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 308-318.	2.0	17
120	Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. <i>Annals of Oncology</i> , 2015, 26, 1859-1865.	0.6	160
122	A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variants. <i>Carcinogenesis</i> , 2015, 36, 757-768.	1.3	47
123	Genomic Predictors of Outcome in Prostate Cancer. <i>European Urology</i> , 2015, 68, 1033-1044.	0.9	166
124	Enzalutamide: Development from bench to bedside. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 280-288.	0.8	36
125	Moving the goal posts in prostate cancer trials. <i>Lancet Oncology</i> , The, 2015, 16, 247-249.	5.1	3
126	Targeting the adaptive molecular landscape of castration-resistant prostate cancer. <i>EMBO Molecular Medicine</i> , 2015, 7, 878-894.	3.3	110
127	Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2315-2324.	3.2	407
128	Enzalutamide: A Review of Its Use in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. <i>Drugs and Aging</i> , 2015, 32, 243-249.	1.3	5
129	Circulating Tumor Cells as Potential Biomarkers in Bladder Cancer. <i>Journal of Urology</i> , 2015, 194, 790-798.	0.2	85
130	Prioritizing precision medicine for prostate cancer. <i>Annals of Oncology</i> , 2015, 26, 1041-1042.	0.6	11
131	Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. <i>British Journal of Cancer</i> , 2015, 112, 1717-1724.	2.9	112
132	Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. <i>Cancer Research</i> , 2015, 75, 1413-1422.	0.4	207
133	Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 967-975.	1.5	16
134	Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study. <i>Science Translational Medicine</i> , 2015, 7, 269ra2.	5.8	205
135	<sup>223</sup> Ra and other bone-targeting radiopharmaceuticals—the translation of radiation biology into clinical practice. <i>British Journal of Radiology</i> , 2015, 88, 20140752.	1.0	17
136	Next-generation sequencing technology in prostate cancer diagnosis, prognosis, and personalized treatment. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 267.e1-267.e13.	0.8	33



#	ARTICLE	IF	CITATIONS
137	Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2015, 18, 161-166.	2.0	9
140	Gene interference strategies as a new tool for the treatment of prostate cancer. <i>Endocrine</i> , 2015, 49, 588-605.	1.1	27
141	The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2015, 51, 2562-2569.	1.3	59
142	Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility. <i>Clinical Cancer Research</i> , 2015, 21, 4786-4800.	3.2	310
143	Plasma <i>AR</i> and abiraterone-resistant prostate cancer. <i>Science Translational Medicine</i> , 2015, 7, 312re10.	5.8	366
144	Liquid biopsy: Clues on prostate cancer drug resistance. <i>Science Translational Medicine</i> , 2015, 7, 312fs45.	5.8	17
145	The Molecular Taxonomy of Primary Prostate Cancer. <i>Cell</i> , 2015, 163, 1011-1025.	13.5	2,435
146	Molecular genetic mechanisms of drug resistance in prostate cancer. <i>Molecular Biology</i> , 2015, 49, 638-648.	0.4	9
147	Determination of synthetic lethal interactions to provide therapeutic direction to end aggressive prostate cancer. <i>Future Oncology</i> , 2015, 11, 1451-1454.	1.1	1
148	Regulation of tumor cell plasticity by the androgen receptor in prostate cancer. <i>Endocrine-Related Cancer</i> , 2015, 22, R165-R182.	1.6	52
149	Sequencing AR-targeted agents might be ineffective in mCRPC. <i>Nature Reviews Urology</i> , 2015, 12, 246-247.	1.9	1
150	A Stepping Stone Toward Personalized Oncology: Genomic Analysis of Circulating Tumor Cells to Guide Management of Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2015, 68, 946-948.	0.9	2
151	Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy. <i>Therapeutic Advances in Urology</i> , 2015, 7, 194-202.	0.9	29
152	Targeting Transcription Factors in Cancer. <i>Trends in Cancer</i> , 2015, 1, 53-65.	3.8	247
153	U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. <i>Oncologist</i> , 2015, 20, 960-966.	1.9	32
154	Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. <i>Nucleic Acids Research</i> , 2015, 43, 5880-5897.	6.5	136
155	Androgen receptor splice variant V7 (AR-V7) in circulating tumor cells: a coming of age for AR splice variants?. <i>Annals of Oncology</i> , 2015, 26, 1805-1807.	0.6	11
156	Therapy escape mechanisms in the malignant prostate. <i>Seminars in Cancer Biology</i> , 2015, 35, 133-144.	4.3	59

#	ARTICLE	IF	CITATIONS
157	Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer. <i>Urology</i> , 2015, 86, 852-861.	0.5	42
158	ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1007-1017.	1.1	63
159	Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 498-506.	2.0	54
160	Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression. <i>Molecular Cancer Research</i> , 2015, 13, 1591-1601.	1.5	41
161	Drug therapies for metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2015, 11, 2395-2403.	1.1	1
162	Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced nonâ€œcastration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 337.e1-337.e6.	0.8	4
163	YAP1 and AR interactions contribute to the switch from androgen-dependent to castration-resistant growth in prostate cancer. <i>Nature Communications</i> , 2015, 6, 8126.	5.8	90
164	Emerging agents for the therapy of advanced prostate cancer. <i>Future Oncology</i> , 2015, 11, 2775-2787.	1.1	10
165	RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. <i>Science</i> , 2015, 349, 1351-1356.	6.0	614
166	Pri sORF peptides induce selective proteasome-mediated protein processing. <i>Science</i> , 2015, 349, 1356-1358.	6.0	90
167	Cancer therapies that are gone with the Wnt. <i>Science</i> , 2015, 349, 1283-1284.	6.0	4
168	Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation. <i>Future Oncology</i> , 2015, 11, 3083-3090.	1.1	8
169	Epithelialâ€œmesenchymal transition in prostatic disease. <i>Future Oncology</i> , 2015, 11, 3197-3206.	1.1	26
170	Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer. <i>Current Treatment Options in Oncology</i> , 2015, 16, 57.	1.3	30
171	The many ways to make a luminal cell and a prostate cancer cell. <i>Endocrine-Related Cancer</i> , 2015, 22, T187-T197.	1.6	23
172	Understanding the Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at the Molecular Level. <i>European Urology</i> , 2015, 67, 470-479.	0.9	225
173	Quo vadis: Advanced prostate cancerâ€œclinical care and clinical research in the era of multiple androgen receptorâ€œdirected therapies. <i>Cancer</i> , 2015, 121, 361-371.	2.0	9
174	Clinical implications of therapeutic sequence in mCRPC. <i>Nature Reviews Urology</i> , 2015, 12, 13-14.	1.9	0

#	ARTICLE	IF	CITATIONS
175	The Role of Prostate-Specific Antigen (PSA) and PSA Kinetics in the Management of Advanced Prostate Cancer. , 2016, , .		0
176	Circulating Nucleic Acids as Prostate Cancer Biomarkers. , 2016, , 557-585.		0
177	Splice variants of androgen receptor and prostate cancer. <i>Oncology Reviews</i> , 2016, 10, 297.	0.8	6
178	Clinical Application of Circulating Tumour Cells in Prostate Cancer: From Bench to Bedside and Back. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1580.	1.8	12
180	Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer. <i>International Journal of Biological Sciences</i> , 2016, 12, 409-426.	2.6	32
181	Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 131-141.	1.8	19
182	Radium-223 and concomitant therapies: prospects and prudence. <i>Translational Andrology and Urology</i> , 2016, 5, 968-970.	0.6	2
183	Analysis of tumor template from multiple compartments in a blood sample provides complementary access to peripheral tumor biomarkers. <i>Oncotarget</i> , 2016, 7, 26724-26738.	0.8	16
184	Novel Research on Fusion Genes and Next-Generation Sequencing. , 2016, , 29-39.		0
185	Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. <i>F1000Research</i> , 2015, 4, 1521.	0.8	1,848
186	Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10s1, CMO.Ss34534.	0.6	14
187	Galeterone for the treatment of advanced prostate cancer: the evidence to date. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 2289-2297.	2.0	43
188	Next generation biomarkers in prostate cancer. <i>Frontiers in Bioscience - Landmark</i> , 2016, 21, 328-342.	3.0	14
189	RNA-Seq following PCR-based sorting reveals rare cell transcriptional signatures. <i>BMC Genomics</i> , 2016, 17, 361.	1.2	21
190	Contemporary agents in the management of metastatic castration-resistant prostate cancer. <i>Canadian Urological Association Journal</i> , 2016, 10, 414.	0.3	24
191	Clinical Applications of NanoVelcro Rare-Cell Assays for Detection and Characterization of Circulating Tumor Cells. <i>Theranostics</i> , 2016, 6, 1425-1439.	4.6	56
192	Cancer-Associated Fibroblasts Modify the Response of Prostate Cancer Cells to Androgen and Anti-Androgens in Three-Dimensional Spheroid Culture. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1458.	1.8	53
193	Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer. <i>Frontiers in Oncology</i> , 2016, 6, 24.	1.3	20

#	ARTICLE	IF	CITATIONS
194	Positron Emission Tomography Imaging of Tumor Cell Metabolism and Application to Therapy Response Monitoring. <i>Frontiers in Oncology</i> , 2016, 6, 44.	1.3	49
195	Droplet Digital PCR Based Androgen Receptor Variant 7 (AR-V7) Detection from Prostate Cancer Patient Blood Biopsies. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1264.	1.8	50
196	Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1097.	1.8	22
197	Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2008.	1.8	18
198	Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further. <i>Journal of UOEH</i> , 2016, 38, 129-138.	0.3	17
199	Novel twists in hormone-mediated carcinogenesis. <i>Endocrine-Related Cancer</i> , 2016, 23, E9-E12.	1.6	0
200	Role of BioResponse 3,3'-Diindolylmethane in the Treatment of Human Prostate Cancer: Clinical Experience. <i>Medical Principles and Practice</i> , 2016, 25, 11-17.	1.1	17
201	Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer. <i>PLoS ONE</i> , 2016, 11, e0152861.	1.1	30
202	The Use of a New CellCollector to Isolate Circulating Tumor Cells from the Blood of Patients with Different Stages of Prostate Cancer and Clinical Outcomes - A Proof-of-Concept Study. <i>PLoS ONE</i> , 2016, 11, e0158354.	1.1	49
203	Molecular Biomarkers in Bladder Cancer: Novel Potential Indicators of Prognosis and Treatment Outcomes. <i>Disease Markers</i> , 2016, 2016, 1-5.	0.6	60
204	Detection of AR-V7 mRNA in whole blood may not predict the effectiveness of novel endocrine drugs for castration-resistant prostate cancer. <i>Research and Reports in Urology</i> , 2016, 8, 21.	0.6	33
205	A sting in the tail: the N-terminal domain of the androgen receptor as a drug target. <i>Asian Journal of Andrology</i> , 2016, 18, 687.	0.8	33
206	Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer. <i>Oncotarget</i> , 2016, 7, 32210-32220.	0.8	87
207	Editorial Comment to Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic. <i>International Journal of Urology</i> , 2016, 23, 666-666.	0.5	2
208	Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer. <i>Medicine (United States)</i> , 2016, 95, e2754.	0.4	2
209	Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2016, 23, 279-290.	1.2	16
210	Editorial Comment to Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations. <i>International Journal of Urology</i> , 2016, 23, 653-653.	0.5	3
211	Biomarkers for prostate cancer: present challenges and future opportunities. <i>Future Science OA</i> , 2016, 2, FSO72.	0.9	35

#	ARTICLE	IF	CITATIONS
212	Androgen receptor-related diseases: what do we know?. <i>Andrology</i> , 2016, 4, 366-381.	1.9	70
213	Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer. <i>Prostate</i> , 2016, 76, 325-334.	1.2	25
214	Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation. <i>Prostate</i> , 2016, 76, 445-455.	1.2	20
215	Liquid biopsies: advancing cancer research through drops of blood. <i>Internal Medicine Journal</i> , 2016, 46, 376-377.	0.5	3
216	Molecular characterization of a novel androgen receptor transgene responsive to MicroRNA mediated post-transcriptional control exerted via 3'-untranslated region. <i>Prostate</i> , 2016, 76, 834-844.	1.2	4
217	The marine triterpene glycoside frondoside <i>A</i> exhibits activity <i>in vitro</i> and <i>in vivo</i> in prostate cancer. <i>International Journal of Cancer</i> , 2016, 138, 2450-2465.	2.3	60
218	Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer. <i>International Journal of Cancer</i> , 2016, 139, 1632-1647.	2.3	9
219	Abiraterone for the Treatment of mCRPC. , 2016, , 125-155.		0
220	Androgen Control in Prostate Cancer. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 2224-2234.	1.2	17
221	NF- $\kappa$ B and androgen receptor variant expression correlate with human BPH progression. <i>Prostate</i> , 2016, 76, 491-511.	1.2	49
222	<i>AXIN2</i> expression predicts prostate cancer recurrence and regulates invasion and tumor growth. <i>Prostate</i> , 2016, 76, 597-608.	1.2	14
223	Hormone Receptors in Breast Cancer. , 2016, , 45-58.		0
225	Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. <i>Nature Communications</i> , 2016, 7, 13668.	5.8	134
226	The Natural History and Outcome Predictors of Metastatic Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2016, 2, 480-487.	1.6	15
227	A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone. <i>Oncologist</i> , 2016, 21, 1296-1297e.	1.9	23
228	Single-Cell Analysis of Circulating Tumor Cells as a Window into Tumor Heterogeneity. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2016, 81, 269-274.	2.0	40
229	Synthesis of IR-780 dye-conjugated abiraterone for prostate cancer imaging and therapy. <i>International Journal of Oncology</i> , 2016, 49, 1911-1920.	1.4	14
230	The promise of circulating tumor cells for precision cancer therapy. <i>Biomarkers in Medicine</i> , 2016, 10, 1269-1285.	0.6	11

#	ARTICLE	IF	CITATIONS
231	Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients. <i>Scientific Reports</i> , 2016, 6, 39736.	1.6	96
232	Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer. <i>Nature Communications</i> , 2016, 7, 13122.	5.8	76
233	Assession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells. <i>Clinical Chemistry</i> , 2016, 62, 1504-1515.	1.5	130
234	Genitourinary tumours in the targeted therapies era. <i>Anti-Cancer Drugs</i> , 2016, 27, 917-943.	0.7	8
235	Androgen Receptor and Beyond, Targeting Androgen Signaling in Castration-Resistant Prostate Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2016, 22, 326-329.	1.0	11
236	Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundationâ€™Supported West Coast Prostate Cancer Dream Team. <i>European Urology Focus</i> , 2016, 2, 469-471.	1.6	12
237	Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2016, 2, 488-498.	1.6	38
238	Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor. <i>European Urology Focus</i> , 2016, 2, 499-505.	1.6	55
239	Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis. <i>BMC Research Notes</i> , 2016, 9, 471.	0.6	16
240	Genomic Aberrations Drive Clonal Evolution of Neuroendocrine Tumors. <i>Trends in Endocrinology and Metabolism</i> , 2016, 27, 242-244.	3.1	1
241	Building a hit list for the fight against metastatic castration resistant prostate cancer. <i>Cancer Biology and Therapy</i> , 2016, 17, 231-232.	1.5	4
242	Targeting persistent androgen receptor signaling in castration-resistant prostate cancer. <i>Medical Oncology</i> , 2016, 33, 44.	1.2	40
243	A Potential Predictive Role for Prostate-specific Antigen Changes at 4 Weeks?. <i>European Urology</i> , 2016, 70, 732-733.	0.9	0
244	Clonal origin and spread of metastatic prostate cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, R207-R217.	1.6	32
245	ASC-J9â€™ suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L. <i>Cancer Letters</i> , 2016, 379, 154-160.	3.2	44
246	Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3Î²-imidazole Carbamate. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 708-713.	1.3	19
247	Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 231-241.	2.0	142
248	Inherited Variants in SULT1E1 and Response to Abiraterone Acetate by Men with Metastatic Castration Refractory Prostate Cancer. <i>Journal of Urology</i> , 2016, 196, 1112-1116.	0.2	12

#	ARTICLE	IF	CITATIONS
249	The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 681-696.	1.1	7
250	Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells. <i>Cancer Research</i> , 2016, 76, 2731-2742.	0.4	79
251	Continuous versus intermittent docetaxel for metastatic castration resistant prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 102, 118-124.	2.0	7
252	Making Predictive Biomarkers Readily Available. <i>European Urology</i> , 2016, 70, 609-610.	0.9	0
253	Genetic traits for hematogeneous tumor cell dissemination in cancer patients. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 41-48.	2.7	20
254	Charting Recent Progress and Challenges in Metastatic Castration-resistant Prostate Cancer: Is There an Optimal Treatment Sequence?. <i>European Urology Focus</i> , 2016, 2, 426-440.	1.6	3
255	Potential of circulating tumor cells as blood-based biomarkers in cancer liquid biopsy. <i>Pharmacogenomics</i> , 2016, 17, 183-186.	0.6	24
256	Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 255-263.	1.6	10
258	Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4623-4633.	3.2	153
259	Improving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer. <i>Trends in Pharmacological Sciences</i> , 2016, 37, 451-462.	4.0	45
260	Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4466-4477.	3.2	87
261	Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors. <i>European Journal of Cancer</i> , 2016, 61, 44-51.	1.3	40
262	Novel Therapies in Castration-Resistant Prostate Cancer. , 2016, , 259-269.		0
263	Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016, 70, 599-608.	0.9	111
264	Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 1598.	3.4	290
265	The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 381-388.	0.9	12
266	The use of circulating tumor cells in guiding treatment decisions for patients with metastatic castration-resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2016, 46, 42-50.	3.4	24
267	Defining actionable mutations for oncology therapeutic development. <i>Nature Reviews Cancer</i> , 2016, 16, 319-329.	12.8	95



#	ARTICLE	IF	CITATIONS
269	Analytic Validation of RNA <i>In Situ</i> Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4651-4663.	3.2	34
270	Pathophysiology of Castration-Resistant Prostate Cancer. , 2016, , 5-22.		1
271	Progress in the mechanism and drug development of castration-resistant prostate cancer. <i>Future Medicinal Chemistry</i> , 2016, 8, 765-788.	1.1	7
272	Treatment of Metastatic Prostate Cancer in Older Adults. <i>Current Oncology Reports</i> , 2016, 18, 63.	1.8	6
273	Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 349-357.	2.0	36
274	Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 398-405.	2.0	12
275	Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer. <i>Asian Journal of Urology</i> , 2016, 3, 185-194.	0.5	20
277	Blood Based Detection of Androgen Receptor Splice Variants in Patients with Advanced Prostate Cancer. <i>Journal of Urology</i> , 2016, 196, 1606-1607.	0.2	5
279	Role of androgen receptor splice variants in prostate cancer metastasis. <i>Asian Journal of Urology</i> , 2016, 3, 177-184.	0.5	30
280	Non-invasive actionable biomarkers for metastatic prostate cancer. <i>Asian Journal of Urology</i> , 2016, 3, 170-176.	0.5	8
281	Applications of circulating tumor cells for prostate cancer. <i>Asian Journal of Urology</i> , 2016, 3, 254-259.	0.5	4
282	Biomarkers for Metastatic Castration-resistant Prostate Cancer (mCRPC): Yes or No? Predictive and Response Biomarkers Towards Precision Medicine in mCRPC. <i>European Urology Focus</i> , 2016, 2, 465-466.	1.6	1
283	The Use of Biomarkers to Manage Men with Metastatic Prostate Cancer: One Day, But Not Yet. <i>European Urology Focus</i> , 2016, 2, 467-468.	1.6	0
284	Androgen receptor variation affects prostate cancer progression and drug resistance. <i>Pharmacological Research</i> , 2016, 114, 152-162.	3.1	37
285	Toward Precision Medicine: A Cancer Molecular Subtyping Nano-Strategy for RNA Biomarkers in Tumor and Urine. <i>Small</i> , 2016, 12, 6233-6242.	5.2	52
286	Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1113-1120.	1.5	5
287	The Cohesive Metastasis Phenotype in Human Prostate Cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1866, 221-231.	3.3	28
288	Achieving resistance specificity in prostate cancer. <i>Chemico-Biological Interactions</i> , 2016, 260, 243-247.	1.7	4



#	ARTICLE	IF	CITATIONS
289	Castration-resistant prostate cancer: Why should urologists care?. <i>Urologia Colombiana</i> , 2016, 25, 198-200.	0.0	0
290	Epigenetic modulators as therapeutic targets in prostate cancer. <i>Clinical Epigenetics</i> , 2016, 8, 98.	1.8	68
291	Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study. <i>International Journal of Clinical Oncology</i> , 2016, 21, 1155-1161.	1.0	21
292	Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 7431-7444.	2.9	33
293	A Whole Blood Assay for AR-V7 and AR <sup>v567es</sup> in Patients with Prostate Cancer. <i>Journal of Urology</i> , 2016, 196, 1758-1763.	0.2	46
294	Multivalent Peptoid Conjugates Which Overcome Enzalutamide Resistance in Prostate Cancer Cells. <i>Cancer Research</i> , 2016, 76, 5124-5132.	0.4	19
295	Enzalutamide Reduces the Bone Mass in the Axial But Not the Appendicular Skeleton in Male Mice. <i>Endocrinology</i> , 2016, 157, 969-977.	1.4	20
296	Role of BET proteins in castration-resistant prostate cancer. <i>Drug Discovery Today: Technologies</i> , 2016, 19, 29-38.	4.0	15
297	Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic. <i>International Journal of Urology</i> , 2016, 23, 654-665.	0.5	65
298	Radium-223 in prostate cancer: emitting the right signals. <i>Lancet Oncology, The</i> , 2016, 17, 1186-1187.	5.1	1
299	Utility of novel androgen receptor therapies in the real world: A nuanced approach. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 340-347.	0.8	2
300	Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2016, 117, 215-225.	1.3	94
301	Novel agents for castration-resistant prostate cancer: Early experience and beyond. <i>International Journal of Urology</i> , 2016, 23, 114-121.	0.5	31
302	Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model. <i>Prostate</i> , 2016, 76, 1536-1545.	1.2	15
303	Uncontrolled diabetes predicts poor response to novel antiandrogens. <i>Endocrine-Related Cancer</i> , 2016, 23, 691-698.	1.6	14
304	Raising the Bar for Therapeutic Trials in Advanced Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2958-2960.	0.8	2
305	Biennial report on genitourinary cancers. <i>European Journal of Cancer</i> , 2016, 66, 125-130.	1.3	1
306	HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. <i>Lancet Oncology, The</i> , 2016, 17, 1435-1444.	5.1	107

#	ARTICLE	IF	CITATIONS
307	Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain. <i>Journal of Biological Chemistry</i> , 2016, 291, 22231-22243.	1.6	47
308	Androgen receptor signaling pathways as a target for breast cancer treatment. <i>Endocrine-Related Cancer</i> , 2016, 23, R485-R498.	1.6	78
309	Risk stratification of prostate cancer 2016. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, S54-S59.	0.6	6
310	Highlights in Genitourinary (Prostate) Cancer. <i>JAMA Oncology</i> , 2016, 2, 1257.	3.4	0
311	Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 106, 14-24.	2.0	10
312	<scp>Androgen receptor</scp> splice variant 7 in castration-resistant prostate cancer: Clinical considerations. <i>International Journal of Urology</i> , 2016, 23, 646-653.	0.5	25
313	How Many Lymph Nodes Are Enough? Assessing the Adequacy of Lymph Node Yield for Papillary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3434-3439.	0.8	85
314	Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. <i>Endocrine-Related Cancer</i> , 2016, 23, T179-T197.	1.6	132
315	Label-Free Detection of AR-V7 mRNA in Prostate Cancer Using Yb<sub>2</sub>Ti<sub>2</sub>O<sub>7</sub>-Based Electrolyte-Insulator-Semiconductor Biosensors. <i>Journal of the Electrochemical Society</i> , 2016, 163, B710-B717.	1.3	10
316	Regulation of aerobic glycolysis by long non-coding RNAs in cancer. <i>Biochemical and Biophysical Research Communications</i> , 2016, 479, 28-32.	1.0	19
317	Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer. <i>Oncologist</i> , 2016, 21, 1427-1435.	1.9	60
318	Inherited HSD3B1 polymorphisms and hormonal therapy resistance. <i>Lancet Oncology</i> , The, 2016, 17, 1347-1349.	5.1	1
319	Liquid biopsy: ready to guide therapy in advanced prostate cancer?. <i>BJU International</i> , 2016, 118, 855-863.	1.3	61
320	Personalized treatment of prostate cancer: better knowledge of the patient, the disease and the medicine. <i>Future Oncology</i> , 2016, 12, 2359-2361.	1.1	4
321	Drug discovery in advanced prostate cancer: translating biology into therapy. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 699-718.	21.5	111
322	Is it time for everolimus-based combination in castration-resistant prostate cancer?. <i>Future Oncology</i> , 2016, 12, 1849-1852.	1.1	1
323	Bipolar Androgen Therapy for Men With Androgen Ablation Na <sup>+</sup> -ve Prostate Cancer: Results From the Phase II BATMAN Study. <i>Prostate</i> , 2016, 76, 1218-1226.	1.2	63
324	Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide. <i>Prostate</i> , 2016, 76, 1484-1490.	1.2	29

#	ARTICLE	IF	CITATIONS
325	Emerging data on androgen receptor splice variants in prostate cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, T199-T210.	1.6	47
326	Complementing genomics and transcriptomics: Phosphoproteomics illuminates systems biology in prostate cancer. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1246075.	0.3	4
327	Recent advances in the biology of human circulating tumour cells and metastasis. <i>ESMO Open</i> , 2016, 1, e000078.	2.0	38
328	Sequencing Treatment for Castration-Resistant Prostate Cancer. <i>Current Treatment Options in Oncology</i> , 2016, 17, 64.	1.3	29
329	Cell-free and circulating tumor cell-based biomarkers in men with metastatic prostate cancer: Tools for real-time precision medicine?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 490-501.	0.8	11
330	Tumor-derived circulating endothelial cell clusters in colorectal cancer. <i>Science Translational Medicine</i> , 2016, 8, 345ra89.	5.8	92
331	Predictive medicine: Using circulating biomarkers to guide management of patients with genitourinary cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 488-489.	0.8	0
332	Regulation of PCGEM1 by p54/nrb in prostate cancer. <i>Scientific Reports</i> , 2016, 6, 34529.	1.6	40
333	Advances in the management of castration resistant prostate cancer. <i>BMJ, The</i> , 2016, 355, i4405.	3.0	71
334	AR aberrations and resistance to abiraterone or enzalutamide. <i>Nature Reviews Urology</i> , 2016, 13, 697-698.	1.9	33
335	Circulating Biomarkers in Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 369-379.	0.2	25
336	The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements. <i>Biomarkers in Cancer</i> , 2016, 8s2, BIC.S31802.	3.6	70
337	Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10s1, CMO.S34535.	0.6	34
338	Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients. <i>Cancer Journal (Sudbury, Mass )</i> , 2016, 22, 315-320.	1.0	54
339	The Role of Next-Generation Sequencing in Castration-Resistant Prostate Cancer Treatment. <i>Cancer Journal (Sudbury, Mass )</i> , 2016, 22, 357-361.	1.0	9
340	The evolving role of chemotherapy in prostate cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2016, 10, 262-265.	0.5	1
341	NF- $\kappa$ B and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance. <i>Prostate</i> , 2016, 76, 1004-1018.	1.2	22
342	Radioligand Therapy With <sup>177</sup> Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2016, 41, 522-528.	0.7	153

#	ARTICLE	IF	CITATIONS
343	Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 1441.	3.4	535
344	Brèves de l'AERIO. <i>Oncologie</i> , 2016, 18, 76-80.	0.2	1
345	AR-V7 Protein in Circulating Tumor Cells—The Decider for Therapy?. <i>JAMA Oncology</i> , 2016, 2, 1450.	3.4	2
346	RNA splicing factors as oncoproteins and tumour suppressors. <i>Nature Reviews Cancer</i> , 2016, 16, 413-430.	12.8	549
347	PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 7124-7129.	3.3	627
348	Androgen Receptor Signaling in Castration Resistant Prostate Cancer. , 2016, , 23-34.		0
349	Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 469-476.	0.8	8
350	Targeting constitutively active androgen receptor splice variants in castration resistant prostate cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 903-906.	1.5	7
351	Circulating Tumor Cell Count as an Indicator of Treatment Benefit in Advanced Prostate Cancer. <i>European Urology</i> , 2016, 70, 993-994.	0.9	4
352	A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2016, 48, 25-33.	3.4	22
353	Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4280-4282.	3.2	20
354	Translational and clinical implications of the genetic landscape of prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 597-610.	12.5	63
355	Improving Survival for Metastatic Castrate-resistant Prostate Cancer: Will Combination Therapy Help Us To Move Forward?. <i>European Urology</i> , 2016, 70, 722-723.	0.9	4
356	Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer. <i>Cell Reports</i> , 2016, 15, 599-610.	2.9	101
357	Implementation of the AUA Castration Resistant Prostate Cancer Guidelines into Practice: Establishing a Multidisciplinary Clinic. <i>Urology Practice</i> , 2016, 3, 203-209.	0.2	4
358	CYP17 inhibitors in prostate cancer: latest evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 267-275.	1.4	45
359	Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer. <i>BMC Cancer</i> , 2016, 16, 214.	1.1	35
360	The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1702-1712.	1.9	73

#	ARTICLE	IF	CITATIONS
361	Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2016, 76, 125-139.	1.2	17
362	Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies. <i>Prostate</i> , 2016, 76, 512-520.	1.2	19
363	An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. <i>Cancer Letters</i> , 2016, 380, 144-152.	3.2	26
364	Phase III trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2016, 118, 590-597.	1.3	23
365	The biology of circulating tumor cells. <i>Oncogene</i> , 2016, 35, 1216-1224.	2.6	421
366	Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 235.e11-235.e16.	0.8	62
367	Hormonal therapy for cancer. <i>Medicine</i> , 2016, 44, 30-33.	0.2	21
368	A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer. <i>International Journal of Clinical Oncology</i> , 2016, 21, 773-782.	1.0	10
369	BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer. <i>Molecular Cancer Research</i> , 2016, 14, 324-331.	1.5	137
370	Role of corticosteroids in prostate cancer progression: implications for treatment strategy in metastatic castration-resistant patients. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 729-738.	1.8	7
371	Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer. <i>Cancer Research</i> , 2016, 76, 912-926.	0.4	71
372	Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy. <i>Nature Reviews Urology</i> , 2016, 13, 47-60.	1.9	65
373	Translating RNA sequencing into clinical diagnostics: opportunities and challenges. <i>Nature Reviews Genetics</i> , 2016, 17, 257-271.	7.7	558
374	Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 697-707.	1.9	13
375	Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion?. <i>Cancer Biology and Therapy</i> , 2016, 17, 467-469.	1.5	5
376	The Clinical Utility of Circulating Tumor Cells: Analysis of These Cells May Have the Potential to Assist with Screening and Diagnosing Cancer. <i>IEEE Pulse</i> , 2016, 7, 27-29.	0.1	0
377	Multifaceted and personalized therapy of advanced prostate cancer. <i>Current Opinion in Oncology</i> , 2016, 28, 222-231.	1.1	5
378	A single-center experience with abiraterone as treatment for metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 291.e1-291.e7.	0.8	10

#	ARTICLE	IF	CITATIONS
379	The implications of ageing and life expectancy in prostate cancer treatment. <i>Nature Reviews Urology</i> , 2016, 13, 289-295.	1.9	7
380	ROR- $\beta$ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. <i>Nature Medicine</i> , 2016, 22, 488-496.	15.2	155
381	CTCs for Biomarker and Companion Diagnostic Development. <i>Current Cancer Research</i> , 2016, , 293-313.	0.2	0
382	Perspectives on Clinical Applications of CTCs. <i>Current Cancer Research</i> , 2016, , 315-323.	0.2	1
383	The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance. <i>Cellular Signalling</i> , 2016, 28, 348-356.	1.7	43
384	The evolving role of enzalutamide on the treatment of prostate cancer. <i>Future Oncology</i> , 2016, 12, 607-616.	1.1	7
385	Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw005.	3.0	56
386	Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted Agents. <i>Drugs</i> , 2016, 76, 421-430.	4.9	4
387	An integrated microfluidic chip for immunomagnetic detection and isolation of rare prostate cancer cells from blood. <i>Biomedical Microdevices</i> , 2016, 18, 22.	1.4	23
388	Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. <i>Nature Medicine</i> , 2016, 22, 298-305.	15.2	1,193
389	Gene expression profiling and DNA methylation analyses of CTCs. <i>Molecular Oncology</i> , 2016, 10, 431-442.	2.1	45
390	Isolation and analysis of discreet human prostate cellular populations. <i>Differentiation</i> , 2016, 91, 139-151.	1.0	16
391	Intermittent Androgen Deprivation in Prostate Cancer: Are We Ready to Quit?. <i>Journal of Clinical Oncology</i> , 2016, 34, 211-214.	0.8	6
392	Austrian recommendations on Targeted Hormone Therapy for metastatic, castration-resistant prostate cancer. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 156-163.	1.0	3
393	Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial. <i>European Journal of Cancer</i> , 2016, 56, 93-100.	1.3	62
394	Circulating Tumor Cells. <i>Current Cancer Research</i> , 2016, , .	0.2	6
396	Diving Into Cabazitaxel's Mode of Action: More Than a Taxane for the Treatment of Castration-Resistant Prostate Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 265-270.	0.9	18
397	Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. <i>Cancer Discovery</i> , 2016, 6, 479-491.	7.7	1,087

#	ARTICLE	IF	CITATIONS
398	The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 72-78.	2.0	20
399	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. <i>Journal of Clinical Oncology</i> , 2016, 34, 1402-1418.	0.8	1,089
400	Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer. <i>Current Urology Reports</i> , 2016, 17, 29.	1.0	22
401	The molecular and cellular origin of human prostate cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 1238-1260.	1.9	92
402	New insights into the androgen biotransformation in prostate cancer: A regulatory network among androgen, androgen receptors and UGTs. <i>Pharmacological Research</i> , 2016, 106, 114-122.	3.1	12
403	Using CTCs for pharmacogenomic analysis. <i>Pharmacological Research</i> , 2016, 106, 92-100.	3.1	4
404	Transcripts of circulating tumor cells detected by a breast cancer-specific platform correlate with clinical stage in bladder cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1013-1020.	1.2	20
405	Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1353-1363.	1.9	15
406	CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (fAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy. <i>Hormones and Cancer</i> , 2016, 7, 196-210.	4.9	20
407	Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 356-367.	0.8	19
408	Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1356-1363.	3.2	71
409	Opportunities and challenges in combination gene cancer therapy. <i>Advanced Drug Delivery Reviews</i> , 2016, 98, 35-40.	6.6	64
410	Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer. <i>Hormones and Cancer</i> , 2016, 7, 84-103.	4.9	47
411	Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer. <i>Current Oncology Reports</i> , 2016, 18, 3.	1.8	22
412	Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2744-2754.	3.2	52
413	AR-V7 and prostate cancer: The watershed for treatment selection?. <i>Cancer Treatment Reviews</i> , 2016, 43, 27-35.	3.4	49
414	Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv371.	3.0	37
415	Prospects for the future of prostate cancer vaccines. <i>Expert Review of Vaccines</i> , 2016, 15, 271-274.	2.0	5



#	ARTICLE	IF	CITATIONS
416	Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials. <i>Annals of Oncology</i> , 2016, 27, 699-705.	0.6	35
417	Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2016, 69, 563-573.	0.9	101
418	Androgen receptor aberrations in the era of abiraterone and enzalutamide. <i>World Journal of Urology</i> , 2016, 34, 297-303.	1.2	21
419	Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, 35-45.	1.6	49
421	Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. <i>Oncogene</i> , 2016, 35, 2413-2427.	2.6	426
422	Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 348-355.	0.8	30
423	Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies. <i>European Urology</i> , 2016, 69, 186-190.	0.9	18
424	Prostate cancer. <i>Lancet, The</i> , 2016, 387, 70-82.	6.3	801
425	Unravelling the transcriptomic landscape of the major phase II UDP-glucuronosyltransferase drug metabolizing pathway using targeted RNA sequencing. <i>Pharmacogenomics Journal</i> , 2016, 16, 60-70.	0.9	31
426	Lessons from tissue compartment-specific analysis of androgen receptor alterations in prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 166, 28-37.	1.2	12
427	Circulating biomarkers in cancer care: What possible use?. <i>Practical Laboratory Medicine</i> , 2017, 7, 45-48.	0.6	2
428	Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. <i>European Urology</i> , 2017, 71, 656-664.	0.9	67
429	Treatment landscape of metastatic prostate cancer: the role of radium-223. <i>Acta Clinica Belgica</i> , 2017, 72, 19-23.	0.5	1
430	Chromogranin A and neuron-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy. <i>BJU International</i> , 2017, 119, 30-37.	1.3	42
431	Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison. <i>Prostate</i> , 2017, 77, 639-646.	1.2	23
432	Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns. <i>European Urology</i> , 2017, 72, 192-200.	0.9	106
433	Recent Advances in Clinical Research that Impact the Office Management of Prostate Cancer. <i>Urology Practice</i> , 2017, 4, 308-314.	0.2	0
434	Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer. <i>Asian Journal of Urology</i> , 2017, 4, 37-43.	0.5	39



#	ARTICLE	IF	CITATIONS
435	Prognostic Value of Automated Bone Scan Index in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide or Abiraterone Acetate. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 472-478.	0.9	13
436	Strategies to design clinical studies to identify predictive biomarkers in cancer research. <i>Cancer Treatment Reviews</i> , 2017, 53, 79-97.	3.4	80
437	Management of Prostate Cancer. , 2017, , .		5
438	6BIO Enhances Oligonucleotide Activity in Cells: A Potential Combinatorial Anti-androgen Receptor Therapy in Prostate Cancer Cells. <i>Molecular Therapy</i> , 2017, 25, 79-91.	3.7	25
439	Chromogranin A and neuroneâ€specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castrationâ€resistant prostate cancer. <i>BJU International</i> , 2017, 120, 226-232.	1.3	27
440	Circulating Tumor Cells: Fluid Surrogates of Solid Tumors. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2017, 12, 419-447.	9.6	82
441	CYP27A1 Loss Dysregulates Cholesterol Homeostasis in Prostate Cancer. <i>Cancer Research</i> , 2017, 77, 1662-1673.	0.4	83
442	Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants. <i>Prostate</i> , 2017, 77, 584-596.	1.2	30
443	Re: The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. <i>European Urology</i> , 2017, 71, 834-835.	0.9	1
444	High levels of the AR-V7 Splice Variant and Co-Amplification of the Golgi Protein Coding<i>YIPF6</i>in<i>AR</i>Amplified Prostate Cancer Bone Metastases. <i>Prostate</i> , 2017, 77, 625-638.	1.2	27
445	Endostatin inhibits androgenâ€independent prostate cancer growth by suppressing nuclear receptorâ€mediated oxidative stress. <i>FASEB Journal</i> , 2017, 31, 1608-1619.	0.2	11
446	Biomarkers for Prostate Cancer. , 2017, , 77-96.		0
447	Prostate Cancer Metastasis. , 2017, , 33-59.		2
448	Practical Polling for Prostate Cancer: AR-V7â€based Treatment Selection. <i>European Urology</i> , 2017, 71, 883-885.	0.9	2
449	Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?. <i>European Journal of Surgical Oncology</i> , 2017, 43, 949-962.	0.5	38
450	Androgen Receptor Splice Variants Are Not Substrates of Nonsenseâ€Mediated Decay. <i>Prostate</i> , 2017, 77, 829-837.	1.2	2
451	Investigating Genomic Aberrations of the Androgen Receptor: Moving Closer to More Precise Prostate Cancer Care?. <i>European Urology</i> , 2017, 72, 201-204.	0.9	2
452	Mechanisms of Therapeutic Resistance in Prostate Cancer. <i>Current Oncology Reports</i> , 2017, 19, 13.	1.8	103

#	ARTICLE	IF	CITATIONS
453	Patient-derived xenografts as in vivo models for research in urological malignancies. <i>Nature Reviews Urology</i> , 2017, 14, 267-283.	1.9	65
454	Integrating phosphoproteomics into the clinical management of prostate cancer. <i>Clinical and Translational Medicine</i> , 2017, 6, 9.	1.7	6
455	Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer. <i>Scientific Reports</i> , 2017, 7, 40957.	1.6	30
456	Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD). <i>Prostate</i> , 2017, 77, 812-821.	1.2	7
457	CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC. <i>Molecular Cancer Research</i> , 2017, 15, 660-669.	1.5	22
458	1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3082-3093.	2.9	44
459	Piecing the puzzle together: Docetaxel cycles and current considerations in the treatment of metastatic castration-resistant prostate cancer. <i>Cancer Biology and Therapy</i> , 2017, 18, 203-204.	1.5	1
460	Molecular mechanisms of therapy resistance in solid tumors: chasing "moving" targets. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 155-164.	1.4	12
461	CCN3-EZH2-AR feedback loop: new targets for enzalutamide and castration resistant prostate cancer. <i>Journal of Cell Communication and Signaling</i> , 2017, 11, 89-91.	1.8	9
462	Navigating the evolving therapeutic landscape in advanced prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, S1-S13.	0.8	53
463	Circulating tumor cells: clinical validity and utility. <i>International Journal of Clinical Oncology</i> , 2017, 22, 421-430.	1.0	170
464	Determinants of bone specific metastasis in prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 112, 59-66.	2.0	18
465	Catch and Release: rare cell analysis from a functionalised medical wire. <i>Scientific Reports</i> , 2017, 7, 43424.	1.6	17
466	Circulating tumor cells capture disease evolution in advanced prostate cancer. <i>Journal of Translational Medicine</i> , 2017, 15, 44.	1.8	27
467	Novel AR-V7 detection in whole blood samples in patients with prostate cancer: not as simple as it seems. <i>World Journal of Urology</i> , 2017, 35, 1625-1627.	1.2	7
468	IAP Antagonists Enhance Apoptotic Response to Enzalutamide in Castration-Resistant Prostate Cancer Cells via Autocrine TNF Signaling. <i>Prostate</i> , 2017, 77, 866-877.	1.2	14
469	LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics. <i>Prostate</i> , 2017, 77, 654-671.	1.2	219
470	Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy. <i>Oncology Letters</i> , 2017, 13, 22-28.	0.8	15

#	ARTICLE	IF	CITATIONS
471	Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer. <i>European Urology</i> , 2017, 72, 34-42.	0.9	179
472	Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel?. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 502-508.	0.9	8
473	Liquid Biopsies, What We Do Not Know (Yet). <i>Cancer Cell</i> , 2017, 31, 172-179.	7.7	395
475	Glycogen synthase kinase-3 inhibitors suppress the AR-mediated transcription and selectively inhibit cell growth in AR-positive prostate cancer cells. <i>Prostate</i> , 2017, 77, 955-961.	1.2	4
477	Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1680-1692.	1.9	44
478	Cellular determinants and microenvironmental regulation of prostate cancer metastasis. <i>Seminars in Cancer Biology</i> , 2017, 44, 83-97.	4.3	54
479	A simple HPLC-UV method for quantification of enzalutamide and its active metabolite N-desmethyl enzalutamide in patients with metastatic castration-resistant prostate cancer. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1058, 102-107.	1.2	12
480	Amino-terminal enhancer of split gene <i>AES</i> encodes a tumor and metastasis suppressor of prostate cancer. <i>Cancer Science</i> , 2017, 108, 744-752.	1.7	15
482	Development and Clinical Utility of a Blood-Based Test Service for the Rapid Identification of Actionable Mutations in Non-Small Cell Lung Carcinoma. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 404-416.	1.2	31
483	Characterization of rodent constitutively active estrogen receptor $\beta$ variants and their constitutive transactivation mechanisms. <i>General and Comparative Endocrinology</i> , 2017, 248, 16-26.	0.8	9
484	Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2017, 57, 16-27.	3.4	156
485	Darolutamide (ODM-201) for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 945-952.	0.9	52
486	Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1521-1530.	1.9	52
487	Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. <i>Annals of Oncology</i> , 2017, 28, 1508-1516.	0.6	213
488	Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance. <i>Clinical Cancer Research</i> , 2017, 23, 4704-4715.	3.2	117
489	Current approaches for avoiding the limitations of circulating tumor cells detection methods—implications for diagnosis and treatment of patients with solid tumors. <i>Translational Research</i> , 2017, 185, 58-84.e15.	2.2	124
490	Label-free isolation of prostate circulating tumor cells using Vortex microfluidic technology. <i>Npj Precision Oncology</i> , 2017, 1, 15.	2.3	72
491	Characterization of single circulating tumor cells. <i>FEBS Letters</i> , 2017, 591, 2241-2250.	1.3	48

#	ARTICLE	IF	CITATIONS
492	Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: The Kyoto-Baltimore collaboration. <i>International Journal of Urology</i> , 2017, 24, 441-448.	0.5	49
493	Liquid biopsies and plasma DNA: paving the way for personalized medicine in metastatic castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2017, 28, 1408-1409.	0.6	3
494	Acquiring evidence for precision prostate cancer care. <i>Annals of Oncology</i> , 2017, 28, 916-917.	0.6	1
495	Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells. <i>Endocrinology</i> , 2017, 158, 2255-2268.	1.4	22
496	Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. <i>Cancer Discovery</i> , 2017, 7, 1006-1017.	7.7	341
497	Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 463-471.	0.9	12
498	Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide. <i>Annals of Oncology</i> , 2017, 28, 2264-2271.	0.6	71
499	The Y-located proto-oncogene TSPY exacerbates and its X-homologue TSPX inhibits transactivation functions of androgen receptor and its constitutively active variants. <i>Human Molecular Genetics</i> , 2017, 26, 901-912.	1.4	22
500	Aberrant TGF- $\beta$ 2 Signaling Drives Castration-Resistant Prostate Cancer in a Male Mouse Model of Prostate Tumorigenesis. <i>Endocrinology</i> , 2017, 158, 1612-1622.	1.4	26
501	<sup>177</sup> Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1663-1670.	3.3	145
502	Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet. <i>Targeted Oncology</i> , 2017, 12, 401-412.	1.7	6
503	High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 733-741.e1.	0.9	16
504	Genomic Tests Should be Used to Help Guide Treatment of Prostate Cancer. <i>Journal of Urology</i> , 2017, 198, 265-266.	0.2	0
505	Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. <i>European Journal of Cancer</i> , 2017, 81, 228-236.	1.3	76
507	Potential and Challenges of Liquid Biopsies. , 2017, , 233-261.		0
508	Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells. <i>Oncology Reports</i> , 2017, 37, 3651-3659.	1.2	4
509	Characterization of a novel p110 $\beta$ -specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells. <i>Prostate</i> , 2017, 77, 1187-1198.	1.2	17
510	Materials and microfluidics: enabling the efficient isolation and analysis of circulating tumour cells. <i>Chemical Society Reviews</i> , 2017, 46, 4245-4280.	18.7	139

#	ARTICLE	IF	CITATIONS
511	Drugging the 'undruggable' cancer targets. <i>Nature Reviews Cancer</i> , 2017, 17, 502-508.	12.8	620
512	Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines. <i>International Journal of Urology</i> , 2017, 24, 566-572.	0.5	22
513	AR-v7 liquid biopsy for treatment stratification in prostate cancer. <i>Current Opinion in Urology</i> , 2017, 27, 500-509.	0.9	5
514	CLDN8, an androgen-regulated gene, promotes prostate cancer cell proliferation and migration. <i>Cancer Science</i> , 2017, 108, 1386-1393.	1.7	32
515	Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer. <i>Endocrinology</i> , 2017, 158, 1533-1542.	1.4	58
516	Pathology and molecular updates in tumors of the prostate: towards a personalized approach. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 781-789.	1.5	9
517	Androgen receptor and miR-206 regulation in prostate cancer. <i>Transcription</i> , 2017, 8, 313-327.	1.7	15
518	Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 <sup>®</sup> to Suppress Enzalutamide-resistant Prostate Cancer Progression. <i>European Urology</i> , 2017, 72, 835-844.	0.9	103
519	Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 319-333.	1.4	18
520	Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge. , 2017, 179, 111-126.		57
521	Downregulation of androgen receptors by NaAsO <sub>2</sub> via inhibition of AKT- $\kappa$ B and HSP90 in castration resistant prostate cancer. <i>Prostate</i> , 2017, 77, 1128-1136.	1.2	7
523	Flow Cytometric Methods for Circulating Tumor Cell Isolation and Molecular Analysis. <i>Advances in Experimental Medicine and Biology</i> , 2017, 994, 105-118.	0.8	4
524	Circulating Tumor Cells as Cancer Biomarkers in the Clinic. <i>Advances in Experimental Medicine and Biology</i> , 2017, 994, 1-41.	0.8	20
525	Strategies for Isolation and Molecular Profiling of Circulating Tumor Cells. <i>Advances in Experimental Medicine and Biology</i> , 2017, 994, 43-66.	0.8	5
527	A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients. <i>Clinical and Translational Oncology</i> , 2017, 19, 1350-1357.	1.2	6
528	ACK1/TNK2 Regulates Histone H4 Tyr88-phosphorylation and AR Gene Expression in Castration-Resistant Prostate Cancer. <i>Cancer Cell</i> , 2017, 31, 790-803.e8.	7.7	88
530	Investigation of Androgen Receptor Signaling Pathways with Epigenetic Machinery in Prostate Cancer. , 2017, , 205-222.		1
531	Clinical Applications of Circulating Tumor Cells in Pharmacotherapy: Challenges and Perspectives. <i>Molecular Pharmacology</i> , 2017, 92, 232-239.	1.0	15

#	ARTICLE	IF	CITATIONS
532	Androgen Receptor in Health and Disease. , 2017, , 21-73.		2
533	RNA splicing and splicing regulator changes in prostate cancer pathology. Human Genetics, 2017, 136, 1143-1154.	1.8	52
534	Association of Tissue Abiraterone Levels and <i>SLCO</i> Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer. Clinical Cancer Research, 2017, 23, 4592-4601.	3.2	31
535	Emerging concepts in liquid biopsies. BMC Medicine, 2017, 15, 75.	2.3	211
536	Androgen Signaling in Prostate Cancer. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a030452.	2.9	278
537	Exosomes and Exosomal MicroRNAs in Prostate Cancer Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 98, 982-995.	0.4	56
538	Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice. International Journal of Urology, 2017, 24, 352-360.	0.5	32
540	Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncology, 2017, 3, e170231.	3.4	9
541	Resistance to Hormonal Therapy in Prostate Cancer. Handbook of Experimental Pharmacology, 2017, 249, 181-194.	0.9	7
542	Circulating Tumour Cells in Primary Disease: The Seed for Metastasis. Cancer Drug Discovery and Development, 2017, , 15-40.	0.2	0
543	Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7). Cancer Letters, 2017, 398, 62-69.	3.2	34
544	ELF5-Mediated AR Activation Regulates Prostate Cancer Progression. Scientific Reports, 2017, 7, 42759.	1.6	11
545	Genomic tests to guide prostate cancer management following diagnosis. Expert Review of Molecular Diagnostics, 2017, 17, 367-377.	1.5	11
546	Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer. Prostate, 2017, 77, 849-858.	1.2	28
547	Management of metastatic castration-resistant prostate cancer: A focus on radium-223. Critical Reviews in Oncology/Hematology, 2017, 113, 43-51.	2.0	28
548	Androgen Receptor Function and Androgen Receptor-targeted Therapies in Breast Cancer. JAMA Oncology, 2017, 3, 1266.	3.4	166
549	The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II). Urology, 2017, 104, 150-159.	0.5	29
550	Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer. Cancer Letters, 2017, 397, 133-143.	3.2	33

#	ARTICLE	IF	CITATIONS
551	Recent advances in genitourinary tumors: A review focused on biology and systemic treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 171-190.	2.0	22
552	Targeting NF-kappa B Signaling by Artesunate Restores Sensitivity of Castrate-Resistant Prostate Cancer Cells to Antiandrogens. <i>Neoplasia</i> , 2017, 19, 333-345.	2.3	62
553	Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 115-125.	1.2	41
554	Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 115-123.	1.6	8
555	Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients. <i>European Journal of Cancer</i> , 2017, 72, 54-61.	1.3	54
556	Extranuclear partners of androgen receptor: at the crossroads of proliferation, migration, and neurogenesis. <i>FASEB Journal</i> , 2017, 31, 1289-1300.	0.2	40
557	Classifying circulating tumor cells to monitor cancer progression. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 153-165.	1.5	9
558	Does Enzalutamide Really Reduce the Risk of Progression Compared With Bicalutamide in Patients With Castration-Resistant Prostate Cancer?. <i>Journal of Clinical Oncology</i> , 2017, 35, 122-122.	0.8	1
559	The RNA helicase DDX39B and its paralog DDX39A regulate androgen receptor splice variant AR-V7 generation. <i>Biochemical and Biophysical Research Communications</i> , 2017, 483, 271-276.	1.0	54
560	Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. <i>Annals of Oncology</i> , 2017, 28, 468-477.	0.6	62
561	Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 167-178.	1.6	14
562	Characterization of an Abiraterone Ultrasensitive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts. <i>Clinical Cancer Research</i> , 2017, 23, 2301-2312.	3.2	20
563	Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2017, 71, 874-882.	0.9	150
564	Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed?. <i>Urologic Clinics of North America</i> , 2017, 44, 611-621.	0.8	46
565	Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy. <i>Oral Oncology</i> , 2017, 74, 40-48.	0.8	74
566	Prostate Cancer: An Update on Molecular Pathology with Clinical Implications. <i>European Urology Supplements</i> , 2017, 16, 253-271.	0.1	2
567	Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2017, 77, 6282-6298.	0.4	62
569	Androgen receptor in estrogen receptor positive breast cancer: Beyond expression. <i>Cancer Treatment Reviews</i> , 2017, 61, 15-22.	3.4	43



#	ARTICLE	IF	CITATIONS
570	BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1391-1397.	1.9	26
571	Clinical relevance of androgen receptor alterations in prostate cancer. <i>Endocrine Connections</i> , 2017, 6, R146-R161.	0.8	87
572	A conduit to metastasis: circulating tumor cell biology. <i>Genes and Development</i> , 2017, 31, 1827-1840.	2.7	330
573	Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer. <i>Oncology Reports</i> , 2017, 38, 2774-2786.	1.2	30
574	Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells. <i>Cancer Immunology Research</i> , 2017, 5, 1074-1085.	1.6	22
575	Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF- $\beta$ 1/STAT3 axis-regulated EMT. <i>Cell Death and Disease</i> , 2017, 8, e3007-e3007.	2.7	84
576	Unravelling biology and shifting paradigms in cancer with single-cell sequencing. <i>Nature Reviews Cancer</i> , 2017, 17, 557-569.	12.8	280
577	Circulating Tumor Cells: Markers and Methodologies for Enrichment and Detection. <i>Methods in Molecular Biology</i> , 2017, 1634, 283-303.	0.4	38
578	AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide. <i>European Urology</i> , 2017, 72, 828-834.	0.9	86
579	Androgen-deprivation therapy with enzalutamide enhances prostate cancer metastasis via decreasing the EPHB6 suppressor expression. <i>Cancer Letters</i> , 2017, 408, 155-163.	3.2	26
580	Castration-naïve metastatic prostate cancer: reshaping old paradigms. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 879-881.	1.1	3
581	Dysregulation of spliceosome gene expression in advanced prostate cancer by RNA-binding protein PSF. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10461-10466.	3.3	93
582	Tissue-based biomarkers in prostate cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 249-260.	0.4	20
583	Biological and Molecular Characterization of Circulating Tumor Cells: A Creative Strategy for Precision Medicine?. <i>Advances in Clinical Chemistry</i> , 2017, 82, 71-103.	1.8	3
584	Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition. <i>Clinical Cancer Research</i> , 2017, 23, 6923-6933.	3.2	30
585	Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer. <i>Prostate</i> , 2017, 77, 1416-1423.	1.2	22
586	Treatment sequence in castration-resistant prostate cancer: A retrospective study in the new anti-androgen era. <i>Molecular and Clinical Oncology</i> , 2017, 7, 601-603.	0.4	3
587	Low TIM3 expression indicates poor prognosis of metastatic prostate cancer and acts as an independent predictor of castration resistant status. <i>Scientific Reports</i> , 2017, 7, 8869.	1.6	40



#	ARTICLE	IF	CITATIONS
588	Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer. <i>International Journal of Cancer</i> , 2017, 141, 2121-2130.	2.3	25
589	Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 565-573.	1.4	58
590	Quercetin Targets hnRNP A1 to Overcome Enzalutamide Resistance in Prostate Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2770-2779.	1.9	81
591	Recent advances in circulating tumor cells and cell-free DNA in metastatic prostate cancer: a review. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 939-949.	1.1	6
592	The evolution of chemotherapy for the treatment of prostate cancer. <i>Annals of Oncology</i> , 2017, 28, 2658-2669.	0.6	57
593	Reply to Julie Steinmetz, Christof Benzenmann, Andres J. Schrader, and Jochen K. Lemmer's Letter to the Editor re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and Second-line Abiraterone and Enzalutamide. <i>J Clin Oncol</i> 2017;35:2149-56. AR-V7 Testing: What's in it for the Patient?. <i>European Urology</i> , 2017, 72, e170-e171.	0.9	1
594	Evidence-based clinical practice guideline for prostate cancer (summary: Japanese Urological) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5</i>	0.5	111
595	Liquid Biopsy in Cancer Patients. <i>Current Clinical Pathology</i> , 2017, , .	0.0	6
596	Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation. <i>Cancer Research</i> , 2017, 77, 4745-4754.	0.4	56
597	Prognostic nutritional index predicts initial response to treatment and prognosis in metastatic castration-resistant prostate cancer patients treated with abiraterone. <i>Prostate</i> , 2017, 77, 1233-1241.	1.2	33
598	Liquid Biopsy in Prostate Cancer. <i>Current Clinical Pathology</i> , 2017, , 95-102.	0.0	0
600	Treatment strategies in low-volume metastatic castration-resistant prostate cancer. <i>Current Opinion in Urology</i> , 2017, 27, 596-603.	0.9	10
601	Histopathological Evaluation in Prostate Cancer. , 2017, , 169-189.		0
602	Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 682-696.	1.2	56
603	Targeting a Single Alternative Polyadenylation Site Coordinately Blocks Expression of Androgen Receptor mRNA Splice Variants in Prostate Cancer. <i>Cancer Research</i> , 2017, 77, 5228-5235.	0.4	52
604	Targeting AR Variant's Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities. <i>Molecular Cancer Research</i> , 2017, 15, 1469-1480.	1.5	21
605	Allosteric alterations in the androgen receptor and activity in prostate cancer. <i>Endocrine-Related Cancer</i> , 2017, 24, R335-R348.	1.6	10
606	Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2017, 77, 5564-5575.	0.4	105

#	ARTICLE	IF	CITATIONS
607	Circulating tumor cells in prostate cancer: Precision diagnosis and therapy. <i>Oncology Letters</i> , 2017, 14, 1223-1232.	0.8	29
608	Heat shock protein 70 inhibitors suppress androgen receptor expression in LNCaP95 prostate cancer cells. <i>Cancer Science</i> , 2017, 108, 1820-1827.	1.7	49
609	Chemotherapy in the Management of Prostate Cancer. , 2017, , 351-365.		0
610	Predicting Response and Recognizing Resistance: Improving Outcomes in Patients With Castration-resistant Prostate Cancer. <i>Urology</i> , 2017, 109, 6-18.	0.5	15
611	The need for immune biomarkers for treatment prognosis and response in genitourinary malignancies. <i>Biomarkers in Medicine</i> , 2017, 11, 1149-1159.	0.6	8
612	Biomarkers in prostate cancer – Current clinical utility and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 120, 180-193.	2.0	135
613	Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells. <i>Nature Communications</i> , 2017, 8, 1733.	5.8	53
614	Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. <i>Cancer Cell</i> , 2017, 32, 792-806.e7.	7.7	61
615	Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer. <i>Scientific Reports</i> , 2017, 7, 15541.	1.6	11
616	Castration-Resistant Prostate Cancer. <i>Urologic Clinics of North America</i> , 2017, 44, 647-655.	0.8	2
617	The Diagnosis and Treatment of Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2532.	3.8	959
618	Liquid Biopsy: Current Status and Future Perspectives. <i>Oncology Research and Treatment</i> , 2017, 40, 404-408.	0.8	177
621	Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2017, 28, 1923-1933.	0.6	153
622	Platelet RNA signatures for the detection of cancer. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 263-272.	2.7	69
623	Re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Lubber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and Second-line Abiraterone and Enzalutamide. <i>J Clin Oncol</i> 2017;35:2149-56. <i>European Urology</i> , 2017, 72, e168-e169.	0.9	9
625	Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate. <i>Anti-Cancer Drugs</i> , 2017, 28, 110-115.	0.7	6
626	Ailanthone: a new potential drug for castration-resistant prostate cancer. <i>Chinese Journal of Cancer</i> , 2017, 36, 25.	4.9	20
627	Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer. <i>Nature Communications</i> , 2017, 8, 15921.	5.8	87

#	ARTICLE	IF	CITATIONS
629	Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 35-44.	1.9	100
630	Circulating Tumor Cells in Advanced Prostate Cancer: Time to Move from Prognostic to Predictive Ability. <i>European Urology</i> , 2017, 71, 172-173.	0.9	4
631	Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain. <i>Oncogene</i> , 2017, 36, 1440-1450.	2.6	6
632	The molecular underpinnings of prostate cancer: impacts on management and pathology practice. <i>Journal of Pathology</i> , 2017, 241, 173-182.	2.1	36
633	German Multicenter Study Investigating <sup>177</sup> Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2017, 58, 85-90.	2.8	646
634	Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. <i>Annals of Oncology</i> , 2017, 28, 90-95.	0.6	24
636	C-terminally truncated constitutively active androgen receptor variants and their biologic and clinical significance in castration-resistant prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 166, 38-44.	1.2	17
637	Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study. <i>Prostate</i> , 2017, 77, 33-40.	1.2	60
638	Getting personal with prostate cancer: DNA repair defects and olaparib in metastatic prostate cancer. <i>BJU International</i> , 2017, 119, 8-9.	1.3	6
639	Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 166, 16-27.	1.2	35
640	Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 726-734.	3.2	95
641	Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response. <i>European Urology</i> , 2017, 71, 776-787.	0.9	81
642	Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges. <i>Nuclear Medicine and Molecular Imaging</i> , 2017, 51, 202-211.	0.6	45
643	Impact of Prior Use of an Androgen Receptor-Axis-Targeted (ARAT) Agent With or Without Subsequent Taxane Therapy on the Efficacy of Another ARAT Agent in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e217-e222.	0.9	14
644	Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. <i>European Urology</i> , 2017, 71, 1-3.	0.9	113
645	The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. <i>European Urology</i> , 2017, 71, 237-246.	0.9	62
646	Do Patients With AR-V7-Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions. <i>European Urology</i> , 2017, 71, 4-6.	0.9	24
647	Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1346-1357.	3.2	58

#	ARTICLE	IF	CITATIONS
648	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2017, 71, 630-642.	0.9	1,215
649	The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. <i>European Urology</i> , 2017, 71, 680-687.	0.9	213
650	High-Content Screening Identifies Src Family Kinases as Potential Regulators of AR-V7 Expression and Androgen-Independent Cell Growth. <i>Prostate</i> , 2017, 77, 82-93.	1.2	21
651	Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075. <i>Molecular Cancer Research</i> , 2017, 15, 35-44.	1.5	54
652	Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins. <i>Future Oncology</i> , 2017, 13, 369-379.	1.1	9
653	A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 935-945.	3.2	30
654	Interplay between Cytoplasmic and Nuclear Androgen Receptor Splice Variants Mediates Castration Resistance. <i>Molecular Cancer Research</i> , 2017, 15, 59-68.	1.5	57
655	Re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. <i>Eur Urol</i> 2017;71:1-3. <i>European Urology</i> , 2017, 71, e105-e106.	0.9	2
656	Recent progress and perspectives on prostate cancer biomarkers. <i>International Journal of Clinical Oncology</i> , 2017, 22, 214-221.	1.0	67
657	Integrated Analysis of Multiple Biomarkers from Circulating Tumor Cells Enabled by Exclusion-Based Analyte Isolation. <i>Clinical Cancer Research</i> , 2017, 23, 746-756.	3.2	52
658	AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate. <i>Journal of Urology</i> , 2017, 197, 135-142.	0.2	106
659	Branched Chain RNA <i>In Situ</i> Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 363-369.	3.2	23
660	Novel 3-methylindoline inhibitors of EZH2: Design, synthesis and SAR. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 217-222.	1.0	8
661	Polycomb-Mediated Disruption of an Androgen Receptor Feedback Loop Drives Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2017, 77, 412-422.	0.4	23
662	Genomic and Biological Markers to Select Treatment for Patients with Prostate Cancer: Choose Wisely, My Friend. <i>Journal of Urology</i> , 2017, 197, 8-9.	0.2	0
663	Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 269-283.	12.5	36
664	Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer. <i>Nature Reviews Urology</i> , 2017, 14, 90-97.	1.9	78
665	Molecular Imaging and Precision Medicine in Prostate Cancer. <i>PET Clinics</i> , 2017, 12, 83-92.	1.5	9

#	ARTICLE	IF	CITATIONS
666	The optimal treatment of metastatic hormone-naive prostate cancer: abiraterone acetate or docetaxel?. <i>Future Oncology</i> , 2017, 13, 2785-2790.	1.1	5
668	Heterogeneity of advanced prostate cancer: clinical implications of genomics. <i>Trends in Urology &amp; Men's Health</i> , 2017, 8, 24-27.	0.2	0
669	Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 358-369.	1.8	9
670	Flüssigbiopsie: Status quo und Zukunftsperspektiven. <i>Karger Kompass Pneumologie</i> , 2017, 5, 206-210.	0.0	0
671	Are Liquid Biopsies Applied Across Every Type of Solid Tumours?. <i>Journal of Neoplasm</i> , 2017, 02, .	0.1	0
672	Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. <i>Oncotarget</i> , 2017, 8, 89848-89866.	0.8	45
674	First Line Androgen Deprivation Therapy Duration Is Associated with the Efficacy of Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer after Docetaxel. <i>Frontiers in Pharmacology</i> , 2017, 8, 55.	1.6	7
675	Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4089-4098.	1.0	8
677	Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells. <i>Theranostics</i> , 2017, 7, 1914-1927.	4.6	41
678	A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland. <i>Cancers</i> , 2017, 9, 14.	1.7	38
679	Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance. <i>Cancers</i> , 2017, 9, 67.	1.7	83
680	Androgen receptor splice variants and prostate cancer: From bench to bedside. <i>Oncotarget</i> , 2017, 8, 18550-18576.	0.8	100
681	Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF- $\kappa$ B) Activation and NF- $\kappa$ B Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1130.	1.8	26
682	AR-Signaling in Human Malignancies: Prostate Cancer and Beyond. <i>Cancers</i> , 2017, 9, 7.	1.7	49
683	Androgen Receptor Signaling in Salivary Gland Cancer. <i>Cancers</i> , 2017, 9, 17.	1.7	69
684	Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2017, 9, 22.	1.7	36
685	The Androgen Receptor and VEGF: Mechanisms of Androgen-Regulated Angiogenesis in Prostate Cancer. <i>Cancers</i> , 2017, 9, 32.	1.7	60
686	Significance of microRNAs in Androgen Signaling and Prostate Cancer Progression. <i>Cancers</i> , 2017, 9, 102.	1.7	31

#	ARTICLE	IF	CITATIONS
687	Circulating Tumor Cells: Back to the Future. <i>Frontiers in Oncology</i> , 2017, 6, 275.	1.3	3
688	Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. <i>ELife</i> , 2017, 6, .	2.8	154
690	Prostate Cancer Stem Cell Markers Drive Progression, Therapeutic Resistance, and Bone Metastasis. <i>Stem Cells International</i> , 2017, 2017, 1-9.	1.2	80
691	The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer. <i>International Journal of Medical Sciences</i> , 2017, 14, 356-366.	1.1	19
693	A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. <i>Canadian Urological Association Journal</i> , 2017, 12, E47-52.	0.3	13
694	Establishment and Application of Prostate Cancer Circulating Tumor Cells in the Era of Precision Medicine. <i>BioMed Research International</i> , 2017, 2017, 1-9.	0.9	6
695	First brazilian consensus of advanced prostate cancer: recommendations for clinical practice. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2017, 43, 407-415.	0.7	5
696	Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer. <i>PLoS ONE</i> , 2017, 12, e0174658.	1.1	16
697	Mapping the STK4/Hippo signaling network in prostate cancer cell. <i>PLoS ONE</i> , 2017, 12, e0184590.	1.1	22
698	stageR: a general stage-wise method for controlling the gene-level false discovery rate in differential expression and differential transcript usage. <i>Genome Biology</i> , 2017, 18, 151.	3.8	97
699	The small vesicular culprits: the investigation of extracellular vesicles as new targets for cancer treatment. <i>Clinical and Translational Medicine</i> , 2017, 6, 45.	1.7	29
700	Rapid Loss of RNA Detection by In Situ Hybridization in Stored Tissue Blocks and Preservation by Cold Storage of Unstained Slides. <i>American Journal of Clinical Pathology</i> , 2017, 148, 398-415.	0.4	52
701	The biological and clinical advances of androgen receptor function in age-related diseases and cancer [Review]. <i>Endocrine Journal</i> , 2017, 64, 933-946.	0.7	13
702	An exploratory analysis of the association between levels of hormones implied in steroid biosynthesis and activity of abiraterone in patients with metastatic castration-resistant prostate cancer. <i>Minerva Urology and Nephrology</i> , 2017, 69, 349-358.	1.3	3
703	Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles. <i>Oncotarget</i> , 2017, 8, 3724-3745.	0.8	95
704	Targeting the androgen receptor in triple-negative breast cancer: current perspectives. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4675-4685.	1.0	48
705	Circulating Tumor Cells in Genitourinary Malignancies: An Evolving Path to Precision Medicine. <i>Frontiers in Oncology</i> , 2017, 7, 6.	1.3	10
706	Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. <i>Journal of Clinical Oncology</i> , 2017, 35, 2149-2156.	0.8	371



#	ARTICLE	IF	CITATIONS
707	Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2017, 2017, 1-9.	1.5	42
708	Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2017, 1, 1-11.	1.5	13
709	Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. <i>Oncotarget</i> , 2017, 8, 3581-3590.	0.8	172
710	Liquid biopsies in lung cancer—time to implement research technologies in routine care?. <i>Annals of Translational Medicine</i> , 2017, 5, 278-278.	0.7	27
711	The current status and clinical value of circulating tumor cells and circulating cell-free tumor DNA in bladder cancer. <i>Translational Andrology and Urology</i> , 2017, 6, 1090-1110.	0.6	22
712	Association Between Androgen Receptor Splice Variants and Prostate Cancer Resistance to Abiraterone and Enzalutamide. <i>Journal of Clinical Oncology</i> , 2017, 35, 2103-2105.	0.8	15
713	Molecular Tests for the Choice of Cancer Therapy. <i>Current Pharmaceutical Design</i> , 2017, 23, 4794-4806.	0.9	10
714	An In-Depth Evaluation of the Validity and Logistics Surrounding the Testing of AR-V7 mRNA Expression in Circulating Tumor Cells. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 316-325.	1.2	15
715	Cellular plasticity and the neuroendocrine phenotype in prostate cancer. <i>Nature Reviews Urology</i> , 2018, 15, 271-286.	1.9	273
717	Molecular Targeted Therapies of Prostate Cancer. <i>Molecular Pathology Library</i> , 2018, , 523-546.	0.1	1
718	TRIM36, a novel androgen-responsive gene, enhances anti-androgen efficacy against prostate cancer by inhibiting MAPK/ERK signaling pathways. <i>Cell Death and Disease</i> , 2018, 9, 155.	2.7	41
719	Circulating tumour cells in prostate cancer. <i>Nature Reviews Urology</i> , 2018, 15, 265-266.	1.9	14
720	AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients. <i>Prostate</i> , 2018, 78, 576-582.	1.2	46
721	Precision Medicine in Prostate Cancer: Approach to the Patient. <i>Molecular Pathology Library</i> , 2018, , 3-12.	0.1	0
722	Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies. <i>Current Treatment Options in Oncology</i> , 2018, 19, 16.	1.3	5
723	Digital Circulating Tumor Cell Analyses for Prostate Cancer Precision Oncology. <i>Cancer Discovery</i> , 2018, 8, 269-271.	7.7	6
724	Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer. <i>Cell Reports</i> , 2018, 22, 2236-2245.	2.9	60
725	Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer. <i>European Journal of Medicinal Chemistry</i> , 2018, 152, 542-559.	2.6	21

#	ARTICLE	IF	CITATIONS
726	An integrated flow cytometry-based platform for isolation and molecular characterization of circulating tumor single cells and clusters. <i>Scientific Reports</i> , 2018, 8, 5035.	1.6	63
727	Clinical indications for, and the future of, circulating tumor cells. <i>Advanced Drug Delivery Reviews</i> , 2018, 125, 143-150.	6.6	57
728	Current and potential targets for drug design in the androgen receptor pathway for prostate cancer. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 489-496.	2.5	5
729	Molecular and cellular mechanisms of castration resistant prostate cancer (Review). <i>Oncology Letters</i> , 2018, 15, 6063-6076.	0.8	116
730	Practice-changing developments in early use of chemohormonal therapy in metastatic prostate cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 33-37.	0.3	0
731	PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 475-486.	1.3	83
732	Blockade of ACK1/TNK2 To Squelch the Survival of Prostate Cancer Stem-like Cells. <i>Scientific Reports</i> , 2018, 8, 1954.	1.6	23
733	Les cellules tumorales circulantes comme biopsie liquide du cancer. <i>Revue Francophone Des Laboratoires</i> , 2018, 2018, 75-80.	0.0	0
734	Carcinogenesis in prostate cancer: The role of long non-coding RNAs. <i>Non-coding RNA Research</i> , 2018, 3, 29-38.	2.4	33
735	Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. <i>Molecular Cancer Research</i> , 2018, 16, 643-654.	1.5	33
736	AR Expression in Breast Cancer CTCs Associates with Bone Metastases. <i>Molecular Cancer Research</i> , 2018, 16, 720-727.	1.5	68
737	Clinical utility of non-EpCAM based circulating tumor cell assays. <i>Advanced Drug Delivery Reviews</i> , 2018, 125, 132-142.	6.6	26
738	Loss of an Androgen-Inactivating and Isoform-Specific HSD17B4 Splice Form Enables Emergence of Castration-Resistant Prostate Cancer. <i>Cell Reports</i> , 2018, 22, 809-819.	2.9	32
739	The Heterogeneity of Prostate Cancer: A Practical Approach. <i>Pathobiology</i> , 2018, 85, 108-116.	1.9	93
740	Clinical applications of the CellSearch platform in cancer patients. <i>Advanced Drug Delivery Reviews</i> , 2018, 125, 102-121.	6.6	185
741	Profiling circulating tumour cells and other biomarkers of invasive cancers. <i>Nature Biomedical Engineering</i> , 2018, 2, 72-84.	11.6	187
742	CXCL12 <sup>3</sup> Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes. <i>Cancer Research</i> , 2018, 78, 2026-2039.	0.4	46
743	Circulating tumor cells in genitourinary tumors. <i>Therapeutic Advances in Urology</i> , 2018, 10, 65-77.	0.9	14



#	ARTICLE	IF	CITATIONS
744	Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. <i>Cancer Discovery</i> , 2018, 8, 444-457.	7.7	376
745	Mutant <i>KRAS</i> Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring. <i>Oncologist</i> , 2018, 23, 566-572.	1.9	69
746	Performance comparison of two androgen receptor splice variant 7 (AR $\psi$ 7) detection methods. <i>BJU International</i> , 2018, 122, 219-226.	1.3	11
747	Fast and Label-Free Isolation of Circulating Tumor Cells from Blood: From a Research Microfluidic Platform to an Automated Fluidic Instrument, VTX-1 Liquid Biopsy System. <i>SLAS Technology</i> , 2018, 23, 16-29.	1.0	40
748	Targeting of Steroid Hormone Receptor Function in Breast and Prostate Cancer. <i>Endocrinology</i> , 2018, , 765-785.	0.1	0
749	Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2018, 121, 871-879.	1.3	23
750	Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer. <i>Hormones and Cancer</i> , 2018, 9, 82-94.	4.9	21
751	Application of single-cell sequencing in human cancer. <i>Briefings in Functional Genomics</i> , 2018, 17, 273-282.	1.3	34
752	BMI1 regulates androgen receptor in prostate cancer independently of the polycomb repressive complex 1. <i>Nature Communications</i> , 2018, 9, 500.	5.8	65
753	Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 645-657.	13.9	386
754	Developing androgen receptor targeting for salivary gland cancers. <i>Annals of Oncology</i> , 2018, 29, 792-794.	0.6	1
755	The potential of AR-V7 as a therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 201-216.	1.5	22
756	Clinical and Novel Biomarkers in the Management of Prostate Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 8.	1.3	16
757	Nuclear Receptor LRH-1 Functions to Promote Castration-Resistant Growth of Prostate Cancer via Its Promotion of Intratumoral Androgen Biosynthesis. <i>Cancer Research</i> , 2018, 78, 2205-2218.	0.4	36
758	Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review. <i>Future Oncology</i> , 2018, 14, 431-442.	1.1	14
759	Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2018, 78, 2065-2080.	0.4	60
760	Current treatment strategies for advanced prostate cancer. <i>International Journal of Urology</i> , 2018, 25, 220-231.	0.5	164
761	The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 306-318.	2.0	21

#	ARTICLE	IF	CITATIONS
762	Predicting therapy response and resistance in metastatic prostate cancer with circulating tumor DNA. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 380-384.	0.8	13
763	DBC1 promotes castration-resistant prostate cancer by positively regulating DNA binding and stability of AR-V7. <i>Oncogene</i> , 2018, 37, 1326-1339.	2.6	28
764	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. <i>European Urology</i> , 2018, 73, 715-723.	0.9	105
765	Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC). <i>Cancer</i> , 2018, 124, 1216-1224.	2.0	52
766	CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 155-163.	1.5	51
767	Size-based separation methods of circulating tumor cells. <i>Advanced Drug Delivery Reviews</i> , 2018, 125, 3-20.	6.6	163
768	Molecular analysis of circulating tumors cells: Biomarkers beyond enumeration. <i>Advanced Drug Delivery Reviews</i> , 2018, 125, 122-131.	6.6	21
769	p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 260-268.	2.0	48
770	Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer. <i>Nucleic Acids Research</i> , 2018, 46, 1895-1911.	6.5	79
771	Molecular Biomarkers in the Clinical Management of Prostate Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a030601.	2.9	11
772	Precision oncology in the age of integrative genomics. <i>Nature Biotechnology</i> , 2018, 36, 46-60.	9.4	104
773	Order within a Disordered Structure. <i>Structure</i> , 2018, 26, 4-6.	1.6	31
774	In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and KRAS Point Mutations in Circulating Tumor Cells. <i>Clinical Chemistry</i> , 2018, 64, 536-546.	1.5	66
775	An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer. <i>Cancer Discovery</i> , 2018, 8, 288-303.	7.7	107
776	Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E4584-E4593.	3.3	73
777	Applications of metabolomics to study cancer metabolism. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1870, 2-14.	3.3	129
778	Implementing Liquid Biopsies in Clinical Trials. <i>Cancer Journal (Sudbury, Mass )</i> , 2018, 24, 61-64.	1.0	12
779	Single-cell mRNA cytometry via sequence-specific nanoparticle clustering and trapping. <i>Nature Chemistry</i> , 2018, 10, 489-495.	6.6	68

#	ARTICLE	IF	CITATIONS
780	PARP inhibitors for homologous recombination-deficient prostate cancer. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 123-133.	1.0	24
781	Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 125, 51-59.	2.0	8
782	Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancer. <i>BJU International</i> , 2018, 122, 152-159.	1.3	21
783	Optimizing the treatment of metastatic castration-resistant prostate cancer: a Latin America perspective. <i>Medical Oncology</i> , 2018, 35, 56.	1.2	4
784	Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC). <i>Clinical Cancer Research</i> , 2018, 24, 3149-3162.	3.2	111
785	Structure-Based Discovery and Optimization of Benzo[ <i>d</i> ]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC). <i>Journal of Medicinal Chemistry</i> , 2018, 61, 3037-3058.	2.9	46
786	Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. <i>American Journal of Pathology</i> , 2018, 188, 1478-1485.	1.9	119
787	New horizons in the management of castrate-resistant prostate cancer. <i>Journal of Clinical Urology</i> , 2018, 11, 258-265.	0.1	2
788	NanoVelcro rare-cell assays for detection and characterization of circulating tumor cells. <i>Advanced Drug Delivery Reviews</i> , 2018, 125, 78-93.	6.6	89
789	Size-Based Enrichment Technologies for Non-cancerous Tumor-Derived Cells in Blood. <i>Trends in Biotechnology</i> , 2018, 36, 511-522.	4.9	24
790	Transcriptional Regulation in Prostate Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a030437.	2.9	57
791	New Opportunities for Targeting the Androgen Receptor in Prostate Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a030478.	2.9	19
792	Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2018, 4, 529-539.	1.6	30
793	Role of androgens in the ovary. <i>Molecular and Cellular Endocrinology</i> , 2018, 465, 36-47.	1.6	63
794	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018, 73, 178-211.	0.9	488
795	Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 72-77.e1.	0.9	24
796	Radio-223 en la secuencia terapéutica del cáncer de próstata resistente a la castración metastásico. <i>Actas Urológicas Españolas</i> , 2018, 42, 227-237.	0.3	2
797	Real-world Characteristics and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy Versus Androgen Receptor-targeted Therapy After Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 50-57.	0.9	19

#	ARTICLE	IF	CITATIONS
798	Nuclear receptor profiling in prostatospheroids and castration-resistant prostate cancer. <i>Endocrine-Related Cancer</i> , 2018, 25, 35-50.	1.6	24
799	Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients. <i>Prostate</i> , 2018, 78, 48-53.	1.2	47
800	Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. <i>Annals of Oncology</i> , 2018, 29, 23-25.	0.6	6
801	Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients. <i>Molecular Oncology</i> , 2018, 12, 48-57.	2.1	52
802	Androgen-receptor splice variant-7-positive prostate cancer: a novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients. <i>Modern Pathology</i> , 2018, 31, 198-208.	2.9	37
803	Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis. <i>European Urology</i> , 2018, 73, 834-844.	0.9	86
804	Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer. <i>Endocrine-Related Cancer</i> , 2018, 25, R1-R9.	1.6	13
805	Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for a 24 weeks in Europe. <i>European Urology</i> , 2018, 74, 37-45.	0.9	86
806	Treatment-induced changes in the androgen receptor axis: Liquid biopsies as diagnostic/prognostic tools for prostate cancer. <i>Molecular and Cellular Endocrinology</i> , 2018, 462, 56-63.	1.6	12
807	Clinical utility of emerging liquid biomarkers in advanced prostate cancer. <i>Cancer Genetics</i> , 2018, 228-229, 151-158.	0.2	11
808	Glycan Stimulation Enables Purification of Prostate Cancer Circulating Tumor Cells on PEDOT NanoVelcro Chips for RNA Biomarker Detection. <i>Advanced Healthcare Materials</i> , 2018, 7, 1700701.	3.9	38
809	Characterization of Differences Between Prostate Cancer Patients Presenting With De Novo Versus Primary Progressive Metastatic Disease. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 85-89.	0.9	34
810	Differences in clinical outcome between docetaxel and abiraterone acetate as the first-line treatment in chemo-naïve metastatic castration-resistant prostate cancer patients with or without the ineligible clinical factors of the COU-AA-302 study. <i>Prostate International</i> , 2018, 6, 24-30.	1.2	8
811	Treatment of Advanced Prostate Cancer—A Review of Current Therapies and Future Promise. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a030635.	2.9	128
812	PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 834-846.	3.2	48
813	Contemporary prognostic indicators for prostate cancer incorporating International Society of Urological Pathology recommendations. <i>Pathology</i> , 2018, 50, 60-73.	0.3	29
814	Oncogenic non-coding RNA NEAT1 promotes the prostate cancer cell growth through the SRC3/IGF1R/AKT pathway. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 94, 125-132.	1.2	48
815	Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer. <i>Prostate</i> , 2018, 78, 266-277.	1.2	28

#	ARTICLE	IF	CITATIONS
816	Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. <i>Lancet Oncology</i> , The, 2018, 19, 76-86.	5.1	149
817	Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 161.e19-161.e30.	0.8	26
818	Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Urology. <i>BJU International</i> , 2018, 121, 703-715.	1.3	8
819	AR-V7 predicting treatment response in metastasized prostate cancer: has it peaked?. <i>World Journal of Urology</i> , 2018, 36, 149-151.	1.2	1
820	The role of alternative splicing in cancer drug resistance. <i>Current Opinion in Genetics and Development</i> , 2018, 48, 16-21.	1.5	118
821	Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2018, 36, 195-205.	1.2	19
822	Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. <i>Prostate</i> , 2018, 78, 121-127.	1.2	28
823	Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells. <i>Prostate</i> , 2018, 78, 64-75.	1.2	41
824	The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 927-938.	3.2	128
825	SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017). <i>Clinical and Translational Oncology</i> , 2018, 20, 57-68.	1.2	17
826	Refining the Assessment and Implications of AR-V7 in Castrate-resistant Prostate Cancer. <i>European Urology</i> , 2018, 73, 736-737.	0.9	1
827	Antiandrogens Reduce Intratumoral Androgen Concentrations and Induce Androgen Receptor Expression in Castration-Resistant Prostate Cancer Xenografts. <i>American Journal of Pathology</i> , 2018, 188, 216-228.	1.9	9
828	Genomic Markers in Prostate Cancer Decision Making. <i>European Urology</i> , 2018, 73, 572-582.	0.9	201
829	Re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. <i>Eur Urol</i> 2017;71:680-7. <i>European Urology</i> , 2018, 73, e9-e10.	0.9	1
830	Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. <i>Journal of Clinical Investigation</i> , 2018, 129, 192-208.	3.9	266
831	Balancing Outcomes: Focusing on Value in Treatment of Prostate Cancer. <i>Journal of Oncology Practice</i> , 2018, 14, 588-590.	2.5	0
832	Liquid Biopsy to Identify Actionable Genomic Alterations. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 978-997.	1.8	54
833	Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. <i>Journal of Clinical Oncology</i> , 2018, 36, 991-999.	0.8	169

#	ARTICLE	IF	CITATIONS
834	Mechanisms of Drug Resistance in Cancer Therapy. Handbook of Experimental Pharmacology, 2018, , .	0.9	1
835	Case Report #9â€”Biomarkers of Prostate Cancer. , 2018, , 93-105.		0
836	Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Medical Journal, 2018, 3, 104-104.	0.4	0
837	AR-V7 and treatment selection in advanced prostate cancer: are we there yet?. Precision Cancer Medicine, 2018, 1, 13-13.	1.8	8
838	Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget, 2018, 9, 28561-28571.	0.8	129
839	Cancer Diagnosis: From Tumor to Liquid Biopsy and Beyond. Lab on A Chip, 2018, 19, 11-34.	3.1	123
840	Abiraterone survival benefit is independent of pain, prostate-specific antigen and Gleason sum in men with chemo-naïve metastatic castration-resistant prostate cancer (analysis of COU-AA-302). AME Medical Journal, 0, 3, 54-54.	0.4	0
841	Expression of Androgen Receptor Variant 7 (AR-V7) in Circulated Tumor Cells and Correlation with Drug Resistance of Prostate Cancer Cells. Medical Science Monitor, 2018, 24, 7051-7056.	0.5	8
842	The Biological Role of Androgen Receptor in Prostate Cancer Progression. , 2018, , .		1
843	Association between CYP17A1 polymorphisms and response to abiraterone in patients with metastatic castration-resistant prostate cancer: a systematic review. AME Medical Journal, 2018, 3, 50-50.	0.4	2
844	Das metastasierte Prostatakarzinom - trotz aller Fortschritte eine Herausforderung. Karger Kompass Onkologie, 2018, 5, 146-147.	0.0	0
845	Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer. Nature Communications, 2018, 9, 4700.	5.8	71
846	Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis. Genome Medicine, 2018, 10, 85.	3.6	94
847	Aberrant RNA Splicing in Cancer and Drug Resistance. Cancers, 2018, 10, 458.	1.7	145
848	Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane Chemotherapy. Journal of Clinical Medicine, 2018, 7, 444.	1.0	17
849	Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer. Asian Journal of Andrology, 2018, 20, 230.	0.8	9
850	Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer. Scientific Reports, 2018, 8, 17307.	1.6	23
851	Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions. OncoTargets and Therapy, 2018, Volume 11, 7353-7368.	1.0	58

#	ARTICLE	IF	CITATIONS
852	Radiomics and liquid biopsy in oncology: the holons of systems medicine. <i>Insights Into Imaging</i> , 2018, 9, 915-924.	1.6	47
853	Dual androgen receptor (<sc>AR</sc>) and <sc>STAT</sc>3 inhibition by a compound targeting the <sc>AR</sc> amino-terminus domain. <i>Pharmacology Research and Perspectives</i> , 2018, 6, e00437.	1.1	11
854	Molecular Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC. <i>Anticancer Research</i> , 2018, 38, 6029-6039.	0.5	18
855	Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 2341-2347.	0.9	11
856	scdNet: a computational tool for single-cell differential network analysis. <i>BMC Systems Biology</i> , 2018, 12, 124.	3.0	13
857	Advanced prostate cancer update 2018. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 9-12.	0.7	6
858	Therapy of Advanced Prostate Cancer: Targeting the Androgen Receptor Axis in Earlier Lines of Treatment. <i>Targeted Oncology</i> , 2018, 13, 679-689.	1.7	15
859	Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 397.	1.3	20
860	Castration-Resistant Prostate Cancer Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents: Opportunities and Challenges. <i>Cancers</i> , 2018, 10, 345.	1.7	24
861	ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. <i>Molecular Cell</i> , 2018, 72, 341-354.e6.	4.5	64
862	Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice?. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 71.	1.8	9
863	Prognostic factors of oncologic outcomes in metastatic chemotherapy-naïve castration-resistant prostate cancer treated with enzalutamide in actual clinical practice in East Asia. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 401.e11-401.e18.	0.8	9
864	Developing prognostic models for advanced prostate cancer when the goal line keeps changing. <i>Annals of Oncology</i> , 2018, 29, 2155-2157.	0.6	1
865	Identification of the Transcription Factor Relationships Associated with Androgen Deprivation Therapy Response and Metastatic Progression in Prostate Cancer. <i>Cancers</i> , 2018, 10, 379.	1.7	21
866	Circulating Tumor Cells and Circulating Tumor DNA. , 2018, , 235-281.		8
867	Molecular & Diagnostic Imaging in Prostate Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2018, , .	0.8	2
868	Castration-Resistant Prostate Cancer: Mechanisms, Targets and Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1096, 117-133.	0.8	58
869	Current therapeutic options in metastatic castration-resistant prostate cancer. <i>Seminars in Oncology</i> , 2018, 45, 303-315.	0.8	63



#	ARTICLE	IF	CITATIONS
870	Plasma androgen receptor and serum chromogranin A in advanced prostate cancer. <i>Scientific Reports</i> , 2018, 8, 15442.	1.6	21
871	Die Heterogenität des Prostatakrebses: Ein praxisorientierter Ansatz. <i>Karger Kompass Onkologie</i> , 2018, 5, 149-157.	0.0	0
872	Chemopreventive effects of angiotensin II receptor type 2 agonist on prostate carcinogenesis by the down-regulation of the androgen receptor. <i>Oncotarget</i> , 2018, 9, 13859-13869.	0.8	10
873	Genitourinary Pathology Reporting Parameters Most Relevant to the Medical Oncologist. <i>Surgical Pathology Clinics</i> , 2018, 11, 877-891.	0.7	0
874	The Androgen Receptor in Breast Cancer. <i>Frontiers in Endocrinology</i> , 2018, 9, 492.	1.5	154
875	Inhibiting Multiple Deubiquitinases to Reduce Androgen Receptor Expression in Prostate Cancer Cells. <i>Scientific Reports</i> , 2018, 8, 13146.	1.6	14
876	Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591879463.	1.4	317
877	ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis. <i>Cancer Letters</i> , 2018, 439, 47-55.	3.2	35
878	Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 500.e1-500.e9.	0.8	41
879	Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management. <i>Biological Research</i> , 2018, 51, 32.	1.5	11
880	RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancer—From Cell Line Models to Liquid Biopsies. <i>Diagnostics</i> , 2018, 8, 60.	1.3	15
881	VTX— Liquid Biopsy System for Fully Automated and Label-Free Isolation of Circulating Tumor Cells with Automated Enumeration by BioView Platform. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2018, 93, 1240-1245.	1.1	19
882	Molecular Diagnostics in Clinical Oncology. <i>Frontiers in Molecular Biosciences</i> , 2018, 5, 76.	1.6	93
883	Outcome of Patients with Metastatic Castration-resistant Prostate Cancer After PSA Progression with Abiraterone Acetate. <i>Anticancer Research</i> , 2018, 38, 5429-5436.	0.5	3
884	Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2018, 29, 2200-2207.	0.6	47
885	Genome-Based Classification and Therapy of Prostate Cancer. <i>Diagnostics</i> , 2018, 8, 62.	1.3	16
886	Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer. <i>Cancer Letters</i> , 2018, 438, 86-96.	3.2	1
887	New Insights in Prostate Cancer Development and Tumor Therapy: Modulation of Nuclear Receptors and the Specific Role of Liver X Receptors. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2545.	1.8	10

#	ARTICLE	IF	CITATIONS
888	Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants. <i>Cancer Science</i> , 2018, 109, 3224-3234.	1.7	21
889	Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 429-436.	0.9	8
890	Genetics and biology of prostate cancer. <i>Genes and Development</i> , 2018, 32, 1105-1140.	2.7	434
891	Liquid Biopsy in Prostate Cancer: Circulating Tumor Cells and Beyond. <i>Cancer Treatment and Research</i> , 2018, 175, 87-104.	0.2	12
892	Alternative RNA Splicing: New Approaches for Molecular Marker Discovery in Cancer. , 2018, , .		1
893	Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. <i>Nature Genetics</i> , 2018, 50, 814-824.	9.4	196
894	Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2018, 78, 4022-4035.	0.4	100
895	Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2018, 73, 818-821.	0.9	35
896	Protocols for Tissue Microarrays in Prostate Cancer Studies. <i>Methods in Molecular Biology</i> , 2018, 1786, 103-116.	0.4	1
898	Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 6810-6815.	3.3	120
899	Concise Review: Prostate Cancer Stem Cells: Current Understanding. <i>Stem Cells</i> , 2018, 36, 1457-1474.	1.4	90
900	Molecular Subtypes of Prostate Cancer. <i>Current Oncology Reports</i> , 2018, 20, 58.	1.8	77
901	Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 553-559.	1.9	18
902	A Convergence-Based Framework for Cancer Drug Resistance. <i>Cancer Cell</i> , 2018, 33, 801-815.	7.7	181
904	Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 1179.	3.4	190
905	Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. <i>Small</i> , 2018, 14, e1801131.	5.2	115
906	Castration-resistance prostate cancer: what is in the pipeline?. <i>Minerva Urology and Nephrology</i> , 2018, 70, 22-41.	1.3	17
907	Detection of AR-V7 transcript with RNA in situ hybridization in human salivary duct cancer. <i>Oral Oncology</i> , 2018, 84, 134-136.	0.8	4

#	ARTICLE	IF	CITATIONS
908	Landmarks in prostate cancer. <i>Nature Reviews Urology</i> , 2018, 15, 627-642.	1.9	78
909	Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2176-2186.	1.9	33
910	Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer. <i>Investigational New Drugs</i> , 2018, 36, 1133-1137.	1.2	19
911	Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer. <i>Oncology Letters</i> , 2018, 15, 6806-6814.	0.8	1
912	Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2079-2090.	1.9	19
913	Multifaceted Roles for Macrophages in Prostate Cancer Skeletal Metastasis. <i>Frontiers in Endocrinology</i> , 2018, 9, 247.	1.5	43
914	Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 28.	1.3	18
915	Development of Neuroendocrine Prostate Cancers by the Ser/Arg Repetitive Matrix 4-Mediated RNA Splicing Network. <i>Frontiers in Oncology</i> , 2018, 8, 93.	1.3	16
916	Extracellular Vesicles in Prostate Cancer Carcinogenesis, Diagnosis, and Management. <i>Frontiers in Oncology</i> , 2018, 8, 222.	1.3	93
917	A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. <i>PLoS ONE</i> , 2018, 13, e0198389.	1.1	86
918	Molecular Basics on Genitourinary Malignancies. , 2018, , 1-15.		0
919	Precision medicine applications in prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877692.	1.4	12
920	Molecular underpinnings of enzalutamide resistance. <i>Endocrine-Related Cancer</i> , 2018, 25, R545-R557.	1.6	28
921	Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases. <i>British Journal of Cancer</i> , 2018, 119, 347-356.	2.9	63
922	Targeting Splicing in Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1287.	1.8	20
923	Chemical modulation of transcription factors. <i>MedChemComm</i> , 2018, 9, 1249-1272.	3.5	11
924	Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5225-5232.	3.2	16
925	Evaluation of Preanalytical Conditions and Implementation of Quality Control Steps for Reliable Gene Expression and DNA Methylation Analyses in Liquid Biopsies. <i>Clinical Chemistry</i> , 2018, 64, 1522-1533.	1.5	42

#	ARTICLE	IF	CITATIONS
926	Recent Advances in Prostate Cancer Treatment and Drug Discovery. International Journal of Molecular Sciences, 2018, 19, 1359.	1.8	183
927	Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date. OncoTargets and Therapy, 2018, Volume 11, 2141-2147.	1.0	33
928	Castration-Resistant Prostate Cancer: Sequencing Oral and Infusion Agents. Current Urology Reports, 2018, 19, 73.	1.0	3
929	Androgen receptor isoforms expression in benign prostatic hyperplasia and primary prostate cancer. PLoS ONE, 2018, 13, e0200613.	1.1	14
930	Molecular mechanism of the TP53-MDM2-AR-AKT signalling network regulation by USP12. Oncogene, 2018, 37, 4679-4691.	2.6	31
932	Gene Expression Analysis of Immunomagnetically Enriched Circulating Tumor Cell Fraction in Castration-Resistant Prostate Cancer. Molecular Diagnosis and Therapy, 2018, 22, 381-390.	1.6	5
933	Liquid biopsy - emergence of a new era in personalized cancer care. Applied Cancer Research, 2018, 38, .	1.0	3
934	Unfavorable Pathology, Tissue Biomarkers and Genomic Tests With Clinical Implications in Prostate Cancer Management. Advances in Anatomic Pathology, 2018, 25, 293-303.	2.4	11
935	LSD1 inhibition attenuates androgen receptor V7 splice variant activation in castration resistant prostate cancer models. Cancer Cell International, 2018, 18, 71.	1.8	19
936	Extracellular vesicles: Toward a clinical application in urological cancer treatment. International Journal of Urology, 2018, 25, 533-543.	0.5	32
937	<sup>68</sup> Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer. Radiologia Medica, 2018, 123, 952-965.	4.7	16
938	Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer – recent developments and future directions. Expert Opinion on Investigational Drugs, 2018, 27, 811-822.	1.9	5
939	Optimal Management of Prostate Cancer Based on its Natural Clinical History. Current Cancer Drug Targets, 2018, 18, 457-467.	0.8	10
940	Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens. Research and Reports in Urology, 2018, Volume 10, 23-32.	0.6	42
941	Identification of an oncogenic network with prognostic and therapeutic value in prostate cancer. Molecular Systems Biology, 2018, 14, e8202.	3.2	33
942	The way towards understanding possible multiple functions of AR V7 in prostate cancer. BJU International, 2018, 122, 169-169.	1.3	1
943	Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC). Journal of Biological Chemistry, 2018, 293, 14328-14341.	1.6	66
944	Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH) Tj ETQq1 1 0z784314 rgeT /Over	1.6	43

#	ARTICLE	IF	CITATIONS
945	Alternative splicing in prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 663-675.	12.5	142
946	Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2018, 78, 5731-5740.	0.4	40
947	Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 411-418.	2.0	32
948	Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. <i>European Urology Oncology</i> , 2018, 1, 151-159.	2.6	28
949	Radium-223 in the therapeutic sequence of metastatic castration-resistant prostate cancer. <i>Actas Urológicas Españolas (English Edition)</i> , 2018, 42, 227-237.	0.2	1
950	Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target. <i>Journal of Oral Pathology and Medicine</i> , 2018, 47, 691-695.	1.4	17
951	Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. <i>Cell</i> , 2018, 174, 433-447.e19.	13.5	258
952	Regulation of prostate cancer by hormone-responsive G protein-coupled receptors. , 2018, 191, 135-147.		22
953	Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. <i>Cancer Research</i> , 2018, 78, 4716-4730.	0.4	56
954	Hormone-Responsive Cancers. , 2019, , 717-741.e8.		2
955	Interference with the androgen receptor protein stability in therapy-resistant prostate cancer. <i>International Journal of Cancer</i> , 2019, 144, 1775-1779.	2.3	22
956	Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression. <i>Prostate</i> , 2019, 79, 54-61.	1.2	20
957	Inhibiting geranylgeranyl diphosphate synthesis reduces nuclear androgen receptor signaling and neuroendocrine differentiation in prostate cancer cell models. <i>Prostate</i> , 2019, 79, 21-30.	1.2	12
958	A Coiled-Coil Domain Containing 50 Splice Variant Is Modulated by Serine/Arginine-Rich Splicing Factor 3 and Promotes Hepatocellular Carcinoma in Mice by the Ras Signaling Pathway. <i>Hepatology</i> , 2019, 69, 179-195.	3.6	67
959	Leelamine Is a Novel Lipogenesis Inhibitor in Prostate Cancer Cells <i>In Vitro</i> and <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1800-1810.	1.9	16
960	Sequencing strategies in the new treatment landscape of prostate cancer. <i>Future Oncology</i> , 2019, 15, 2967-2982.	1.1	6
961	Nuclear receptors: recent drug discovery for cancer therapies. <i>Endocrine Reviews</i> , 2019, 40, 1207-1249.	8.9	65
962	The small molecule WNT/ $\beta$ -catenin inhibitor CWP232291 blocks the growth of castration-resistant prostate cancer by activating the endoplasmic reticulum stress pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 342.	3.5	46

#	ARTICLE	IF	CITATIONS
963	Roobos suppresses proliferation of castration-resistant prostate cancer cells via inhibition of Akt signaling. <i>Phytomedicine</i> , 2019, 64, 153068.	2.3	15
964	Radium-223 plus abiraterone in metastatic castration-resistant prostate cancer: a cautionary tale. <i>Translational Andrology and Urology</i> , 2019, 8, S341-S345.	0.6	7
965	Pathological Assessment of Prostate Cancer. , 2019, , 159-177.		0
966	Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer. <i>Cells</i> , 2019, 8, 860.	1.8	34
967	Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications. <i>Medicines (Basel, Switzerland)</i> , 2019, 6, 82.	0.7	68
968	Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial). <i>Cancers</i> , 2019, 11, 1099.	1.7	18
969	Molecular Basics on Genitourinary Malignancies. , 2019, , 3-17.		0
970	AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1875-1886.	1.9	51
971	Reply to L. Dirix, B. De Laere et al, and A. Sharp et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 2184-2186.	0.8	7
972	Detection of AR-V7 in Liquid Biopsies of Castrate Resistant Prostate Cancer Patients: A Comparison of AR-V7 Analysis in Circulating Tumor Cells, Circulating Tumor RNA and Exosomes. <i>Cells</i> , 2019, 8, 688.	1.8	40
973	AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy. <i>Prostate</i> , 2019, 79, 1553-1562.	1.2	22
974	In Vivo Detection of Circulating Tumor Cells in High-Risk Non-Metastatic Prostate Cancer Patients Undergoing Radiotherapy. <i>Cancers</i> , 2019, 11, 933.	1.7	18
975	AR-V7 expression in circulating tumor cells as a potential prognostic marker in metastatic hormone-sensitive prostate cancer. <i>Acta Oncologica</i> , 2019, 58, 1660-1664.	0.8	7
976	An exploratory retrospective multicenter study of prognostic factors in mCRPC patients undergoing enzalutamide treatment: Focus on early PSA decline and kinetics at time of progression. <i>Prostate</i> , 2019, 79, 1457-1465.	1.2	21
977	Recent advances in microfluidic methods in cancer liquid biopsy. <i>Biomicrofluidics</i> , 2019, 13, 041503.	1.2	39
978	Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience. <i>Cancers</i> , 2019, 11, 980.	1.7	18
979	Molecular Underpinnings Governing Genetic Complexity of ETS-Fusion-Negative Prostate Cancer. <i>Trends in Molecular Medicine</i> , 2019, 25, 1024-1038.	3.5	10
980	Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. <i>Scientific Reports</i> , 2019, 9, 10739.	1.6	69

#	ARTICLE	IF	CITATIONS
981	Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer. <i>Translational Research</i> , 2019, 212, 89-103.	2.2	47
982	GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1811-1821.	1.9	11
983	Precision oncology in Latin America: current situation, challenges and perspectives. <i>Ecancermedicalscience</i> , 2019, 13, 920.	0.6	11
984	New Trisulfated Steroids from the Vietnamese Marine Sponge <i>Halichondria vansoesti</i> and Their PSA Expression and Glucose Uptake Inhibitory Activities. <i>Marine Drugs</i> , 2019, 17, 445.	2.2	9
985	Toward Microfluidic Label-Free Isolation and Enumeration of Circulating Tumor Cells from Blood Samples. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2019, 95, 1085-1095.	1.1	18
986	A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer. <i>Prostate</i> , 2019, 79, 1597-1603.	1.2	18
987	Biomarkers for Diagnosis and Prognosis of Prostate Cancer. , 2019, , .		8
988	<p></p>Current status of liquid biopsies for the detection and management of prostate cancer</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 5271-5291.	0.9	47
989	<p></p>Androgen upregulates the palmitoylation of eIF3L in human prostate LNCaP cells</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4451-4459.	1.0	10
990	Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide. <i>Prostate</i> , 2019, 79, 1211-1220.	1.2	17
991	A Novel FGFR3 Splice Variant Preferentially Expressed in African American Prostate Cancer Drives Aggressive Phenotypes and Docetaxel Resistance. <i>Molecular Cancer Research</i> , 2019, 17, 2115-2125.	1.5	9
992	Phenotypic Profiling of Circulating Tumor Cells in Metastatic Prostate Cancer Patients Using Nanoparticle-Mediated Ranking. <i>Analytical Chemistry</i> , 2019, 91, 9348-9355.	3.2	29
993	Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-resistant Prostate Cancer: Single Center Experience. <i>Anticancer Research</i> , 2019, 39, 3901-3908.	0.5	14
994	Circulating Tumor Cell-Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer. <i>Neoplasia</i> , 2019, 21, 802-809.	2.3	32
995	Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients. <i>Prostate</i> , 2019, 79, 1767-1776.	1.2	51
996	Translational Application of Circulating DNA in Oncology: Review of the Last Decades Achievements. <i>Cells</i> , 2019, 8, 1251.	1.8	53
997	Enzalutamide in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 1493-1495.	13.9	4
998	<i>ANO7</i> rs77559646 Is Associated With First-line Docetaxel Treatment Response in Metastatic Castration-resistant Prostate Cancer. <i>Anticancer Research</i> , 2019, 39, 5353-5359.	0.5	7



#	ARTICLE	IF	CITATIONS
999	Androgen Receptor Modulation Optimized for Responseâ€”Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7â€”expressing Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 76, 843-851.	0.9	36
1000	Apalutamide Sensitizes Prostate Cancer to Ionizing Radiation via Inhibition of Non-Homologous End-Joining DNA Repair. <i>Cancers</i> , 2019, 11, 1593.	1.7	21
1001	Incidence of androgen receptor and androgen receptor variant 7 coexpression in prostate cancer. <i>Prostate</i> , 2019, 79, 1811-1822.	1.2	7
1002	Plasma Androgen Receptor in Prostate Cancer. <i>Cancers</i> , 2019, 11, 1719.	1.7	13
1003	&lt;p&gt;Darolutamide For Castration-Resistant Prostate Cancer&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 8769-8777.	1.0	24
1005	Successful Targeting of the Warburg Effect in Prostate Cancer by Glucose-Conjugated 1,4-Naphthoquinones. <i>Cancers</i> , 2019, 11, 1690.	1.7	34
1006	Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer Patients. <i>European Urology Oncology</i> , 2021, 4, 609-617.	2.6	16
1007	Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted Therapies. <i>ACS Pharmacology and Translational Science</i> , 2019, 2, 453-467.	2.5	20
1008	Effective targeting of RNA polymerase I in treatmentâ€”resistant prostate cancer. <i>Prostate</i> , 2019, 79, 1837-1851.	1.2	21
1009	Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3 <sup>12</sup> Exert Potent Therapeutic Effects in Castration-/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo. <i>Cancers</i> , 2019, 11, 1637.	1.7	20
1010	Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling. <i>Cancer Medicine</i> , 2019, 8, 7322-7329.	1.3	46
1011	Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel. <i>Cancers</i> , 2019, 11, 1212.	1.7	21
1012	CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation. <i>Cancer Discovery</i> , 2019, 9, 1538-1555.	7.7	88
1013	Androgen receptor splicing variant 7: Beyond being a constitutively active variant. <i>Life Sciences</i> , 2019, 234, 116768.	2.0	17
1014	Liquid Biopsy in Oligometastatic Prostate Cancerâ€”A Biologist's Point of View. <i>Frontiers in Oncology</i> , 2019, 9, 775.	1.3	21
1015	Profiling Circulating Tumour Cells for Clinical Applications. , 0, , .		0
1016	Role of Androgen Receptor in Prostate Cancer: A Review. <i>World Journal of Men's Health</i> , 2019, 37, 288.	1.7	270
1017	Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 858.	1.3	125

#	ARTICLE	IF	CITATIONS
1018	A high-resolution 3D epigenomic map reveals insights into the creation of the prostate cancer transcriptome. <i>Nature Communications</i> , 2019, 10, 4154.	5.8	87
1019	TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer. <i>PLoS ONE</i> , 2019, 14, e0213488.	1.1	20
1020	Loss of Fibroblast-Dependent Androgen Receptor Activation in Prostate Cancer Cells is Involved in the Mechanism of Acquired Resistance to Castration. <i>Journal of Clinical Medicine</i> , 2019, 8, 1379.	1.0	4
1021	Detection of Androgen Receptor Variant 7 (ARV7) mRNA Levels in EpCAM-Enriched CTC Fractions for Monitoring Response to Androgen Targeting Therapies in Prostate Cancer. <i>Cells</i> , 2019, 8, 1067.	1.8	18
1023	Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2506-2518.	13.9	403
1024	Aberrant KIF20A Expression Is Associated with Adverse Clinical Outcome and Promotes Tumor Progression in Prostate Cancer. <i>Disease Markers</i> , 2019, 2019, 1-10.	0.6	31
1026	Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 801.	1.3	205
1027	Orally Bioavailable Androgen Receptor Degradar, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6764-6780.	3.2	46
1028	Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2019, 121, 48-54.	1.3	20
1029	Towards precision oncology in advanced prostate cancer. <i>Nature Reviews Urology</i> , 2019, 16, 645-654.	1.9	156
1030	Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients. <i>Cancers</i> , 2019, 11, 1365.	1.7	24
1031	Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis. <i>Oncogene</i> , 2019, 38, 3696-3709.	2.6	26
1032	Creating a potential diagnostic for prostate cancer risk stratification (InformMDx <sup>®</sup> , <sup>®</sup> ) by translating novel scientific discoveries concerning cAMP degrading phosphodiesterase-4D7 (PDE4D7). <i>Clinical Science</i> , 2019, 133, 269-286.	1.8	8
1033	Gene therapy for castration-resistant prostate cancer cells using JC polyomavirus-like particles packaged with a PSA promoter driven-suicide gene. <i>Cancer Gene Therapy</i> , 2019, 26, 208-215.	2.2	22
1034	Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells. <i>Prostate</i> , 2019, 79, 667-677.	1.2	41
1035	Treatment of Advanced Prostate Cancer. <i>Annual Review of Medicine</i> , 2019, 70, 479-499.	5.0	417
1036	Current strategies for targeting the activity of androgen receptor variants. <i>Asian Journal of Urology</i> , 2019, 6, 42-49.	0.5	18
1037	The Expression of Androgen Receptor and Its Variants in Human Prostate Cancer Tissue according to Disease Status, and Its Prognostic Significance. <i>World Journal of Men's Health</i> , 2019, 37, 68.	1.7	4

#	ARTICLE	IF	CITATIONS
1038	Urine-based liquid biopsy: non-invasive and sensitive AR-V7 detection in urinary EVs from patients with prostate cancer. <i>Lab on A Chip</i> , 2019, 19, 87-97.	3.1	56
1039	Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4624-4633.	3.2	21
1040	Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines. <i>European Journal of Medicinal Chemistry</i> , 2019, 179, 483-492.	2.6	13
1041	Evolution of the Liquid Biopsy in Metastatic Prostate Cancer. <i>Urology</i> , 2019, 132, 1-9.	0.5	13
1042	Biomarkers of Prostate Cancer. , 2019, , 125-132.		0
1043	Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	36
1044	Incorporating liquid biopsies into treatment decision-making: obstacles and possibilities. <i>Drug Discovery Today</i> , 2019, 24, 1715-1719.	3.2	10
1045	The Pros and Cons of Incorporating Transcriptomics in the Age of Precision Oncology. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1016-1022.	3.0	8
1046	AR variants: lost in translation to clinical practice?. <i>Nature Reviews Urology</i> , 2019, 16, 451-452.	1.9	3
1047	AR splice variants in circulating tumor cells of patients with castration-resistant prostate cancer: relation with outcome to cabazitaxel. <i>Molecular Oncology</i> , 2019, 13, 1795-1807.	2.1	23
1049	Lipid Metabolism and Endocrine Resistance in Prostate Cancer, and New Opportunities for Therapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2626.	1.8	80
1050	Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2019, 116, 158-168.	1.3	29
1051	Targeting Nuclear Receptors with PROTAC degraders. <i>Molecular and Cellular Endocrinology</i> , 2019, 493, 110452.	1.6	58
1052	Circulating tumor cells and their role in prostate cancer. <i>Asian Journal of Andrology</i> , 2019, 21, 24.	0.8	13
1053	Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study. <i>Investigative and Clinical Urology</i> , 2019, 60, 195.	1.0	5
1054	BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAK. <i>Molecular Cancer Research</i> , 2019, 17, 1627-1638.	1.5	37
1055	Androgen receptor (AR) splice variant 7 and full-length AR expression is associated with clinical outcome: a translational study in patients with castration-resistant prostate cancer. <i>BJU International</i> , 2019, 124, 693-700.	1.3	32
1056	Genomic correlates of clinical outcome in advanced prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 11428-11436.	3.3	839

#	ARTICLE	IF	CITATIONS
1057	Simvastatin delays castration-resistant prostate cancer metastasis and androgen receptor antagonist resistance by regulating the expression of caveolin-1. <i>International Journal of Oncology</i> , 2019, 54, 2054-2068.	1.4	11
1058	Castration-resistant prostate cancer: Androgen receptor inactivation induces telomere DNA damage, and damage response inhibition leads to cell death. <i>PLoS ONE</i> , 2019, 14, e0211090.	1.1	10
1060	Consideration of breast cancer subtype in targeting the androgen receptor. , 2019, 200, 135-147.		65
1061	Circulating oestrogen receptor mutations and splice variants in advanced prostate cancer. <i>BJU International</i> , 2019, 124, 50-56.	1.3	9
1062	Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 1436-1447.	2.8	30
1063	A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. <i>Theranostics</i> , 2019, 9, 2812-2826.	4.6	20
1064	A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities. <i>Nucleic Acids Research</i> , 2019, 47, 5634-5647.	6.5	41
1065	Differential expression of androgen receptor variants in hormone-sensitive prostate cancer xenografts, castration-resistant sublines, and patient specimens according to the treatment sequence. <i>Prostate</i> , 2019, 79, 1043-1052.	1.2	4
1066	State of the Art and Future Direction for the Analysis of Cell-Free Circulating DNA. , 2019, , 133-188.		2
1067	Comparative Analysis of AR Variant AR-V567es mRNA Detection Systems Reveals Eminent Variability and Questions the Role as a Clinical Biomarker in Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3856-3864.	3.2	17
1069	Prognostic Significance of Sites of Visceral Metastatic Disease in Prostate Cancer: A Population-based Study of 12,180 Patients. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 260-267.	0.9	17
1070	Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	1.5	8
1071	Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 76, 676-685.	0.9	62
1072	Circular RNAs and RNA Splice Variants as Biomarkers for Prognosis and Therapeutic Response in the Liquid Biopsies of Lung Cancer Patients. <i>Frontiers in Genetics</i> , 2019, 10, 390.	1.1	68
1073	A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1813.	1.8	96
1074	A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling. <i>Prostate</i> , 2019, 79, 937-948.	1.2	14
1075	Extracellular vesicles as cancer liquid biopsies: from discovery, validation, to clinical application. <i>Lab on A Chip</i> , 2019, 19, 1114-1140.	3.1	70
1076	Preclinical study using circular RNA 17 and micro RNA 181c-5p to suppress the enzalutamide-resistant prostate cancer progression. <i>Cell Death and Disease</i> , 2019, 10, 37.	2.7	74

#	ARTICLE	IF	CITATIONS
1077	A simple method to estimate prediction intervals and predictive distributions: Summarizing meta-analyses beyond means and confidence intervals. <i>Research Synthesis Methods</i> , 2019, 10, 255-266.	4.2	37
1078	Raddeanin A down-regulates androgen receptor and its splice variants in prostate cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 3656-3664.	1.6	8
1079	Liquid Biopsy in Solid Malignancy. <i>Genetic Testing and Molecular Biomarkers</i> , 2019, 23, 284-296.	0.3	13
1080	Inhibition of Autophagy Improves the Efficacy of Abiraterone for the Treatment of Prostate Cancer. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2019, 34, 181-188.	0.7	6
1081	Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer. <i>Scientific Reports</i> , 2019, 9, 4030.	1.6	54
1082	Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1120-1129.	0.8	267
1083	Splicing Factors Have an Essential Role in Prostate Cancer Progression and Androgen Receptor Signaling. <i>Biomolecules</i> , 2019, 9, 131.	1.8	36
1084	Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	1.5	23
1085	Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable ROR $\beta$ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 4716-4730.	2.9	34
1086	Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management. <i>Nature Reviews Urology</i> , 2019, 16, 302-317.	1.9	86
1087	Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond. <i>Endocrine-Related Cancer</i> , 2019, 26, R31-R52.	1.6	49
1088	Combination Targeting of the Bromodomain and Acetyltransferase Active Site of p300/CBP. <i>Biochemistry</i> , 2019, 58, 2133-2143.	1.2	30
1089	NCL1, A Highly Selective Lysine-Specific Demethylase 1 Inhibitor, Suppresses Castration-Resistant Prostate Cancer Growth via Regulation of Apoptosis and Autophagy. <i>Journal of Clinical Medicine</i> , 2019, 8, 442.	1.0	19
1090	Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers. <i>Endocrine Connections</i> , 2019, 8, R10-R26.	0.8	33
1091	Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. <i>Cancer Research</i> , 2019, 79, 2580-2592.	0.4	85
1092	Liquid biopsy and minimal residual disease – latest advances and implications for cure. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 409-424.	12.5	671
1093	Computer-Aided Discovery of Small Molecules Targeting the RNA Splicing Activity of hnRNP A1 in Castration-Resistant Prostate Cancer. <i>Molecules</i> , 2019, 24, 763.	1.7	29
1094	Development of a microfluidic platform for size-based hydrodynamic enrichment and PSMA-targeted immunomagnetic isolation of circulating tumour cells in prostate cancer. <i>Biomicrofluidics</i> , 2019, 13, 014110.	1.2	6

#	ARTICLE	IF	CITATIONS
1095	Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma. <i>European Journal of Cancer</i> , 2019, 110, 62-70.	1.3	46
1096	Biological Evolution of Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2019, 5, 147-154.	1.6	71
1097	Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: utilization of neutrophil-to-lymphocyte ratio. <i>World Journal of Urology</i> , 2019, 37, 2375-2384.	1.2	10
1098	Recent advances in extracellular vesicle research for urological cancers: From technology to application. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 342-360.	3.3	16
1099	Androgen deprivation therapy with chemotherapy or abiraterone for patients with metastatic hormone-naïve prostate cancer: a systematic review and meta-analysis. <i>Future Oncology</i> , 2019, 15, 1167-1179.	1.1	8
1100	The influence of BRCA2 mutation on localized prostate cancer. <i>Nature Reviews Urology</i> , 2019, 16, 281-290.	1.9	53
1101	Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide. <i>BioMed Research International</i> , 2019, 2019, 1-5.	0.9	25
1102	Androgen receptor variant 12 promotes migration and invasion by regulating MYLK in gastric cancer. <i>Journal of Pathology</i> , 2019, 248, 304-315.	2.1	22
1103	MiR-644a Disrupts Oncogenic Transformation and Warburg Effect by Direct Modulation of Multiple Genes of Tumor-Promoting Pathways. <i>Cancer Research</i> , 2019, 79, 1844-1856.	0.4	35
1104	TGF $\beta$ 2 receptor I inhibitor enhances response to enzalutamide in a preclinical model of advanced prostate cancer. <i>Prostate</i> , 2019, 79, 31-43.	1.2	46
1105	A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer. <i>Oncogene</i> , 2019, 38, 4977-4989.	2.6	80
1106	Detection of androgen receptor (AR) and AR-V7 in small cell prostate carcinoma: Diagnostic and therapeutic implications. <i>Asian Journal of Urology</i> , 2019, 6, 109-113.	0.5	7
1107	Prostate tumor neuroendocrine differentiation via EMT: The road less traveled. <i>Asian Journal of Urology</i> , 2019, 6, 82-90.	0.5	32
1108	Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer. <i>Cancers</i> , 2019, 11, 238.	1.7	26
1109	Alternative RNA Splicing as a Potential Major Source of Untapped Molecular Targets in Precision Oncology and Cancer Disparities. <i>Clinical Cancer Research</i> , 2019, 25, 2963-2968.	3.2	43
1110	ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. <i>Cancer Cell</i> , 2019, 35, 401-413.e6.	7.7	127
1111	Androgen receptor nuclear localization correlates with AR-V7 mRNA expression in circulating tumor cells (CTCs) from metastatic castration resistance prostate cancer patients. <i>Physical Biology</i> , 2019, 16, 036003.	0.8	13
1113	Circulating tumor cell-based or tissue biopsy-based AR-V7 detection: which provides the greatest clinical utility?. <i>Annals of Translational Medicine</i> , 2019, 7, S354-S354.	0.7	4



#	ARTICLE	IF	CITATIONS
1114	Considerations for AR-V7 testing in clinical routine practice. <i>Annals of Translational Medicine</i> , 2019, 7, S378-S378.	0.7	4
1116	Taxane-based Chemotherapy Induced Androgen Receptor Splice Variant 7 in Patients with Castration-Resistant Prostate Cancer: A Tissue-based Analysis. <i>Scientific Reports</i> , 2019, 9, 16794.	1.6	7
1117	PROTACs: great opportunities for academia and industry. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 64.	7.1	367
1118	Hormonal Therapy or Chemotherapy for Metastatic Prostate Cancer – Playing the Right CARD. <i>New England Journal of Medicine</i> , 2019, 381, 2564-2566.	13.9	5
1119	Expression pattern of androgen receptors, <i>AR-V7</i> and <i>AR-567es</i> , in circulating tumor cells and paired plasma-derived extracellular vesicles in metastatic castration resistant prostate cancer. <i>Analyst, The</i> , 2019, 144, 6671-6680.	1.7	21
1120	Characterization of a Prostate- and Prostate Cancer-Specific Circular RNA Encoded by the Androgen Receptor Gene. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 18, 916-926.	2.3	30
1121	Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer. <i>Cancer Communications</i> , 2019, 39, 76.	3.7	90
1122	Clinical implications of genetic aberrations in metastatic prostate cancer. <i>Current Opinion in Urology</i> , 2019, 29, 319-325.	0.9	0
1124	Circulating tumor cells in precision oncology: clinical applications in liquid biopsy and 3D organoid model. <i>Cancer Cell International</i> , 2019, 19, 341.	1.8	90
1125	Targeting the androgen receptor and overcoming resistance in prostate cancer. <i>Current Opinion in Oncology</i> , 2019, 31, 175-182.	1.1	36
1126	Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 399-406.	0.6	34
1127	Androgen receptor variant 7 (AR-V7) in sequencing therapeutic agents for castratrion resistant prostate cancer. <i>Medicine (United States)</i> , 2019, 98, e15608.	0.4	33
1128	GABARAPL1 Promotes AR+ Prostate Cancer Growth by Increasing FL-AR/AR-V Transcription Activity and Nuclear Translocation. <i>Frontiers in Oncology</i> , 2019, 9, 1254.	1.3	10
1129	mRNA expressions of androgen receptor and its variants in matched hormone-sensitive and castration-resistant prostate cancer. <i>Scandinavian Journal of Urology</i> , 2019, 53, 365-371.	0.6	5
1130	Interaction between androgen receptor and coregulator SLIRP is regulated by Ack1 tyrosine kinase and androgen. <i>Scientific Reports</i> , 2019, 9, 18637.	1.6	7
1131	Inositol polyphosphate 4-phosphatase type II regulation of androgen receptor activity. <i>Oncogene</i> , 2019, 38, 1121-1135.	2.6	10
1132	Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 52-63.	3.2	44
1133	Immunotherapy for Prostate Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019, 9, a030627.	2.9	41



#	ARTICLE	IF	CITATIONS
1134	<i>TP53</i> Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 1766-1773.	3.2	117
1135	Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management. <i>Methods in Molecular Biology</i> , 2019, 1909, 47-73.	0.4	19
1137	Are liquid biopsies ready for primetime?. <i>Cancer</i> , 2019, 125, 834-837.	2.0	2
1138	Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 631-640.	3.3	198
1139	Health Care Delivery for Metastatic Hormone-sensitive Prostate Cancer Across the Globe. <i>European Urology Focus</i> , 2019, 5, 155-158.	1.6	13
1140	Circulating Tumor Cells in Prostate Cancer: From Discovery to Clinical Utility. <i>Clinical Chemistry</i> , 2019, 65, 87-99.	1.5	109
1141	Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies. <i>Nature Reviews Urology</i> , 2019, 16, 7-22.	1.9	39
1142	Targeting AR-Beclin 1 complex-modulated growth factor signaling increases the antiandrogen Enzalutamide sensitivity to better suppress the castration-resistant prostate cancer growth. <i>Cancer Letters</i> , 2019, 442, 483-490.	3.2	10
1143	Circulating Tumor Cells as Surrogate Biomarker for Overall Survival in Metastatic Prostate Cancer. , 2019, , 565-572.		0
1144	Detection of CTC Clusters and a Dedifferentiated RNA Expression Survival Signature in Prostate Cancer. <i>Advanced Science</i> , 2019, 6, 1801254.	5.6	30
1145	Prognostic and Predictive Role of Circulating Tumor Cells. , 2019, , 181-190.		1
1146	Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 163-172.	0.9	24
1147	Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 171-182.	2.0	93
1148	Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era. <i>Cancer Treatment Reviews</i> , 2019, 74, 35-42.	3.4	30
1149	Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells. <i>Prostate</i> , 2019, 79, 206-214.	1.2	18
1150	Prostate Cancer Research at the Crossroads. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019, 9, a036277.	2.9	3
1151	Systemic Treatment of Castration-Resistant Metastatic Prostate Cancer. , 2019, , 1-14.		0
1152	Liquid biopsies. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 219-232.	1.5	117

#	ARTICLE	IF	CITATIONS
1153	Steroid Hormone and Nuclear Receptor Signaling Pathways. , 2019, , 183-197.		0
1154	Plasma DNA Analysis in Prostate Cancer: Opportunities for Improving Clinical Management. Clinical Chemistry, 2019, 65, 100-107.	1.5	16
1155	Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration-sensitive prostate cancer. BJU International, 2019, 124, 258-267.	1.3	16
1156	Pathological Assessment of Prostate Cancer. , 2019, , 1-19.		0
1157	Metastatic prostate cancer remains incurable, why?. Asian Journal of Urology, 2019, 6, 26-41.	0.5	103
1158	Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY. Clinical Cancer Research, 2019, 25, 1880-1888.	3.2	92
1159	A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer. Oncogene, 2019, 38, 1136-1150.	2.6	15
1160	Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9A® led to increase docetaxel sensitivity via suppressing the p21 expression. Cancer Letters, 2019, 444, 35-44.	3.2	21
1161	Expression pattern of androgen receptor and AR-V7 in androgen-deprivation therapy-naïve salivary duct carcinomas. Human Pathology, 2019, 84, 173-182.	1.1	15
1162	Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. European Urology, 2019, 75, 88-99.	0.9	333
1164	Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts. European Urology, 2020, 77, 144-155.	0.9	46
1165	Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer. European Urology, 2020, 77, 14-21.	0.9	51
1166	Androgen receptor in breast cancer: A wolf in sheep's clothing? A lesson from prostate cancer.. Seminars in Cancer Biology, 2020, 60, 132-137.	4.3	38
1167	Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients. European Urology Oncology, 2020, 3, 119-127.	2.6	20
1168	Clinical utility of emerging biomarkers in prostate cancer liquid biopsies. Expert Review of Molecular Diagnostics, 2020, 20, 219-230.	1.5	36
1169	Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, 1-10.	0.9	52
1170	Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors. Molecular Cancer Therapeutics, 2020, 19, 231-246.	1.9	16
1171	Targeting mRNA processing as an anticancer strategy. Nature Reviews Drug Discovery, 2020, 19, 112-129.	21.5	131

#	ARTICLE	IF	CITATIONS
1172	An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 207-217.	1.5	5
1173	Sex Hormones and Prostate Cancer. <i>Annual Review of Medicine</i> , 2020, 71, 33-45.	5.0	58
1174	Nanostructured Substrates for Detection and Characterization of Circulating Rare Cells: From Materials Research to Clinical Applications. <i>Advanced Materials</i> , 2020, 32, e1903663.	11.1	66
1175	Physiological and pathological functions of prostasomes: From basic research to clinical application. , 2020, , 101-121.		4
1176	Tumor Liquid Biopsies. <i>Recent Results in Cancer Research</i> , 2020, , .	1.8	11
1178	Practical Molecular Testing in a Clinical Genitourinary Service. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 277-289.	1.2	5
1179	GPRC5A facilitates cell proliferation through cell cycle regulation and correlates with bone metastasis in prostate cancer. <i>International Journal of Cancer</i> , 2020, 146, 1369-1382.	2.3	33
1180	Syntaxin 6â€mediated exosome secretion regulates enzalutamide resistance in prostate cancer. <i>Molecular Carcinogenesis</i> , 2020, 59, 62-72.	1.3	41
1181	Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 225-239.	1.5	18
1182	Anti-androgen hormonal therapy for cancer and other diseases. <i>European Journal of Pharmacology</i> , 2020, 866, 172783.	1.7	38
1183	The role of adrenal derived androgens in castration resistant prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2020, 197, 105506.	1.2	37
1184	Targets, pitfalls and reference materials for liquid biopsy tests in cancer diagnostics. <i>Molecular Aspects of Medicine</i> , 2020, 72, 100828.	2.7	104
1185	Transcriptionally Active Androgen Receptor Splice Variants Promote Hepatocellular Carcinoma Progression. <i>Cancer Research</i> , 2020, 80, 561-575.	0.4	27
1186	Biomarkers for prostate cancer: prostate-specific antigen and beyond. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 326-339.	1.4	123
1187	Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 69-76.e4.	0.9	11
1188	Gene Expression Alterations during Development of Castration-Resistant Prostate Cancer Are Detected in Circulating Tumor Cells. <i>Cancers</i> , 2020, 12, 39.	1.7	17
1189	Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment. <i>Neoplasia</i> , 2020, 22, 111-119.	2.3	101
1190	Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer. <i>EBioMedicine</i> , 2020, 51, 102547.	2.7	71

#	ARTICLE	IF	CITATIONS
1191	Combined androgen deprivation therapy in recurrent androgen-receptor-positive salivary duct carcinoma—A case report and review of the literature. <i>Journal of Stomatology, Oral and Maxillofacial Surgery</i> , 2020, 121, 599-603.	0.5	2
1192	Identification of a novel C-terminally truncated estrogen receptor $\beta$ variant (ER $\beta$ 34) with constitutive transactivation and estrogen receptor antagonist resistance. <i>Molecular and Cellular Endocrinology</i> , 2020, 503, 110693.	1.6	4
1193	Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer. <i>Prostate</i> , 2020, 80, 256-266.	1.2	22
1194	PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study. <i>Prostate</i> , 2020, 80, 99-108.	1.2	45
1195	Lipogenic effects of androgen signaling in normal and malignant prostate. <i>Asian Journal of Urology</i> , 2020, 7, 258-270.	0.5	27
1196	The Genomic and Molecular Pathology of Prostate Cancer: Clinical Implications for Diagnosis, Prognosis, and Therapy. <i>Advances in Anatomic Pathology</i> , 2020, 27, 11-19.	2.4	12
1198	Understanding aberrant RNA splicing to facilitate cancer diagnosis and therapy. <i>Oncogene</i> , 2020, 39, 2231-2242.	2.6	53
1199	Extracellular vesicles in urological malignancies: an update. <i>Nature Reviews Urology</i> , 2020, 17, 11-27.	1.9	79
1200	Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2020, 80, 113-132.	1.2	25
1201	Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer. <i>Carcinogenesis</i> , 2020, 41, 1145-1157.	1.3	37
1202	Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by antiandrogens. <i>Prostate</i> , 2020, 80, 214-224.	1.2	10
1203	P5 eHealth: An Agenda for the Health Technologies of the Future. , 2020, , .		21
1204	Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020, 12, 8.	1.7	18
1205	Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope. <i>Cancers</i> , 2020, 12, 51.	1.7	37
1206	Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget's disease. <i>Cancer Medicine</i> , 2020, 9, 1441-1450.	1.3	22
1207	Circulating Tumor Cells Expressing the Prostate Specific Membrane Antigen (PSMA) Indicate Worse Outcome in Primary, Non-Metastatic Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1658.	1.3	17
1208	Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide. <i>Frontiers in Oncology</i> , 2020, 10, 567809.	1.3	5
1209	A Direct Comparison between the Lateral Magnetophoretic Microseparator and AdnaTest for Isolating Prostate Circulating Tumor Cells. <i>Micromachines</i> , 2020, 11, 870.	1.4	7

#	ARTICLE	IF	CITATIONS
1210	MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer. <i>Oncogene</i> , 2020, 39, 7209-7223.	2.6	28
1211	Protein phosphatase 1 in tumorigenesis: is it worth a closer look?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188433.	3.3	20
1212	The miR-361-3p increases enzalutamide (Enz) sensitivity via targeting the ARv7 and MKNK2 to better suppress the Enz-resistant prostate cancer. <i>Cell Death and Disease</i> , 2020, 11, 807.	2.7	26
1213	Genomic Instability in Circulating Tumor Cells. <i>Cancers</i> , 2020, 12, 3001.	1.7	8
1214	The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115712.	1.4	16
1215	ARe we there yet? Understanding androgen receptor signaling in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 47.	2.3	57
1216	Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. <i>Oncogene</i> , 2020, 39, 6935-6949.	2.6	60
1217	Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving <sup>177</sup> Lu-PSMA-617 Radioligand Therapy. <i>Theranostics</i> , 2020, 10, 7645-7655.	4.6	23
1218	Rapamycin inhibits AR signaling pathway in prostate cancer by interacting with the FK1 domain of FKBP51. <i>Biochemistry and Biophysics Reports</i> , 2020, 23, 100778.	0.7	5
1219	Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2020, 24, 100193.	0.7	2
1220	Magnetic Ranking Cytometry: Profiling Rare Cells at the Single-Cell Level. <i>Accounts of Chemical Research</i> , 2020, 53, 1445-1457.	7.6	18
1221	Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. <i>Cancer Cell</i> , 2020, 38, 279-296.e9.	7.7	135
1222	Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes. <i>Molecular Cell</i> , 2020, 79, 812-823.e4.	4.5	94
1223	Predictors of resistance to abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer in post-docetaxel setting: a single-center cohort study. <i>Anti-Cancer Drugs</i> , 2020, 31, 742-746.	0.7	0
1224	Phenotypic plasticity and lineage switching in prostate cancer. , 2020, , 591-615.		3
1225	Evaluation of [ <sup>131</sup> I]- and [ <sup>177</sup> Lu]Lu-DTPA-A11 Minibody for Radioimmunotherapy in a Preclinical Model of PSCA-Expressing Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2020, 22, 1380-1391.	1.3	10
1226	Current and Emerging Bone-Targeted Therapies for The Treatment of Bone Metastases From Solid Tumors. , 2020, , 403-420.		0
1227	Accelerating precision medicine in metastatic prostate cancer. <i>Nature Cancer</i> , 2020, 1, 1041-1053.	5.7	45

#	ARTICLE	IF	CITATIONS
1228	Quadruple-negative breast cancer: novel implications for a new disease. <i>Breast Cancer Research</i> , 2020, 22, 127.	2.2	17
1229	Re: Maha Hussain, Joaquin Mateo, Karim Fizazi, et al. Survival with Olaparib in Metastatic Castration-resistant Prostate Cancer. <i>N Engl J Med</i> . In press. <a href="https://doi.org/10.1056/NEJMoa2022485">https://doi.org/10.1056/NEJMoa2022485</a> . <i>European Urology Oncology</i> , 2020, 3, 806.	2.6	2
1230	Inhibition of Serum Response Factor Improves Response to Enzalutamide in Prostate Cancer. <i>Cancers</i> , 2020, 12, 3540.	1.7	4
1231	lncRNA and Mechanisms of Drug Resistance in Cancers of the Genitourinary System. <i>Cancers</i> , 2020, 12, 2148.	1.7	27
1232	Identification of long non-coding RNAs in advanced prostate cancer associated with androgen receptor splicing factors. <i>Communications Biology</i> , 2020, 3, 393.	2.0	34
1233	A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5338-5347.	3.2	76
1234	AR-V7 as a Biomarker for Resistance to Treatment with Abiraterone/Enzalutamide in Three Latin American Countries: A Hypothetical Cost-Saving Analysis. <i>Oncologist</i> , 2020, 25, e1990-e1995.	1.9	4
1235	Identification of Potential Key Genes and Pathways in Enzalutamide-Resistant Prostate Cancer Cell Lines: A Bioinformatics Analysis with Data from the Gene Expression Omnibus (GEO) Database. <i>BioMed Research International</i> , 2020, 2020, 1-12.	0.9	4
1236	Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer. <i>Molecular Oncology</i> , 2020, 14, 2455-2470.	2.1	31
1237	Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer. <i>Cancers</i> , 2020, 12, 2092.	1.7	14
1238	An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer. <i>Diagnostics</i> , 2020, 10, 549.	1.3	34
1239	Coordinated AR and microRNA regulation in prostate cancer. <i>Asian Journal of Urology</i> , 2020, 7, 233-250.	0.5	14
1240	Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies. <i>Journal of Hematology and Oncology</i> , 2020, 13, 103.	6.9	69
1241	Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy. <i>Molecular Pharmaceutics</i> , 2020, 17, 3392-3402.	2.3	20
1242	Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer. <i>Cell Death and Disease</i> , 2020, 11, 942.	2.7	10
1243	Hormonal control of cancer: an outdated topic?. <i>ESMO Open</i> , 2020, 5, e000769.	2.0	0
1244	Noninvasive biomarkers to guide intervention: toward personalized patient management in prostate cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 383-400.	0.4	4
1245	Liquid Biopsy to Detect Circulating Tumor Cells: Is It Ready for a Value Proposition in Laboratory Medicine?. <i>Journal of applied laboratory medicine</i> , The, 2020, 5, 1027-1037.	0.6	3

#	ARTICLE	IF	CITATIONS
1246	Omics Derived Biomarkers and Novel Drug Targets for Improved Intervention in Advanced Prostate Cancer. <i>Diagnostics</i> , 2020, 10, 658.	1.3	7
1247	Genetic testing for the clinician in prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 933-946.	1.5	4
1248	Comparative performance of different methods for circulating tumor cell enrichment in metastatic breast cancer patients. <i>PLoS ONE</i> , 2020, 15, e0237308.	1.1	42
1249	The clinical benefit of sequential therapy with androgen receptor axis-targeted agents alone in patients with castration-resistant prostate cancer: A propensity score-matched comparison study. <i>Prostate</i> , 2020, 80, 1373-1380.	1.2	0
1250	Androgen Receptor in Breast Cancer: From Bench to Bedside. <i>Frontiers in Endocrinology</i> , 2020, 11, 573.	1.5	31
1251	Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5847.	1.8	14
1252	Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer. <i>Nature Genetics</i> , 2020, 52, 1011-1017.	9.4	78
1253	Exploring Spatial-Temporal Changes in <sup>18</sup> F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide. <i>Journal of Clinical Oncology</i> , 2020, 38, 3662-3671.	0.8	16
1254	Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 193.	7.1	66
1255	Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer. <i>Oncogene</i> , 2020, 39, 6556-6571.	2.6	29
1256	ACK1-AR and AR-HOXB13 signaling axes: epigenetic regulation of lethal prostate cancers. <i>NAR Cancer</i> , 2020, 2, zcaa018.	1.6	22
1257	Fundamentals of liquid biopsies in metastatic prostate cancer: from characterization to stratification. <i>Current Opinion in Oncology</i> , 2020, 32, 527-534.	1.1	5
1259	YB-1 variant and androgen receptor axis-targeted agents in metastatic castration-resistant prostate cancer patients. <i>Pharmacogenomics</i> , 2020, 21, 919-928.	0.6	3
1260	Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer. <i>Nature Communications</i> , 2020, 11, 4153.	5.8	62
1261	A Multi-Analyte Approach for Improved Sensitivity of Liquid Biopsies in Prostate Cancer. <i>Cancers</i> , 2020, 12, 2247.	1.7	18
1262	Circulating Tumor Cells: From the Laboratory to the Cancer Clinic. <i>Cancers</i> , 2020, 12, 2361.	1.7	22
1263	Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 562504.	1.3	10
1264	Position of Circulating Tumor Cells in the Clinical Routine in Prostate Cancer and Breast Cancer Patients. <i>Cancers</i> , 2020, 12, 3782.	1.7	7



#	ARTICLE	IF	CITATIONS
1265	Targeting therapy-resistant prostate cancer via a direct inhibitor of the human heat shock transcription factor 1. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	36
1266	Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications. <i>Cells</i> , 2020, 9, 2653.	1.8	98
1267	Clinical implications of genomic evaluations for prostate cancer risk stratification, screening, and treatment: a narrative review. <i>Prostate International</i> , 2020, 8, 99-106.	1.2	16
1268	Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1285-1301.	1.5	42
1269	The Role of Crosstalk between AR3 and E2F1 in Drug Resistance in Prostate Cancer Cells. <i>Cells</i> , 2020, 9, 1094.	1.8	9
1270	Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer. <i>Asian Journal of Urology</i> , 2020, 7, 271-283.	0.5	17
1271	Predictive Biomarkers in Prostate Cancer: Is It Time To Go "All In" on Liquid Biopsies?. <i>European Urology</i> , 2020, 78, 181-183.	0.9	3
1272	Strategies for enrichment of circulating tumor cells. <i>Translational Cancer Research</i> , 2020, 9, 2012-2025.	0.4	21
1273	Challenges, applications and future directions of precision medicine in prostate cancer – the role of organoids and patient-derived xenografts. <i>BJU International</i> , 2020, 126, 65-72.	1.3	9
1274	In Situ Hybridization Protocols. <i>Methods in Molecular Biology</i> , 2020, , .	0.4	5
1275	The characteristics of androgen receptor splice variant 7 in the treatment of hormonal sensitive prostate cancer: a systematic review and meta-analysis. <i>Cancer Cell International</i> , 2020, 20, 149.	1.8	10
1276	Clinical outcomes of abiraterone acetate and predictors of its treatment duration in metastatic castration-resistant prostate cancer: Real-world experience in the Southeast Asian cohort. <i>Cancer Medicine</i> , 2020, 9, 4613-4621.	1.3	4
1277	PIM-1 Is Overexpressed at a High Frequency in Circulating Tumor Cells from Metastatic Castration-Resistant Prostate Cancer Patients. <i>Cancers</i> , 2020, 12, 1188.	1.7	14
1278	Inspired by Sea Urchins: Warburg Effect Mediated Selectivity of Novel Synthetic Non-Glycoside 1,4-Naphthoquinone-6S-Glucose Conjugates in Prostate Cancer. <i>Marine Drugs</i> , 2020, 18, 251.	2.2	23
1279	The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer. <i>Nature Communications</i> , 2020, 11, 2689.	5.8	41
1280	Liquid Biopsy Strategies to Distinguish Progression from Pseudoprogression and Radiation Necrosis in Glioblastomas. <i>Advanced Biology</i> , 2020, 4, 2000029.	3.0	12
1281	Emerging Subtypes and New Treatments for Castration-Resistant Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e319-e332.	1.8	3
1282	Blood platelet volume predicts treatment-specific outcomes of metastatic castration-resistant prostate cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1695-1703.	1.0	3

#	ARTICLE	IF	CITATIONS
1283	Clinical Theragnostic Potential of Diverse miRNA Expressions in Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020, 12, 1199.	1.7	20
1284	The association between androgen receptor splice variant 7 status and prognosis of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis. <i>Andrologia</i> , 2020, 52, e13642.	1.0	2
1285	Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study. <i>Clinical Chemistry</i> , 2020, 66, 842-851.	1.5	25
1286	When Less Is More: Specific Capture and Analysis of Tumor Exosomes in Plasma Increases the Sensitivity of Liquid Biopsy for Comprehensive Detection of Multiple Androgen Receptor Phenotypes in Advanced Prostate Cancer Patients. <i>Biomedicines</i> , 2020, 8, 131.	1.4	33
1287	Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer. <i>European Urology</i> , 2020, 78, 173-180.	0.9	45
1288	Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 258-267.e1.	0.9	11
1289	Advanced Prostate Cancer: Treatment Advances and Future Directions. <i>Trends in Cancer</i> , 2020, 6, 702-715.	3.8	122
1290	Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer. <i>American Journal of Surgical Pathology</i> , 2020, 44, e15-e29.	2.1	40
1291	p300-Mediated Acetylation of Histone Demethylase JMJD1A Prevents Its Degradation by Ubiquitin Ligase STUB1 and Enhances Its Activity in Prostate Cancer. <i>Cancer Research</i> , 2020, 80, 3074-3087.	0.4	36
1292	Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer. <i>Prostate</i> , 2020, 80, 926-937.	1.2	3
1293	The role of taxane-based chemotherapy in the treatment of prostate cancer. <i>Current Opinion in Urology</i> , 2020, 30, 527-533.	0.9	5
1294	Cell-Free DNA Alterations in the <i>AR</i> Enhancer and Locus Predict Resistance to AR-Directed Therapy in Patients With Metastatic Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 680-713.	1.5	20
1295	Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 629-638.	1.1	4
1296	Clinical Applications of Molecular Biomarkers in Prostate Cancer. <i>Cancers</i> , 2020, 12, 1550.	1.7	21
1297	Novel small-molecule LG1836 inhibits the in vivo growth of castration-resistant prostate cancer. <i>Prostate</i> , 2020, 80, 993-1005.	1.2	2
1298	Urupocidin C: a new marine guanidine alkaloid which selectively kills prostate cancer cells via mitochondria targeting. <i>Scientific Reports</i> , 2020, 10, 9764.	1.6	18
1299	RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer. <i>Prostate</i> , 2020, 80, 799-810.	1.2	7
1300	Early Chemotherapy in Metastatic Prostate Cancer Improves Survival: a Quick Note to Surgical Colleagues. <i>Indian Journal of Surgery</i> , 2020, 82, 1206-1211.	0.2	1

#	ARTICLE	IF	CITATIONS
1301	High Content Screening Using New U2OS Reporter Cell Models Identifies Harmol Hydrochloride as a Selective and Competitive Antagonist of the Androgen Receptor. <i>Cells</i> , 2020, 9, 1469.	1.8	11
1302	Cellular rewiring in lethal prostate cancer: the architect of drug resistance. <i>Nature Reviews Urology</i> , 2020, 17, 292-307.	1.9	59
1303	Functions and mechanisms of circular RNAs in cancer radiotherapy and chemotherapy resistance. <i>Molecular Cancer</i> , 2020, 19, 58.	7.9	124
1304	Inhibition of the erythropoietin-producing receptor EPHB4 antagonizes androgen receptor overexpression and reduces enzalutamide resistance. <i>Journal of Biological Chemistry</i> , 2020, 295, 5470-5483.	1.6	7
1305	Tracking cancer progression: from circulating tumor cells to metastasis. <i>Genome Medicine</i> , 2020, 12, 31.	3.6	201
1306	Cabazitaxel in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 1286-1286.	13.9	5
1307	A Modified Vaccine against Smallpox. <i>New England Journal of Medicine</i> , 2020, 382, 1285-1286.	13.9	0
1308	Exosomes in Prostate Cancer Diagnosis, Prognosis and Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2118.	1.8	79
1309	Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1205-1212.	1.3	24
1310	Antitumor Activity of the IGF-1/IGF-2 Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1059-1069.	1.9	12
1311	KLF5 Is Crucial for Androgen-AR Signaling to Transactivate Genes and Promote Cell Proliferation in Prostate Cancer Cells. <i>Cancers</i> , 2020, 12, 748.	1.7	14
1312	Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLC $\beta$ /PKC $\beta$ Signaling Pathway. <i>Frontiers in Oncology</i> , 2020, 10, 75.	1.3	1
1313	A Novel, Circulating Tumor Cell Enrichment Method Reduces ARv7 False Positivity in Patients with Castration-Resistant Prostate Cancer. <i>Diagnostics</i> , 2020, 10, 151.	1.3	2
1314	Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy. <i>Theranostics</i> , 2020, 10, 3366-3381.	4.6	50
1315	Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2020, 31, 1119-1134.	0.6	485
1316	Androgen receptor variants: RNA-based mechanisms and therapeutic targets. <i>Human Molecular Genetics</i> , 2020, 29, R19-R26.	1.4	14
1317	Immunotherapy in Prostate Cancer. <i>Cancers</i> , 2020, 12, 1752.	1.7	58
1318	Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer. <i>Cells</i> , 2020, 9, 1495.	1.8	8

#	ARTICLE	IF	CITATIONS
1319	Orphan nuclear receptor ROR $\beta$ confers doxorubicin resistance in prostate cancer. <i>Cell Biology International</i> , 2020, 44, 2170-2176.	1.4	10
1320	The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer. <i>Trials</i> , 2020, 21, 579.	0.7	16
1321	Dynamics of Cellular Plasticity in Prostate Cancer Progression. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 130.	1.6	22
1322	Role of the neutrophil/lymphocyte ratio in patients with metastatic castration-resistant prostate cancer treated first-line with abiraterone. <i>Actas Urológicas Españolas (English Edition)</i> , 2020, 44, 164-171.	0.2	0
1323	Targeting castration-resistant prostate cancer with a novel ROR $\beta$ antagonist elaiophylin. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 2313-2322.	5.7	20
1324	Antibody selection influences the detection of AR-V7 in primary prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2020, 24, 100186.	0.7	10
1325	Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 220-231.	2.0	39
1326	Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 507-516.	2.0	10
1327	Androgen receptor variant-driven prostate cancer II: advances in clinical investigation. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 367-380.	2.0	22
1328	Discovery of drugs that directly target the intrinsically disordered region of the androgen receptor. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 551-560.	2.5	45
1329	Analysis of Single Circulating Tumor Cells in Renal Cell Carcinoma Reveals Phenotypic Heterogeneity and Genomic Alterations Related to Progression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1475.	1.8	25
1330	A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2020, 31, 619-625.	0.6	54
1331	Genomic Strategies to Personalize Use of Androgen Deprivation Therapy With Radiotherapy. <i>Cancer Journal (Sudbury, Mass.)</i> , 2020, 26, 13-20.	1.0	1
1332	Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer. <i>Cells</i> , 2020, 9, 203.	1.8	15
1333	Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer. <i>Nature Communications</i> , 2020, 11, 384.	5.8	56
1334	Circulating cell-free DNA: Translating prostate cancer genomics into clinical care. <i>Molecular Aspects of Medicine</i> , 2020, 72, 100837.	2.7	6
1335	Alleviation of Multidrug Resistance by Flavonoid and Non-Flavonoid Compounds in Breast, Lung, Colorectal and Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 401.	1.8	48
1336	Emerging role of glucocorticoid receptor in castration resistant prostate cancer: A potential therapeutic target. <i>Journal of Cancer</i> , 2020, 11, 696-701.	1.2	22

#	ARTICLE	IF	CITATIONS
1337	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020, 77, 508-547.	0.9	278
1338	Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells. <i>Antioxidants</i> , 2020, 9, 68.	2.2	19
1339	Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer. <i>PLoS ONE</i> , 2020, 15, e0226219.	1.1	26
1340	A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2020, 127, 67-75.	1.3	6
1341	Biomarkers of response to advanced prostate cancer therapy. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 195-205.	1.5	12
1342	AR-V7 Protein Expression in Circulating Tumour Cells Is Not Predictive of Treatment Response in mCRPC. <i>Urologia Internationalis</i> , 2020, 104, 253-262.	0.6	4
1343	Significance of alternative splicing in cancer cells. <i>Chinese Medical Journal</i> , 2020, 133, 221-228.	0.9	29
1344	Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 3693-3710.	2.4	48
1345	Abiraterone Rechallenge Based on Sequential Testing of Androgen Receptor Splice Variant 7 Expression in Circulating Tumor Cells: A Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 495.	1.3	5
1346	Metabolically stable diphenylamine derivatives suppress androgen receptor and BET protein in prostate cancer. <i>Biochemical Pharmacology</i> , 2020, 177, 113946.	2.0	5
1347	Alternative Splicing in the Nuclear Receptor Superfamily Expands Gene Function to Refine Endo-Xenobiotic Metabolism. <i>Drug Metabolism and Disposition</i> , 2020, 48, 272-287.	1.7	10
1348	Circulating tumor cells as Trojan Horse for understanding, preventing, and treating cancer: a critical appraisal. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 3671-3690.	2.4	20
1349	Dysmetabolic Circulating Tumor Cells Are Prognostic in Metastatic Breast Cancer. <i>Cancers</i> , 2020, 12, 1005.	1.7	5
1351	Novel Dual BET and PLK1 Inhibitor WNY0824 Exerts Potent Antitumor Effects in CRPC by Inhibiting Transcription Factor Function and Inducing Mitotic Abnormality. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1221-1231.	1.9	15
1352	Liquid biopsy and prostate cancer. Current evidence applied to clinical practice. <i>Actas Urológicas Españolas (English Edition)</i> , 2020, 44, 139-147.	0.2	5
1353	Roles and mechanisms of alternative splicing in cancer – implications for care. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 457-474.	12.5	400
1354	Metastatic castration-resistant prostate cancer: Academic insights and perspectives through bibliometric analysis. <i>Medicine (United States)</i> , 2020, 99, e19760.	0.4	34
1355	The Prospect of Identifying Resistance Mechanisms for Castrate-Resistant Prostate Cancer Using Circulating Tumor Cells: Is Epithelial-to-Mesenchymal Transition a Key Player?. <i>Prostate Cancer</i> , 2020, 2020, 1-16.	0.4	10

#	ARTICLE	IF	CITATIONS
1356	Diverse <i>AR</i> Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1965-1976.	3.2	55
1357	Targeting the KIF4A/ <i>AR</i> Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1516-1528.	3.2	34
1358	Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation. <i>Cancers</i> , 2020, 12, 831.	1.7	11
1359	The Role of Circulating Tumor Cells in the Metastatic Cascade: Biology, Technical Challenges, and Clinical Relevance. <i>Cancers</i> , 2020, 12, 867.	1.7	63
1360	Anti-tumor activities of <i>Panax quinquefolius</i> saponins and potential biomarkers in prostate cancer. <i>Journal of Ginseng Research</i> , 2021, 45, 273-286.	3.0	10
1361	A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. <i>European Urology</i> , 2021, 79, 692-699.	0.9	49
1362	Clinical recommendations in the management of advanced prostate cancer: International Gastrointestinal, Liver and Uro-oncology (IGILUC 2019) experts. <i>World Journal of Urology</i> , 2021, 39, 1421-1429.	1.2	4
1363	Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. <i>British Journal of Pharmacology</i> , 2021, 178, 239-261.	2.7	53
1364	An up-to-date evaluation of darolutamide for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 397-402.	0.9	2
1365	Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 448-456.	2.0	0
1366	The development of apalutamide for the treatment of prostate cancer. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 217-226.	2.5	5
1367	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II 2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. <i>European Urology</i> , 2021, 79, 263-282.	0.9	633
1368	Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors. <i>Cell Chemical Biology</i> , 2021, 28, 134-147.e14.	2.5	44
1369	Exploration of Circulating Tumour Cell (CTC) Biology: A Paradigm Shift in Liquid Biopsy. <i>Indian Journal of Clinical Biochemistry</i> , 2021, 36, 131-142.	0.9	9
1370	Prostatic aspirated cellular RNA analysis enables fast diagnosis and staging of prostate cancer. <i>Translational Oncology</i> , 2021, 14, 100963.	1.7	0
1371	To treat or not to treat: is it acceptable to avoid active therapies in advanced prostate cancer today?. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 389-400.	1.1	2
1372	A Multifunctional LNA Oligonucleotide-Based Strategy Blocks AR Expression and Transactivation Activity in PCa Cells. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 23, 63-75.	2.3	5
1373	Photonic Technologies for Liquid Biopsies: Recent Advances and Open Research Challenges. <i>Laser and Photonics Reviews</i> , 2021, 15, .	4.4	10



#	ARTICLE	IF	CITATIONS
1374	Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103185.	2.0	41
1375	A review of the effects and molecular mechanisms of dimethylcurcumin (ASCâ€9) on androgen receptorâ€related diseases. <i>Chemical Biology and Drug Design</i> , 2021, 97, 821-835.	1.5	14
1376	KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer. <i>Cancer Research</i> , 2021, 81, 1026-1039.	0.4	35
1377	Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 490-499.	1.9	55
1378	Clinical utility of circulating tumor cells: an update. <i>Molecular Oncology</i> , 2021, 15, 1647-1666.	2.1	101
1379	T-LAK cell-originated protein kinase (TOPK) enhances androgen receptor splice variant (ARv7) and drives androgen-independent growth in prostate cancer. <i>Carcinogenesis</i> , 2021, 42, 423-435.	1.3	3
1380	Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer. <i>Theranostics</i> , 2021, 11, 958-973.	4.6	29
1381	Molecular pathology of prostate cancer: a practical approach. <i>Pathology</i> , 2021, 53, 36-43.	0.3	17
1382	Splicing factors: Insights into their regulatory network in alternative splicing in cancer. <i>Cancer Letters</i> , 2021, 501, 83-104.	3.2	22
1383	Identification of Genes Required for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells <i>in Vitro</i> . <i>Molecular Cancer Therapeutics</i> , 2021, 20, 398-409.	1.9	17
1384	Isoform-specific Activities of Androgen Receptor and its Splice Variants in Prostate Cancer Cells. <i>Endocrinology</i> , 2021, 162, .	1.4	11
1385	Gene amplification of YBâ€1 in castrationâ€resistant prostate cancer in association with aberrant androgen receptor expression. <i>Cancer Science</i> , 2021, 112, 323-330.	1.7	7
1386	Novel case of androgen receptorâ€positive cancer of unknown primary without serum prostateâ€specific antigen elevation that became progression free in the long term after primary combined androgen blockade. <i>IJU Case Reports</i> , 2021, 4, 59-63.	0.1	0
1387	A detailed characterization of stepwise activation of the androgen receptor variant 7 in prostate cancer cells. <i>Oncogene</i> , 2021, 40, 1106-1117.	2.6	24
1388	Genomic and phenotypic heterogeneity in prostate cancer. <i>Nature Reviews Urology</i> , 2021, 18, 79-92.	1.9	215
1389	Multigene model for predicting metastatic prostate cancer using circulating tumor cells by microfluidic magnetophoresis. <i>Cancer Science</i> , 2021, 112, 859-870.	1.7	11
1390	Overall Survival Among Chemotherapy-Naive Patients With Castration-Resistant Prostate Cancer Under Abiraterone Versus Enzalutamide: A Direct Comparison Based on a 2014â€2018 French Population Study (the SPEAR Cohort). <i>American Journal of Epidemiology</i> , 2021, 190, 413-422.	1.6	16
1391	Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones. <i>Human Cell</i> , 2021, 34, 211-218.	1.2	10



#	ARTICLE	IF	CITATIONS
1392	Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2021, 7, 63-70.	1.6	10
1394	Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells. <i>Clinical Cancer Research</i> , 2021, 27, 2087-2099.	3.2	15
1395	Tissue Expression of Androgen Receptor Splice Variant 7 at Radical Prostatectomy Predicts Risk of Progression in Untreated Nonmetastatic Prostate Cancer. <i>Oncology</i> , 2021, 99, 251-255.	0.9	11
1396	Regulation of carcinogenesis and mediation through Wnt/ $\beta$ 2-catenin signaling by 3,3'-diindolylmethane in an enzalutamide-resistant prostate cancer cell line. <i>Scientific Reports</i> , 2021, 11, 1239.	1.6	4
1397	New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer. <i>Cells</i> , 2021, 10, 193.	1.8	26
1398	Targeting the p300/CBP Axis in Lethal Prostate Cancer. <i>Cancer Discovery</i> , 2021, 11, 1118-1137.	7.7	124
1399	Developing Inhibitors to the Amino-Terminus Domains of Steroid Hormone Receptors. , 2021, , 613-642.		0
1400	Androgen Receptors in the Pathology of Disease. , 2021, , 411-461.		0
1401	Eighty Years of Targeting Androgen Receptor Activity in Prostate Cancer: The Fight Goes on. <i>Cancers</i> , 2021, 13, 509.	1.7	29
1402	Liquid biopsy enters the clinic " implementation issues and future challenges. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 297-312.	12.5	609
1403	Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 524-531.	2.0	32
1404	Circulating Tumor Cells in Prostate Cancer. , 2021, , 93-102.		0
1405	Suppressing BCL-XL increased the high dose androgens therapeutic effect to better induce the Enzalutamide-resistant prostate cancer autophagic cell death. <i>Cell Death and Disease</i> , 2021, 12, 68.	2.7	9
1406	Targeting androgen receptor signaling with MicroRNAs and Curcumin: a promising therapeutic approach for Prostate Cancer Prevention and intervention. <i>Cancer Cell International</i> , 2021, 21, 77.	1.8	5
1407	Emerging role of circulating tumor cells in immunotherapy. <i>Theranostics</i> , 2021, 11, 8057-8075.	4.6	19
1408	Development of novel androgen receptor inhibitors to overcome castrate-resistant prostate cancer. , 2021, , 23-46.		0
1409	Noncoding RNAs regulate alternative splicing in Cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 11.	3.5	81
1410	Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 334.	1.7	44

#	ARTICLE	IF	CITATIONS
1411	The role of liquid biopsies in prostate cancer management. <i>Lab on A Chip</i> , 2021, 21, 3263-3288.	3.1	9
1412	Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 268.	1.7	16
1413	Can local treatment prolong the sensitivity of metastatic prostate cancer to androgen deprivation or even prevent castration resistance?. <i>World Journal of Urology</i> , 2021, 39, 3231-3237.	1.2	5
1414	Androgen metabolism in castration-resistant prostate cancer. , 2021, , 339-368.		0
1415	Finding the optimal treatment sequence in metastatic castration-resistant prostate cancer—a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 3931-3945.	0.6	3
1416	Epigenetics in prostate cancer treatment. , 2021, 5, 341-356.		3
1417	Using biochemistry and biophysics to extinguish androgen receptor signaling in prostate cancer. <i>Journal of Biological Chemistry</i> , 2021, 296, 100240.	1.6	17
1418	Clinical implications of genomic alterations in metastatic prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 310-322.	2.0	12
1419	Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted <sup>18</sup> F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1430-1437.	2.8	24
1420	Differential CircRNA Expression Signatures May Serve as Potential Novel Biomarkers in Prostate Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 605686.	1.8	11
1421	Nivolumab plus ipilimumab, with or without enzalutamide, in AR <sup>V7</sup> -expressing metastatic castration-resistant prostate cancer: A phase <sup>2</sup> nonrandomized clinical trial. <i>Prostate</i> , 2021, 81, 326-338.	1.2	35
1422	V-ATPase Inhibition Decreases Mutant Androgen Receptor Activity in Castrate-resistant Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 739-748.	1.9	5
1423	Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2100.	1.8	13
1424	Huaier Extract Inhibits Prostate Cancer Growth via Targeting AR/AR-V7 Pathway. <i>Frontiers in Oncology</i> , 2021, 11, 615568.	1.3	9
1425	Optimal treatment sequencing of abiraterone acetate plus prednisone and enzalutamide in patients with castration-resistant metastatic prostate cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 93, 102152.	3.4	10
1426	Diagnostic Strategies for Treatment Selection in Advanced Prostate Cancer. <i>Diagnostics</i> , 2021, 11, 345.	1.3	14
1427	Antitumor Activity of NLC207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 915-924.	1.9	13
1428	Prognostic Significance of Gene Expression and DNA Methylation Markers in Circulating Tumor Cells and Paired Plasma Derived Exosomes in Metastatic Castration Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 780.	1.7	40

#	ARTICLE	IF	CITATIONS
1429	A Review of Circulating Tumour Cell Enrichment Technologies. <i>Cancers</i> , 2021, 13, 970.	1.7	102
1430	Overcoming oncogene addiction in breast and prostate cancers: a comparative mechanistic overview. <i>Endocrine-Related Cancer</i> , 2021, 28, R31-R46.	1.6	3
1431	A narrative review of proteolytic targeting chimeras (PROTACs): future perspective for prostate cancer therapy. <i>Translational Andrology and Urology</i> , 2021, 10, 954-962.	0.6	5
1432	Circulating tumor cell profiling for precision oncology. <i>Molecular Oncology</i> , 2021, 15, 1622-1646.	2.1	33
1433	Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer. <i>Biomarker Research</i> , 2021, 9, 14.	2.8	24
1434	MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	31
1435	Down regulation of U2AF1 promotes ARV7 splicing and prostate cancer progression. <i>Biochemical and Biophysical Research Communications</i> , 2021, 541, 56-62.	1.0	7
1436	Magnetic Resonance Imaging Based Radiomic Models of Prostate Cancer: A Narrative Review. <i>Cancers</i> , 2021, 13, 552.	1.7	21
1437	Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers. <i>Clinical and Experimental Metastasis</i> , 2021, 38, 239-251.	1.7	8
1438	The tumor immune contexture of salivary duct carcinoma. <i>Head and Neck</i> , 2021, 43, 1213-1219.	0.9	10
1439	Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy. <i>European Journal of Cancer</i> , 2021, 144, 302-309.	1.3	29
1440	NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 134-143.	2.3	299
1441	Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation. <i>Cancers</i> , 2021, 13, 1483.	1.7	18
1442	Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling. <i>Nature Communications</i> , 2021, 12, 1426.	5.8	176
1443	Salivary Duct Carcinoma. <i>Surgical Pathology Clinics</i> , 2021, 14, 111-126.	0.7	4
1444	Novel Strategies for Treating Castration-Resistant Prostate Cancer. <i>Biomedicines</i> , 2021, 9, 339.	1.4	14
1445	A noncanonical AR addiction drives enzalutamide resistance in prostate cancer. <i>Nature Communications</i> , 2021, 12, 1521.	5.8	43
1446	A narrative review of individualized treatments of genitourinary tumors: is the future brighter with molecular evaluations?. <i>Translational Andrology and Urology</i> , 2021, 10, 1553-1561.	0.6	5

#	ARTICLE	IF	CITATIONS
1447	Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2493.	1.8	17
1448	Resistance to second-generation androgen receptor antagonists in prostate cancer. <i>Nature Reviews Urology</i> , 2021, 18, 209-226.	1.9	59
1449	Transcriptional mediators of treatment resistance in lethal prostate cancer. <i>Nature Medicine</i> , 2021, 27, 426-433.	15.2	90
1450	Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer. <i>Molecular Cancer Research</i> , 2021, 19, 1040-1050.	1.5	17
1451	A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	34
1452	Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 763-774.	1.9	2
1453	<i>In Vivo</i> isolation of circulating tumor cells in patients with different stages of prostate cancer. <i>Oncology Letters</i> , 2021, 21, 357.	0.8	12
1454	RNA-Based CTC Analysis Provides Prognostic Information in Metastatic Breast Cancer. <i>Diagnostics</i> , 2021, 11, 513.	1.3	15
1455	YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer. <i>Oncogene</i> , 2021, 40, 2407-2421.	2.6	37
1456	Androgen receptor splice variant 7 detected by immunohistochemical is an independent poor prognostic marker in men receiving adjuvant androgen-deprivation therapy after radical prostatectomy. <i>Biomarker Research</i> , 2021, 9, 23.	2.8	1
1457	Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer. <i>Scientific Reports</i> , 2021, 11, 6377.	1.6	38
1458	Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 454-467.	12.5	11
1459	Pin1 inhibition improves the efficacy of ralaniten compounds that bind to the N-terminal domain of androgen receptor. <i>Communications Biology</i> , 2021, 4, 381.	2.0	10
1461	Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective study. <i>BMC Cancer</i> , 2021, 21, 399.	1.1	17
1462	Urinary extracellular vesicles: a rising star in bladder cancer management. <i>Translational Andrology and Urology</i> , 2021, 10, 1878-1889.	0.6	12
1463	<i>MAP3K7</i> Loss Drives Enhanced Androgen Signaling and Independently Confers Risk of Recurrence in Prostate Cancer with Joint Loss of <i>CHD1</i> . <i>Molecular Cancer Research</i> , 2021, 19, 1123-1136.	1.5	8
1464	Which Way to Choose for the Treatment of Metastatic Prostate Cancer: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2021, 11, 659442.	1.3	3
1465	TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1371-1382.	0.8	65

#	ARTICLE	IF	CITATIONS
1466	Increased transcription and high translation efficiency lead to accumulation of androgen receptor splice variant after androgen deprivation therapy. <i>Cancer Letters</i> , 2021, 504, 37-48.	3.2	17
1467	Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians. <i>European Urology</i> , 2021, 79, 519-529.	0.9	30
1468	Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment. <i>Prostate</i> , 2021, 81, 543-552.	1.2	20
1469	Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance. <i>Clinical Cancer Research</i> , 2021, 27, 3610-3619.	3.2	17
1470	Depletion of androgen receptor low molecular weight isoform reduces bladder tumor cell viability and induces apoptosis. <i>Cancer Letters</i> , 2021, 504, 49-57.	3.2	5
1471	Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies. <i>Cancer Discovery</i> , 2021, 11, 874-899.	7.7	107
1472	Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer. <i>Translational Andrology and Urology</i> , 2021, 10, 1688-1699.	0.6	1
1473	NF- $\kappa$ B Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants. <i>Molecular Cancer Research</i> , 2021, 19, 1137-1145.	1.5	9
1474	Computing the Role of Alternative Splicing in Cancer. <i>Trends in Cancer</i> , 2021, 7, 347-358.	3.8	19
1475	Extracellular vesicles in prostate cancer: a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 1890-1907.	0.6	17
1476	Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. <i>Clinical Cancer Research</i> , 2021, 27, 4077-4088.	3.2	21
1477	Regulation of RNA Splicing: Aberrant Splicing Regulation and Therapeutic Targets in Cancer. <i>Cells</i> , 2021, 10, 923.	1.8	19
1478	Narrative review of urinary glycan biomarkers in prostate cancer. <i>Translational Andrology and Urology</i> , 2021, 10, 1850-1864.	0.6	3
1479	Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System. <i>Cancers</i> , 2021, 13, 1861.	1.7	4
1480	Changing the History of Prostate Cancer with New Targeted Therapies. <i>Biomedicines</i> , 2021, 9, 392.	1.4	16
1481	Novel approaches to target the microenvironment of bone metastasis. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 488-505.	12.5	91
1482	Resistance to the Androgen Receptor Centred Therapies: Biology and Management. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 1593-1609.	0.3	0
1483	AR Splicing Variants and Resistance to AR Targeting Agents. <i>Cancers</i> , 2021, 13, 2563.	1.7	27

#	ARTICLE	IF	CITATIONS
1484	Current State of Personalized Genitourinary Cancer Radiotherapy in the Era of Precision Medicine. <i>Frontiers in Oncology</i> , 2021, 11, 675311.	1.3	6
1485	Targeting Epigenetic and Posttranscriptional Gene Regulation by PSF Impairs Hormone Therapyâ€”Refractory Cancer Growth. <i>Cancer Research</i> , 2021, 81, 3495-3508.	0.4	11
1486	Treatment Strategies for Metastatic Castration-Sensitive Prostate Cancer: From â€œAll-Comersâ€”to â€œPersonalizedâ€”Approach. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2967-2974.	1.0	11
1487	Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment. <i>Molecular Oncology</i> , 2021, 15, 2453-2465.	2.1	9
1488	11-Ketotestosterone: the resilience of a potent androgen in prostate cancer patients after castration. <i>JCI Insight</i> , 2021, 6, .	2.3	5
1489	Identification of novel androgen receptor degrading agents to treat advanced prostate cancer. <i>European Journal of Medicinal Chemistry</i> , 2021, 217, 113376.	2.6	5
1490	Proliferating cell nuclear antigen directly interacts with androgen receptor and enhances androgen receptor-mediated signaling. <i>International Journal of Oncology</i> , 2021, 59, .	1.4	2
1491	Triple-arm androgen blockade for advanced prostate cancer: a review. <i>Medical Oncology</i> , 2021, 38, 75.	1.2	4
1492	The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1198-1207.	2.0	24
1494	Cross-resistance and drug sequence in prostate cancer. <i>Drug Resistance Updates</i> , 2021, 56, 100761.	6.5	36
1495	Advances in targeting â€”undruggableâ€” transcription factors with small molecules. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 669-688.	21.5	152
1496	AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5515.	1.8	20
1497	Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p. <i>Scientific Reports</i> , 2021, 11, 10765.	1.6	10
1498	Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer. <i>Cells</i> , 2021, 10, 1133.	1.8	13
1499	Upregulation of miR-3195, miR-3687 and miR-4417 is associated with castration-resistant prostate cancer. <i>World Journal of Urology</i> , 2021, 39, 3789-3797.	1.2	14
1500	A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5501.	1.8	10
1501	MicroRNAs as Epigenetic Determinants of Treatment Response and Potential Therapeutic Targets in Prostate Cancer. <i>Cancers</i> , 2021, 13, 2380.	1.7	12
1502	Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy. <i>European Urology</i> , 2021, 79, 879-886.	0.9	26

#	ARTICLE	IF	CITATIONS
1503	Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage. <i>Communications Biology</i> , 2021, 4, 785.	2.0	3
1504	Loss of <i>SNAI2</i> in Prostate Cancer Correlates With Clinical Response to Androgen Deprivation Therapy. <i>JCO Precision Oncology</i> , 2021, 5, 1048-1059.	1.5	9
1505	Novel Treatment Strategy Using Second-Generation Androgen Receptor Inhibitors for Non-Metastatic Castration-Resistant Prostate Cancer. <i>Biomedicines</i> , 2021, 9, 661.	1.4	7
1506	Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients. <i>Cancers</i> , 2021, 13, 2939.	1.7	12
1507	Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6676.	1.8	5
1508	A new role of GRP75-USP1-SIX1 protein complex in driving prostate cancer progression and castration resistance. <i>Oncogene</i> , 2021, 40, 4291-4306.	2.6	18
1509	Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease. <i>Clinical Cancer Research</i> , 2021, 27, 4539-4548.	3.2	6
1511	A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer. <i>Research and Reports in Urology</i> , 2021, Volume 13, 457-472.	0.6	21
1512	Fatty Acid Synthesis in Prostate Cancer: Vulnerability or Epiphenomenon?. <i>Cancer Research</i> , 2021, 81, 4385-4393.	0.4	30
1513	Seed-mediated RNA interference of androgen signaling and survival networks induces cell death in prostate cancer cells. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 24, 337-351.	2.3	9
1514	Identification of Enzalutamide Resistance-Related circRNA-miRNA-mRNA Regulatory Networks in Patients with Prostate Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 3833-3848.	1.0	4
1515	Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1245-1252.	1.3	3
1516	Bidirectional Cross-talk between MAOA and AR Promotes Hormone-Dependent and Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2021, 81, 4275-4289.	0.4	9
1517	A pharmacoeconomic evaluation of pharmaceutical treatment options for prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1685-1728.	0.9	4
1518	Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells. <i>European Journal of Cancer</i> , 2021, 150, 179-189.	1.3	47
1519	Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1. <i>Clinical and Translational Medicine</i> , 2021, 11, e449.	1.7	22
1520	Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer. <i>European Urology</i> , 2021, 79, 762-771.	0.9	47
1521	Role of ZEB Family Members in Proliferation, Metastasis, and Chemoresistance of Prostate Cancer Cells: Revealing Signaling Networks. <i>Current Cancer Drug Targets</i> , 2021, 21, 749-767.	0.8	16



#	ARTICLE	IF	CITATIONS
1522	Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials. <i>Pathology Research and Practice</i> , 2021, 222, 153440.	1.0	10
1523	BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. <i>Clinical Cancer Research</i> , 2021, 27, 4923-4936.	3.2	33
1524	Discovery and Characterization of Benzimidazole Derivative XY123 as a Potent, Selective, and Orally Available ROR $\beta$ Inverse Agonist. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 8775-8797.	2.9	12
1525	Alternative polyadenylation: An untapped source for prostate cancer biomarkers and therapeutic targets?. <i>Asian Journal of Urology</i> , 2021, 8, 407-415.	0.5	1
1526	Association of Circulating Tumor Cells with Inflammatory and Biomarkers in the Blood of Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Life</i> , 2021, 11, 664.	1.1	3
1527	ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling. <i>Oncogene</i> , 2021, 40, 5379-5392.	2.6	16
1528	Prostate Cancer Theranostics. <i>PET Clinics</i> , 2021, 16, 391-396.	1.5	11
1529	Tissue- and Liquid-Based Biomarkers in Prostate Cancer Precision Medicine. <i>Journal of Personalized Medicine</i> , 2021, 11, 664.	1.1	11
1530	Suppression of bone metastatic castration-resistant prostate cancer cell growth by a suicide gene delivered by JC polyomavirus-like particles. <i>Gene Therapy</i> , 2023, 30, 534-537.	2.3	3
1531	Prognostic significance of third-line treatment for patients with metastatic castration-resistant prostate cancer: comparative assessments between cabazitaxel and other agents. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1745-1751.	1.0	6
1532	Alternative RNA Splicing—The Trojan Horse of Cancer Cells in Chemotherapy. <i>Genes</i> , 2021, 12, 1085.	1.0	13
1533	<sup>177</sup> Lu-PSMA-617 and Idroneoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial. <i>Journal of Nuclear Medicine</i> , 2022, 63, 560-566.	2.8	22
1534	PPM1G promotes the progression of hepatocellular carcinoma via phosphorylation regulation of alternative splicing protein SRSF3. <i>Cell Death and Disease</i> , 2021, 12, 722.	2.7	27
1535	MicroRNA-1205 Regulation of FRYL in Prostate Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 647485.	1.8	6
1536	Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations. <i>Cancer Research</i> , 2021, 81, 4685-4695.	0.4	6
1537	Targeted protein degradation: A promise for undruggable proteins. <i>Cell Chemical Biology</i> , 2021, 28, 934-951.	2.5	115
1538	Differential Expression of the Androgen Receptor, Splice Variants and Relaxin 2 in Renal Cancer. <i>Life</i> , 2021, 11, 731.	1.1	6
1539	The novel indomethacin derivative CZ-212-3 exerts antitumor effects on castration-resistant prostate cancer by degrading androgen receptor and its variants. <i>Acta Pharmacologica Sinica</i> , 2021, , .	2.8	3

#	ARTICLE	IF	CITATIONS
1540	Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted <i>Listeria monocytogenes</i> -based immunotherapy, in metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 219-228.	2.0	12
1541	Revision of CHARTED and LATITUDE criteria among Japanese de novo metastatic prostate cancer patients. <i>Prostate International</i> , 2021, 9, 208-214.	1.2	5
1542	Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide. <i>Clinical and Translational Medicine</i> , 2021, 11, e495.	1.7	17
1543	DNA binding alters ARv7 dimer interactions. <i>Journal of Cell Science</i> , 2021, 134, .	1.2	7
1544	Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer. <i>Cancer</i> , 2021, 127, 4557-4564.	2.0	5
1545	Exosomes and prostate cancer management. <i>Seminars in Cancer Biology</i> , 2022, 86, 101-111.	4.3	11
1546	Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer. <i>Life</i> , 2021, 11, 884.	1.1	5
1548	A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer. <i>Annual Review of Pharmacology and Toxicology</i> , 2022, 62, 131-153.	4.2	55
1549	The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2021, 81, 1191-1201.	1.2	9
1550	Overexpression of CXCR7 is a Novel Indicator for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Patients. <i>Disease Markers</i> , 2021, 2021, 1-10.	0.6	2
1551	The effect of chemotherapy on the exposure-response relation of abiraterone in metastatic castration-resistant prostate cancer. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1170-1178.	1.1	5
1552	Somatic Alterations Impact AR Transcriptional Activity and Efficacy of AR-Targeting Therapies in Prostate Cancer. <i>Cancers</i> , 2021, 13, 3947.	1.7	5
1553	Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in <i>BRCA1</i> , <i>BRCA2</i> or <i>ATM</i> ? <i>Pharmacogenomics</i> , 2021, 22, 809-819.	0.6	6
1554	Context-Specific Efficacy of Apalutamide Therapy in Preclinical Models of Pten-Deficient Prostate Cancer. <i>Cancers</i> , 2021, 13, 3975.	1.7	4
1555	Real-world genetic testing patterns in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2021, 17, 2907-2921.	1.1	12
1556	Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. <i>European Urology Open Science</i> , 2021, 30, 47-62.	0.2	2
1557	The Contribution of Evolutionary Game Theory to Understanding and Treating Cancer. <i>Dynamic Games and Applications</i> , 2022, 12, 313-342.	1.1	42
1558	Liquid biopsy: the current state of the issue. <i>Innovative Medicine of Kuban</i> , 2021, , 57-63.	0.0	1

#	ARTICLE	IF	CITATIONS
1559	Molecular Pathology of Prostate Cancer. <i>Surgical Pathology Clinics</i> , 2021, 14, 387-401.	0.7	9
1560	Genomic analysis of circulating tumor cells in adenosquamous carcinoma of the prostate: a case report. <i>BMC Medical Genomics</i> , 2021, 14, 217.	0.7	4
1561	AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer. <i>Endocrine-Related Cancer</i> , 2021, 28, 645-655.	1.6	5
1562	Anticancer Effects of I-BET151, an Inhibitor of Bromodomain and Extra-Terminal Domain Proteins. <i>Frontiers in Oncology</i> , 2021, 11, 716830.	1.3	5
1563	Inhibition of Scavenger Receptor Class B Type 1 (SR-B1) Expression and Activity as a Potential Novel Target to Disrupt Cholesterol Availability in Castration-Resistant Prostate Cancer. <i>Pharmaceutics</i> , 2021, 13, 1509.	2.0	2
1564	Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies. <i>Oncologist</i> , 2021, 26, e2227-e2238.	1.9	23
1565	Impact of STAT Proteins in Tumor Progress and Therapy Resistance in Advanced and Metastasized Prostate Cancer. <i>Cancers</i> , 2021, 13, 4854.	1.7	12
1566	Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer. <i>Nature Reviews Urology</i> , 2021, 18, 739-762.	1.9	38
1567	Efficacy and safety of bipolar androgen therapy in mCRPC after progression on abiraterone or enzalutamide: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 4.e19-4.e28.	0.8	7
1568	Selective degradation of AR-V7 to overcome castration resistance of prostate cancer. <i>Cell Death and Disease</i> , 2021, 12, 857.	2.7	23
1569	Targeting the Lnc-OPHN1-5/androgen receptor/hnRNPA1 complex increases Enzalutamide sensitivity to better suppress prostate cancer progression. <i>Cell Death and Disease</i> , 2021, 12, 855.	2.7	10
1570	Clinical Relevance of Circulating Tumor Cells in Prostate Cancer Management. <i>Biomedicines</i> , 2021, 9, 1179.	1.4	17
1571	Androgens in prostate cancer: A tale that never ends. <i>Cancer Letters</i> , 2021, 516, 1-12.	3.2	23
1572	Activity of New Synthetic (2-Chloroethylthio)-1,4-naphthoquinones in Prostate Cancer Cells. <i>Pharmaceutics</i> , 2021, 14, 949.	1.7	6
1573	Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer. <i>Cancers</i> , 2021, 13, 4522.	1.7	22
1574	Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2926-2937.	0.8	36
1575	LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance. <i>Cell Death and Disease</i> , 2021, 12, 856.	2.7	25
1576	25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 521-527.	0.8	3

#	ARTICLE	IF	CITATIONS
1577	Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. <i>Urology</i> , 2021, 155, 165-171.	0.5	11
1578	Clinicopathological characteristics of androgen receptor splicing variant 7 (AR-V7) expression in patients with castration resistant prostate cancer: A systematic review and meta-analysis. <i>Translational Oncology</i> , 2021, 14, 101145.	1.7	8
1579	Transcriptional network involving ERG and AR orchestrates Distal-less/ homeobox-1 mediated prostate cancer progression. <i>Nature Communications</i> , 2021, 12, 5325.	5.8	23
1580	Androgen Receptor Pathway in Salivary Gland Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 4069-4072.	0.8	5
1581	Assessment of Total, PTEN <sup>+</sup> , and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e286-e298.	0.9	18
1582	Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells. <i>Cancer Letters</i> , 2021, 519, 172-184.	3.2	13
1583	Mechanisms and markers of resistance to androgen signaling inhibitors in patients with metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 728.e13-728.e24.	0.8	8
1584	Blocking GRP/GRP-R signaling decreases expression of androgen receptor splice variants and inhibits tumor growth in castration-resistant prostate cancer. <i>Translational Oncology</i> , 2021, 14, 101213.	1.7	5
1585	Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics. , 2021, 228, 107932.		44
1586	Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2034633.	2.8	29
1588	PRPF6 promotes androgen receptor/androgen receptor-variant 7 actions in castration-resistant prostate cancer cells. <i>International Journal of Biological Sciences</i> , 2021, 17, 188-203.	2.6	8
1589	Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC). <i>Journal of Medicinal Chemistry</i> , 2021, 64, 909-924.	2.9	16
1590	Hormonal Therapy for Prostate Cancer. <i>Endocrine Reviews</i> , 2021, 42, 354-373.	8.9	136
1591	Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-ectin-like transcript 1 signals. <i>Prostate</i> , 2020, 80, 742-752.	1.2	8
1592	Liquid Biopsy: Application in Early Diagnosis and Monitoring of Cancer. <i>Small Structures</i> , 2020, 1, 2000063.	6.9	19
1593	Role of Alternative Splicing in Prostate Cancer Aggressiveness and Drug Resistance in African Americans. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1164, 119-139.	0.8	14
1594	Liquid Biopsy: Translating Minimally Invasive Disease Profiling from the Lab to the Clinic. , 2019, , 145-167.		1
1595	Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1168, 9-30.	0.8	114

#	ARTICLE	IF	CITATIONS
1596	Genetic Analysis of Circulating Tumour Cells. <i>Recent Results in Cancer Research</i> , 2020, 215, 57-76.	1.8	12
1597	Role of Next-Generation Sequencing Technologies in Personalized Medicine. , 2020, , 125-154.		13
1598	Androgen Receptor Dependence. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1210, 333-350.	0.8	19
1599	Wnt/Beta-Catenin Signaling and Prostate Cancer Therapy Resistance. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1210, 351-378.	0.8	55
1600	The Tumor Microenvironments of Lethal Prostate Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1210, 149-170.	0.8	7
1601	Biopsia líquida y cáncer de próstata. Evidencia actual aplicada a la clínica. <i>Actas Urológicas Españolas</i> , 2020, 44, 139-147.	0.3	7
1602	Management of Hsp90-Dependent Protein Folding by Small Molecules Targeting the Aha1 Co-Chaperone. <i>Cell Chemical Biology</i> , 2020, 27, 292-305.e6.	2.5	13
1603	Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2018, 73, 727-735.	0.9	55
1604	The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer. <i>Urologic Clinics of North America</i> , 2020, 47, e17-e54.	0.8	39
1605	Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer. <i>Oncogene</i> , 2018, 37, 710-721.	2.6	69
1606	Analysis of AR-FL and AR-V1 in Whole Blood of Patients with Castration Resistant Prostate Cancer as a Tool for Predicting Response to Abiraterone Acetate. <i>Journal of Urology</i> , 2020, 204, 71-78.	0.2	8
1616	Systematic profiling of alternative splicing signature reveals prognostic predictor for prostate cancer. <i>Cancer Science</i> , 2020, 111, 3020-3031.	1.7	15
1617	Hormone-Targeted Therapy and Resistance. <i>Annual Review of Cancer Biology</i> , 2018, 2, 291-312.	2.3	11
1618	Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1708-1718.	1.9	42
1619	Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy. <i>JCI Insight</i> , 2019, 4, .	2.3	26
1620	An imaging agent to detect androgen receptor and its active splice variants in prostate cancer. <i>JCI Insight</i> , 2016, 1, .	2.3	16
1621	Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. <i>Journal of Clinical Investigation</i> , 2020, 130, 1653-1668.	3.9	122
1622	Genomics of lethal prostate cancer at diagnosis and castration resistance. <i>Journal of Clinical Investigation</i> , 2020, 130, 1743-1751.	3.9	180

#	ARTICLE	IF	CITATIONS
1623	Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. <i>Journal of Clinical Investigation</i> , 2017, 127, 2326-2338.	3.9	40
1624	Role of steroid receptor and coregulator mutations in hormone-dependent cancers. <i>Journal of Clinical Investigation</i> , 2017, 127, 1126-1135.	3.9	42
1625	Tumour Cell Heterogeneity. <i>F1000Research</i> , 2016, 5, 238.	0.8	91
1626	Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. <i>F1000Research</i> , 2015, 4, 1521.	0.8	2,612
1627	Advances in genetics: widening our understanding of prostate cancer. <i>F1000Research</i> , 2016, 5, 1512.	0.8	2
1628	Prostate Cancer Characteristics Associated with Response to Pre-Receptor Targeting of the Androgen Axis. <i>PLoS ONE</i> , 2014, 9, e111545.	1.1	6
1629	Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 358-369.	1.8	8
1630	Inhibition of TAMs improves the response to docetaxel in castration-resistant prostate cancer. <i>Endocrine-Related Cancer</i> , 2019, 26, 131-140.	1.6	28
1631	Interplay between the androgen receptor signaling axis and microRNAs in prostate cancer. <i>Endocrine-Related Cancer</i> , 2019, 26, R237-R257.	1.6	20
1632	Chromatin reprogramming as an adaptation mechanism in advanced prostate cancer. <i>Endocrine-Related Cancer</i> , 2019, 26, R211-R235.	1.6	15
1633	SEQUENTIAL THERAPY OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: NEW POSSIBILITIES. <i>Onkourologiya</i> , 2018, 14, 120-127.	0.1	2
1634	Establishment and characterization of patient-derived xenografts for hormone-naïve and castrate-resistant prostate cancers to improve treatment modality evaluation. <i>Aging</i> , 2020, 12, 3848-3861.	1.4	5
1635	HOTAIR expands the population of prostatic cancer stem-like cells and causes Docetaxel resistance via activating STAT3 signaling. <i>Aging</i> , 2020, 12, 12771-12782.	1.4	18
1636	miR-5089-5p suppresses castration-resistant prostate cancer resistance to enzalutamide and metastasis via miR-5089-5p/SPINK1/ MAPK/MMP9 signaling. <i>Aging</i> , 2020, 12, 14418-14433.	1.4	3
1637	Comprehensive analysis of m6A regulators prognostic value in prostate cancer. <i>Aging</i> , 2020, 12, 14863-14884.	1.4	45
1638	Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer. <i>Oncotarget</i> , 2016, 7, 50507-50521.	0.8	44
1639	Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. <i>Oncotarget</i> , 2016, 7, 64447-64470.	0.8	130
1640	Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide. <i>Oncotarget</i> , 2016, 7, 59781-59794.	0.8	52

#	ARTICLE	IF	CITATIONS
1641	Technical challenges in the isolation and analysis of circulating tumor cells. <i>Oncotarget</i> , 2016, 7, 62754-62766.	0.8	84
1642	Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression. <i>Oncotarget</i> , 2016, 7, 61955-61969.	0.8	18
1643	Targeted suppression of AR-V7 using PIP5K1 $\beta$ inhibitor overcomes enzalutamide resistance in prostate cancer cells. <i>Oncotarget</i> , 2016, 7, 63065-63081.	0.8	38
1644	Marine compound rhizochalinin shows high <i>in vitro</i> and <i>in vivo</i> efficacy in castration resistant prostate cancer. <i>Oncotarget</i> , 2016, 7, 69703-69717.	0.8	16
1645	Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures. <i>Oncotarget</i> , 2017, 8, 10324-10347.	0.8	34
1646	Detection fidelity of AR mutations in plasma derived cell-free DNA. <i>Oncotarget</i> , 2017, 8, 15651-15662.	0.8	20
1647	Prospects of estrogen receptor $\beta$ activation in the treatment of castration-resistant prostate cancer. <i>Oncotarget</i> , 2017, 8, 34971-34979.	0.8	15
1648	Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade. <i>Oncotarget</i> , 2017, 8, 56051-56065.	0.8	70
1649	Resveratrol enhances polyubiquitination-mediated ARV7 degradation in prostate cancer cells. <i>Oncotarget</i> , 2017, 8, 54683-54693.	0.8	13
1650	Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients. <i>Oncotarget</i> , 2017, 8, 54708-54721.	0.8	22
1651	The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapy. <i>Oncotarget</i> , 2017, 8, 55374-55383.	0.8	30
1652	Novel galeterone analogs act independently of AR and AR-V7 for the activation of the unfolded protein response and induction of apoptosis in the CWR22Rv1 prostate cancer cell model. <i>Oncotarget</i> , 2017, 8, 88501-88516.	0.8	10
1653	STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer. <i>Oncotarget</i> , 2017, 8, 85997-86010.	0.8	32
1654	Testosterone metabolites inhibit proliferation of castration- and therapy-resistant prostate cancer. <i>Oncotarget</i> , 2018, 9, 16951-16961.	0.8	10
1655	Synthesis and anticancer activity of the derivatives of marine compound rhizochalin in castration resistant prostate cancer. <i>Oncotarget</i> , 2018, 9, 16962-16973.	0.8	15
1656	Circulating tumor cells mirror bone metastatic phenotype in prostate cancer. <i>Oncotarget</i> , 2018, 9, 29403-29413.	0.8	21
1657	MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligand. <i>Oncotarget</i> , 2015, 6, 288-304.	0.8	30
1658	Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer. <i>Oncotarget</i> , 2020, 11, 15-21.	0.8	9



#	ARTICLE	IF	CITATIONS
1659	Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression. <i>Oncotarget</i> , 2015, 6, 20474-20484.	0.8	20
1660	Marine alkaloid Monanchocidin a overcomes drug resistance by induction of autophagy and lysosomal membrane permeabilization. <i>Oncotarget</i> , 2015, 6, 17328-17341.	0.8	61
1661	Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy. <i>Oncotarget</i> , 2015, 6, 26029-26040.	0.8	27
1662	Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents. <i>Oncotarget</i> , 2015, 6, 23358-23371.	0.8	79
1663	Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts <i>in vivo</i> . <i>Oncotarget</i> , 2015, 6, 27440-27460.	0.8	91
1664	Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer. <i>Oncotarget</i> , 2015, 6, 35542-35555.	0.8	60
1665	FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer. <i>Oncotarget</i> , 2015, 6, 29782-29794.	0.8	35
1666	Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells. <i>Oncotarget</i> , 2015, 6, 31997-32012.	0.8	73
1667	AR-v7 protein expression is regulated by protein kinase and phosphatase. <i>Oncotarget</i> , 2015, 6, 33743-33754.	0.8	43
1668	Expression of androgen receptor splice variants in clinical breast cancers. <i>Oncotarget</i> , 2015, 6, 44728-44744.	0.8	77
1669	Regulation of androgen receptor splice variant AR3 by PCGEM1. <i>Oncotarget</i> , 2016, 7, 15481-15491.	0.8	59
1670	Efficacy of targeted AKT inhibition in genetically engineered mouse models of <i>PTEN</i> -deficient prostate cancer. <i>Oncotarget</i> , 2016, 7, 15959-15976.	0.8	20
1671	Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer. <i>Oncotarget</i> , 2016, 7, 26259-26274.	0.8	83
1672	Heterogeneous PSMA expression on circulating tumor cells - a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer. <i>Oncotarget</i> , 2016, 7, 34930-34941.	0.8	71
1673	Circulating <i>AR</i> copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer. <i>Oncotarget</i> , 2016, 7, 37839-37845.	0.8	69
1674	Targeting BET bromodomain proteins in solid tumors. <i>Oncotarget</i> , 2016, 7, 53997-54009.	0.8	86
1675	Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. <i>Oncotarget</i> , 2016, 7, 40690-40703.	0.8	12
1676	Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathways. , 2020, 3, 726-741.		6

#	ARTICLE	IF	CITATIONS
1677	Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms. , 2020, 3, 742-761.		13
1678	Application of liquid biopsies to identify genomic factors associated with therapy resistance in castration resistant prostate cancer. <i>Annals of Translational Medicine</i> , 2016, 4, S64-S64.	0.7	1
1679	Current status of circulating tumor cell androgen receptor splice variant-7 in metastatic castration-resistant prostate cancer. <i>Annals of Translational Medicine</i> , 2019, 7, S375-S375.	0.7	2
1680	Clinical utility of the nuclear-localized AR-V7 biomarker for treatment choice in metastatic castration-resistant prostate cancer. <i>Translational Andrology and Urology</i> , 2020, 9, 2483-2487.	0.6	1
1681	Analysis of novel enzalutamide-resistant cells: upregulation of testis-specific Y-encoded protein gene promotes the expression of androgen receptor splicing variant 7. <i>Translational Cancer Research</i> , 2020, 9, 6232-6245.	0.4	2
1682	A Clinical Evaluation of Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Guiding Principles for Treatment Selection and Perspectives on Research. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 13247-13263.	1.0	8
1683	Non-Steroidal Androgen Receptor Antagonists and Prostate Cancer: A Survey on Chemical Structures Binding this Fast-Mutating Target. <i>Current Medicinal Chemistry</i> , 2019, 26, 6053-6073.	1.2	7
1684	Precision Medicine Approach in Prostate Cancer. <i>Current Pharmaceutical Design</i> , 2020, 26, 3783-3798.	0.9	9
1685	Consequences of an Early PSA Response to Enzalutamide Treatment for Japanese Patients with Metastatic Castration-resistant Prostate Cancer. <i>Anticancer Research</i> , 2016, 36, 6141-6150.	0.5	21
1686	Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial. <i>JMIR Research Protocols</i> , 2018, 7, e11191.	0.5	8
1687	The Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer Treated With Novel Hormonal Therapy or Chemotherapy: A Systematic Review and Meta-analysis. <i>Frontiers in Oncology</i> , 2020, 10, 572590.	1.3	11
1688	Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2015, 7, 2290-2308.	1.7	51
1689	Ailanthone: A novel potential drug for treating human cancer (Review). <i>Oncology Letters</i> , 2020, 20, 1489-1503.	0.8	15
1690	Inhibition of Rac1 reverses enzalutamide resistance in castration-resistant prostate cancer. <i>Oncology Letters</i> , 2020, 20, 2997-3005.	0.8	10
1691	Androgen receptor and prostate cancer. <i>AIMS Molecular Science</i> , 2016, 3, 280-299.	0.3	22
1692	Prostate cancer metastasis: roles of recruitment and reprogramming, cell signal network and three-dimensional growth characteristics. <i>Translational Andrology and Urology</i> , 2015, 4, 438-54.	0.6	43
1693	Hormonal therapy and chemotherapy in hormone-naïve and castration resistant prostate cancer. <i>Translational Andrology and Urology</i> , 2015, 4, 355-64.	0.6	19
1694	Mechanisms of resistance in castration-resistant prostate cancer (CRPC). <i>Translational Andrology and Urology</i> , 2015, 4, 365-80.	0.6	310

#	ARTICLE	IF	CITATIONS
1695	Chemotherapy options in castration-resistant prostate cancer. <i>Indian Journal of Urology</i> , 2016, 32, 262.	0.2	19
1696	Immunotherapy in metastatic prostate cancer. <i>Indian Journal of Urology</i> , 2016, 32, 271.	0.2	6
1697	What is the next generation therapeutic strategy for castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2015, 17, 223.	0.8	3
1698	Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2015, 17, 439.	0.8	8
1699	Androgen receptor splice variants and polycystic ovary syndrome: cause or effect?. <i>Asian Journal of Andrology</i> , 2016, 18, 442.	0.8	13
1700	The promising role of poly(ADP-ribose) polymerase inhibitors in prostate cancer. <i>Asian Journal of Andrology</i> , 2016, 18, 592.	0.8	2
1701	Genomic predictors for treatment of late stage prostate cancer. <i>Asian Journal of Andrology</i> , 2016, 18, 586.	0.8	7
1702	Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2016, 18, 580.	0.8	38
1703	Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice. <i>Asian Journal of Andrology</i> , 2017, 19, 143.	0.8	23
1704	Personalized prostate cancer care: from screening to treatment. <i>Asian Journal of Andrology</i> , 2016, 18, 505.	0.8	8
1705	Risk of complications and urinary incontinence following cytoreductive prostatectomy: a multi-institutional study. <i>Asian Journal of Andrology</i> , 2018, 20, 9.	0.8	9
1706	Current opinion and mechanistic interpretation of combination therapy for castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2019, 21, 270.	0.8	15
1707	B lymphoma Moloney murine leukemia virus insertion region 1: An oncogenic mediator in prostate cancer. <i>Asian Journal of Andrology</i> , 2019, 21, 224.	0.8	8
1708	The path forward in prostate cancer therapeutics. <i>Asian Journal of Andrology</i> , 2018, 20, 213.	0.8	3
1709	The resurgence of estrogens in the treatment of castration-resistant prostate cancer. <i>Indian Journal of Urology</i> , 2019, 35, 189.	0.2	6
1710	Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years. <i>World Journal of Nuclear Medicine</i> , 2020, 19, 15-20.	0.3	17
1711	Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10, 1.	0.6	68
1712	How Precisely Can Prostate Cancer Be Managed?. <i>International Neurourology Journal</i> , 2016, 20, S120-130.	0.5	10

#	ARTICLE	IF	CITATIONS
1713	Circulating cell-free nucleic acids as prognostic and therapy predictive tools for metastatic castrate-resistant prostate cancer. <i>World Journal of Clinical Oncology</i> , 2020, 11, 450-463.	0.9	5
1714	Circulating Tumor Cells: A Window to Understand Cancer Metastasis, Monitor and Fight Against Cancers. <i>Journal of Cancer Research Updates</i> , 2015, 4, .	0.3	9
1715	TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth. <i>ELife</i> , 2019, 8, .	2.8	25
1716	Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study. <i>In Vivo</i> , 2021, 35, 3509-3519.	0.6	5
1717	Multiwalled Carbon Nanotubes as Nanomaterial Tool in the Management of Prostate Cancer: A Possible Nanoformulation Approach. <i>Advanced Pharmaceutical Bulletin</i> , 2021, , .	0.6	0
1718	Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome. <i>Molecular Oncology</i> , 2022, 16, 538-548.	2.1	4
1719	Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?. <i>Cancers</i> , 2021, 13, 5204.	1.7	13
1720	Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer. <i>Oncology Letters</i> , 2021, 22, 831.	0.8	3
1721	The Role of Androgen Receptor in Cross Talk Between Stromal Cells and Prostate Cancer Epithelial Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 729498.	1.8	5
1723	Prognostic and Predictive Biomarkers for Men With Castration-Resistant Prostate Cancer. , 2014, , 1-27.		0
1724	Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2015, 17, 936.	0.8	1
1727	How to approach castration-resistant prostate cancer?. <i>Marmara Medical Journal</i> , 2015, 28, 24.	0.2	1
1728	CUA-CUOG CRPC Guidelines: A useful compendium. <i>Canadian Urological Association Journal</i> , 2015, 9, 224.	0.3	0
1729	Androgen Receptor Splice Variants in Prostate Cancer. <i>Journal of Cancer Prevention &amp; Current Research</i> , 2015, 3, .	0.1	0
1731	Pathology of Prostate Cancer: What Has Changed in the Last 30 Years. , 2016, , 17-31.		0
1732	Circulating Tumor Cells as an Analytical Tool in the Management of Patients with Cancer. , 0, , 1051-1061.		0
1733	Targeting of Steroid Hormone Receptor Function in Breast and Prostate Cancer. <i>Endocrinology</i> , 2016, , 1-21.	0.1	0
1734	Rapid bench to bed in management of metastatic prostate cancer. <i>Indian Journal of Urology</i> , 2016, 32, 255.	0.2	0

#	ARTICLE	IF	CITATIONS
1735	Enzalutamide in Metastatic Castration Resistant Prostate Cancer. , 2016, , 157-169.		0
1736	Sequencing Therapies in Metastatic Castration-Resistant Prostate Cancer. , 2016, , 215-230.		0
1737	Docetaxel in Advanced and Castration Resistant Prostate Cancer. , 2016, , 77-92.		0
1738	Personalized hormonal treatment for prostate cancer: An opportunity for improvement. Advances in Modern Oncology Research, 2016, 2, 1.	0.1	0
1740	New Frontiers in Treatment. , 2017, , 209-221.		0
1741	Bone Metastases from Prostate Cancer: Hormonal Therapy. , 2017, , 105-120.		0
1742	Circulating Tumor Cells (CTCs) and Metastatic Prostate Cancer (mPCa). , 2017, , 47-59.		0
1743	Chapter 8 Kava in Prostate Cancer Prevention and Treatment. Traditional Herbal Medicines for Modern Times, 2016, , 161-172.	0.1	0
1744	Chapter 1 Prostate Cancer: An Introduction. Traditional Herbal Medicines for Modern Times, 2016, , 1-16.	0.1	0
1745	Chemotherapy and Androgen Receptor-Directed Treatment of Castration Resistant Metastatic Prostate Cancer. , 2017, , 327-342.		0
1746	Targeting the Androgen Receptor Signaling Axis. , 2017, , 134-153.		0
1747	Molecular Pathogenesis of Prostate Cancer. , 2017, , 171-189.		0
1748	The Liquid Biopsy: Its Present and Future. Japanese Journal of Lung Cancer, 2017, 57, 733-738.	0.0	1
1749	New diagnostic options and prognosis prediction of urinary bladder cancer. Urologie Pro Praxi, 2017, 18, 64-68.	0.0	1
1750	The Role of Androgen Receptor in Prostate Cancer. Molecular Pathology Library, 2018, , 345-365.	0.1	1
1751	AR Splice Variant in Prostate Cancer. , 2018, , 293-298.		0
1752	Systemic Treatment of Castration-Resistant Metastatic Prostate Cancer. , 2018, , 1-14.		0
1753	Optimization of Sequential AR Targeted Therapy for CRPC. , 2018, , 225-229.		0

#	ARTICLE	IF	CITATIONS
1754	Prognostic and predictive biomarkers of prostate cancer. <i>Onkourologiya</i> , 2018, 13, 111-121.	0.1	3
1755	Detection of Circulating Tumor Cells in Castration-Resistant Prostate Cancer. , 2018, , 299-305.		0
1758	Role of the androgen signaling axis in genitourinary malignancies. <i>Translational Cancer Research</i> , 2018, 7, 1135-1142.	0.4	2
1760	Scene text detection and recognition system for visually impaired people in real world. , 2018, ,		3
1761	Molecular Pathology of Genitourinary Cancers: Translating the Cancer Genome to the Clinic. , 2019, , 419-443.		0
1762	Unifying Next-Generation Biomarkers and Nanodiagnostic Platforms for Precision Prostate Cancer Management. <i>Springer Theses</i> , 2019, , 1-29.	0.0	0
1764	Molecular mechanisms of enzalutamide resistance in prostate cancer. , 2019, 2, 189-197.		2
1765	Systemic Treatment of Castration-Resistant Metastatic Prostate Cancer. , 2019, , 241-253.		0
1768	Current clinical utility of prostate cancer markers. <i>Onkologie (Czech Republic)</i> , 2019, 13, 78-82.	0.0	0
1769	Cabazitaxel in the treatment of castration-resistant cancer: hitting the balance of efficacy and safety. <i>Meditinskiy Sovet</i> , 2019, , 146-154.	0.1	0
1771	Enzalutamide in treatment of the metastatic castrate resistant prostate cancer. <i>Onkologie (Czech)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.0	0
1772	Androgen receptor splice variant 7 in castration resistant prostate cancer treated with hormonal therapy: what is in the pipeline?. <i>Translational Cancer Research</i> , 2019, 8, S595-S597.	0.4	0
1773	Genomic Testing for Advanced Prostate Cancer: Ready for Prime Time. <i>Healthbook TIMES Oncology Hematology</i> , 2019, , 10-17.	0.1	1
1774	Intracrine androgen biosynthesis and drug resistance. , 2020, 3, 912-929.		1
1776	Gli2 mediates the development of castration-resistant prostate cancer. <i>International Journal of Oncology</i> , 2020, 57, 100-112.	1.4	9
1779	Management of Patients With Advanced Prostate Cancer: Establishment of Treatment Guidelines Through Prostate Cancer Summit (PCAS) 2016 Composed of Korean Prostate Cancer Experts. <i>The Korean Journal of Urological Oncology</i> , 2020, 18, 124-139.	0.1	0
1780	Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second-line antiandrogen therapy era. <i>Cancer Medicine</i> , 2021, 10, 7909-7920.	1.3	2
1781	Deciphering Evolutionary Dynamics and Lineage Plasticity in Aggressive Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11645.	1.8	0

#	ARTICLE	IF	CITATIONS
1782	Efficiency and safety of radium-223 in the treatment of metastatic castration-resistant prostate cancer. Meditsinskiy Sovet, 2020, , 70-82.	0.1	0
1784	A review of current clinical biomarkers for prostate cancer: towards personalised and targeted therapy. Journal of Radiotherapy in Practice, 2022, 21, 277-286.	0.2	1
1785	Molekularpathologie und Biomarker. , 2020, , 173-183.		0
1786	Using In Situ Padlock Probe Technology to Detect mRNA Splice Variants in Tumor Cells. Methods in Molecular Biology, 2020, 2148, 361-378.	0.4	2
1787	Androgen Signaling in Metastatic Bone Disease. , 2020, , 305-314.		0
1788	Papel del Índice neutrófilo/linfocito en pacientes con cáncer de próstata resistente a castración metastásicos tratados en primera línea con abiraterona. Actas Urológicas Españolas, 2020, 44, 164-171.	0.3	1
1789	Enzalutamide-Resistant Progression of Castration-Resistant Prostate Cancer Is Driven via the JAK2/STAT1-Dependent Pathway. Frontiers in Molecular Biosciences, 2021, 8, 652443.	1.6	7
1790	SPP1 Promotes Enzalutamide Resistance and Epithelial-Mesenchymal-Transition Activation in Castration-Resistant Prostate Cancer via PI3K/AKT and ERK1/2 Pathways. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-15.	1.9	37
1791	Type I Interferon Promotes Antitumor T Cell Response in CRPC by Regulating MDSC. Cancers, 2021, 13, 5574.	1.7	4
1792	Loss of Long Noncoding RNA <i>NXTAR</i> in Prostate Cancer Augments Androgen Receptor Expression and Enzalutamide Resistance. Cancer Research, 2022, 82, 155-168.	0.4	29
1794	Analysis of key genes reveal lysine demethylase 5B promotes prostate cancer progression. Oncology Letters, 2020, 20, 62.	0.8	4
1795	Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells. Aging, 2020, 12, 17694-17712.	1.4	2
1797	Prostate Cancer Academy 2017 Summaries. Reviews in Urology, 2017, 19, 252-260.	0.9	2
1798	Therapeutic Considerations for Ron Receptor Expression in Prostate Cancer. , 2018, 1, .		1
1799	Summer School in Flow Cytometry for Immunology: Report From a Successful ESCCA Experience. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2019, 30, 438-451.	0.7	0
1800	Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol. BMJ Open, 2019, 9, e034708.	0.8	2
1801	Targeting treatment options for castration-resistant prostate cancer. American Journal of Clinical and Experimental Urology, 2021, 9, 101-120.	0.4	4
1802	Gene polymorphism-related differences in the outcomes of abiraterone for prostate cancer: a systematic overview. American Journal of Cancer Research, 2021, 11, 1873-1894.	1.4	2



#	ARTICLE	IF	CITATIONS
1803	Development of PARP inhibitor combinations for castration resistant prostate cancer unselected for homologous recombination repair mutations. American Journal of Translational Research (discontinued), 2021, 13, 7427-7439.	0.0	1
1804	The Hippo pathway: an emerging role in urologic cancers. American Journal of Clinical and Experimental Urology, 2021, 9, 301-317.	0.4	1
1805	Biomarkers for Treatment Response in Advanced Prostate Cancer. Cancers, 2021, 13, 5723.	1.7	14
1806	Cell-Free DNA Variant Sequencing Using Plasma and AR-V7 Testing of Circulating Tumor Cells in Prostate Cancer Patients. Cells, 2021, 10, 3223.	1.8	4
1807	Her2 Expression in Circulating Tumor Cells Is Associated with Poor Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer. Cancers, 2021, 13, 6014.	1.7	4
1808	Fatty Acid Metabolism Reprogramming in Advanced Prostate Cancer. Metabolites, 2021, 11, 765.	1.3	21
1809	Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Ralaniten Analogs for the Treatment of Androgen Receptor-“positive Prostate and Breast Cancers. Molecular Cancer Therapeutics, 2022, 21, 294-309.	1.9	7
1810	Circulating tumor cells: biology and clinical significance. Signal Transduction and Targeted Therapy, 2021, 6, 404.	7.1	286
1811	Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression. Nature Communications, 2021, 12, 7033.	5.8	27
1812	Liquid biopsy in prostate cancer: current status and future challenges of clinical application. Aging Male, 2021, 24, 58-71.	0.9	11
1813	Therapeutic potential of TRPM8 antagonists in prostate cancer. Scientific Reports, 2021, 11, 23232.	1.6	22
1814	Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer. Technology in Cancer Research and Treatment, 2021, 20, 153303382110521.	0.8	5
1815	Relevance of Circulating Tumor Cells as Predictive Markers for Cancer Incidence and Relapse. Pharmaceuticals, 2022, 15, 75.	1.7	11
1816	Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer. Prostate International, 2022, 10, 14-20.	1.2	8
1817	The prostate cancer landscape in Europe: Current challenges, future opportunities. Cancer Letters, 2022, 526, 304-310.	3.2	16
1818	A network-based integration for understanding racial disparity in prostate cancer. Translational Oncology, 2022, 17, 101327.	1.7	2
1819	Novel Strategy of Proxalutamide for the Treatment of Prostate Cancer through Coordinated Blockade of Lipogenesis and Androgen Receptor Axis. International Journal of Molecular Sciences, 2021, 22, 13222.	1.8	13
1820	Delivery of antisense oligonucleotides for splice-“correction of androgen receptor pre-“mRNA in castration-“resistant prostate cancer models using cell-“penetrating peptides. Prostate, 2022, 82, 657-665.	1.2	7

#	ARTICLE	IF	CITATIONS
1821	Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling. <i>Prostate</i> , 2022, 82, 505-516.	1.2	9
1822	Prostate luminal progenitor cells: from mouse to human, from health to disease. <i>Nature Reviews Urology</i> , 2022, 19, 201-218.	1.9	12
1823	Presence of CD133-positive circulating tumor cells predicts worse progression-free survival in patients with metastatic castration-sensitive prostate cancer. <i>International Journal of Urology</i> , 2022, 29, 383-389.	0.5	6
1824	Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKC $\beta$ 1. <i>Oncogene</i> , 2022, , .	2.6	5
1825	Biomarkers of Castrate Resistance in Prostate Cancer: Androgen Receptor Amplification and T877A Mutation Detection by Multiplex Droplet Digital PCR. <i>Journal of Clinical Medicine</i> , 2022, 11, 257.	1.0	6
1826	SOX2 mediates metabolic reprogramming of prostate cancer cells. <i>Oncogene</i> , 2022, 41, 1190-1202.	2.6	22
1827	Differential Gene Expression Profiles between N-Terminal Domain and Ligand-Binding Domain Inhibitors of Androgen Receptor Reveal Ralaniten Induction of Metallothionein by a Mechanism Dependent on MTF1. <i>Cancers</i> , 2022, 14, 386.	1.7	4
1828	Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel. <i>BMC Medicine</i> , 2022, 20, 48.	2.3	8
1829	Selective vulnerabilities in the proteostasis network of castration-resistant prostate cancer. <i>Cell Chemical Biology</i> , 2022, 29, 490-501.e4.	2.5	6
1830	Advances with androgen deprivation therapy for prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1015-1033.	0.9	10
1831	A novel small-molecule activator of unfolded protein response suppresses castration-resistant prostate cancer growth. <i>Cancer Letters</i> , 2022, 532, 215580.	3.2	5
1832	Liquid biopsy as a new tool for diagnosis, monitoring, and personalized medicine in urogenital cancers. , 2022, , 31-43.		0
1833	Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancer-Where Are We Now?. <i>Cancers</i> , 2022, 14, 801.	1.7	23
1834	New Insights and Emerging Therapeutic Approaches in Prostate Cancer. <i>Frontiers in Endocrinology</i> , 2022, 13, 840787.	1.5	6
1835	Circular RNAs and Drug Resistance in Genitourinary Cancers: A Literature Review. <i>Cancers</i> , 2022, 14, 866.	1.7	5
1836	Current strategies and progress for targeting the "undruggable" transcription factors. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 2474-2481.	2.8	11
1837	A Small Peptide Targeting the Ligand-Induced Androgen Receptor/Filamin a Interaction Inhibits the Invasive Phenotype of Prostate Cancer Cells. <i>Cells</i> , 2022, 11, 14.	1.8	8
1838	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 7: PD-L1 Expression in Liquid Biopsy. <i>Journal of Personalized Medicine</i> , 2021, 11, 1312.	1.1	6

#	ARTICLE	IF	CITATIONS
1839	New TRPM8 Blockers Exert Anticancer Activity Over Castration-Resistant Prostate Cancer Models. SSRN Electronic Journal, 0, , .	0.4	0
1840	In vitro cultures of circulating tumor cells: a potential tool to unravel drug sensitivity. Cancer Drug Resistance (Alhambra, Calif ), 2022, 5, 245-260.	0.9	2
1841	<i>In silico</i> design of ROR $\beta$ inverse agonists based on 3D-QSAR and molecular docking. New Journal of Chemistry, 2022, 46, 8464-8477.	1.4	1
1842	Precision Targets for Intercepting the Lethal Progression of Prostate Cancer: Potential Avenues for Personalized Therapy. Cancers, 2022, 14, 892.	1.7	7
1843	Antiandrogen enzalutamide induced genetic, cellular, and hepatic damages: amelioration by triterpene Lupeol. Drug and Chemical Toxicology, 2023, 46, 380-391.	1.2	11
1844	A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer. Cell Reports, 2022, 38, 110417.	2.9	17
1845	Non-Invasive Profiling of Advanced Prostate Cancer via Multi-Parametric Liquid Biopsy and Radiomic Analysis. International Journal of Molecular Sciences, 2022, 23, 2571.	1.8	8
1846	Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patientsâ€™ selection. Clinical and Experimental Metastasis, 2022, 39, 449-457.	1.7	5
1847	Application of Surface-Enhanced Raman Spectroscopy to Guide Therapy for Advanced Prostate Cancer Patients. ACS Sensors, 2022, 7, 827-838.	4.0	7
1848	Combinatorial Power of cfDNA, CTCs and EVs in Oncology. Diagnostics, 2022, 12, 870.	1.3	18
1849	Cistrome and transcriptome analysis identifies unique androgen receptor (AR) and AR-V7 splice variant chromatin binding and transcriptional activities. Scientific Reports, 2022, 12, 5351.	1.6	14
1850	Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Molecular Cancer, 2022, 21, 79.	7.9	219
1851	Development of a High-Throughput Screening Assay for Small-Molecule Inhibitors of Androgen Receptor Splice Variants. Assay and Drug Development Technologies, 2022, 20, 111-124.	0.6	3
1852	Targeting key proteins involved in transcriptional regulation for cancer therapy: Current strategies and future prospective. Medicinal Research Reviews, 2022, 42, 1607-1660.	5.0	20
1853	Prognostic and Predictive Value of Liquid Biopsy-Derived Androgen Receptor Variant 7 (AR-V7) in Prostate Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2022, 12, 868031.	1.3	7
1854	Knockdown of RhoA expression reverts enzalutamide resistance via the p38 MAPK pathway in castrationâ€™resistant prostate cancer. Recent Patents on Anti-Cancer Drug Discovery, 2022, 17, .	0.8	1
1855	A Metabolism-Related Gene Landscape Predicts Prostate Cancer Recurrence and Treatment Response. Frontiers in Immunology, 2022, 13, 837991.	2.2	6
1856	Inhibiting 3Î²HSD1 to eliminate the oncogenic effects of progesterone in prostate cancer. Cell Reports Medicine, 2022, 3, 100561.	3.3	12

#	ARTICLE	IF	CITATIONS
1857	The potential of liquid biopsy in the management of cancer patients. <i>Seminars in Cancer Biology</i> , 2022, 84, 69-79.	4.3	55
1858	Targeting the androgen receptor signaling pathway in advanced prostate cancer. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, 1224-1235.	0.5	5
1859	Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2237-2247.	3.2	16
1860	Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist-Treated Prostate Cancers. <i>Molecular Cancer Research</i> , 2022, 20, 841-853.	1.5	3
1861	Molecular mechanisms and genetic alterations in prostate cancer: From diagnosis to targeted therapy. <i>Cancer Letters</i> , 2022, 534, 215619.	3.2	18
1862	Monoamine oxidase A drives neuroendocrine differentiation in prostate cancer. <i>Biochemical and Biophysical Research Communications</i> , 2022, 606, 135-141.	1.0	6
1863	m6A-induced repression of SIAH1 facilitates alternative splicing of androgen receptor variant 7 by regulating CPSF1. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 28, 219-230.	2.3	7
1864	Are we ready to embrace novel therapeutic targets for women with AR-positive or AR-negative metastatic Triple-Negative Breast Cancer ?. <i>Asia-Pacific Journal of Oncology</i> , 2021, , .	0.2	0
1866	An Update on the Molecular and Clinical Characteristics of Apocrine Carcinoma of the Breast. <i>Clinical Breast Cancer</i> , 2022, 22, e576-e585.	1.1	15
1867	Current androgen receptor antagonists under investigation for resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 191-202.	1.1	5
1868	hsa_circ_0001275 Is One of a Number of circRNAs Dysregulated in Enzalutamide Resistant Prostate Cancer and Confers Enzalutamide Resistance In Vitro. <i>Cancers</i> , 2021, 13, 6383.	1.7	3
1869	Biomarkers of Response to Neoadjuvant Androgen Deprivation in Localised Prostate Cancer. <i>Cancers</i> , 2022, 14, 166.	1.7	0
1870	RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 6279.	1.7	5
1871	Exosomes in Cancer Diagnosis and Radiation Therapy. <i>Physiology</i> , 0, , .	4.0	0
1872	Overcoming prostate cancer drug resistance with a novel organosilicon small molecule. <i>Neoplasia</i> , 2021, 23, 1261-1274.	2.3	4
1873	Novel lipid mediators contributing to androgen receptor therapy resistance in prostate cancer. <i>EBioMedicine</i> , 2021, 74, 103696.	2.7	0
1874	Influence of statins in metastatic castration-resistant prostate cancer patients treated with new antiandrogen therapies: a systematic review and meta-analysis. <i>Einstein (Sao Paulo, Brazil)</i> , 2022, 20, eRW6339.	0.3	2
1875	Understanding Drug Sensitivity and Tackling Resistance in Cancer. <i>Cancer Research</i> , 2022, 82, 1448-1460.	0.4	24

#	ARTICLE	IF	CITATIONS
1876	The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 431-443.	2.0	44
1877	The emerging role of cross-resistance between taxanes and AR-targeting therapy in metastatic prostate cancer. <i>Journal of Clinical Urology</i> , 2024, 17, 182-189.	0.1	0
1886	Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol. <i>BMJ Open</i> , 2019, 9, e034708.	0.8	6
1888	A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide. <i>Oncologist</i> , 2022, 27, 718-e694.	1.9	3
1889	PDZRN4 suppresses tumorigenesis and androgen therapy-resistance in prostate cancer. <i>Journal of Cancer</i> , 2022, 13, 2293-2300.	1.2	2
1890	Mechanisms of Resistance to Second-Generation Antiandrogen Therapy for Prostate Cancer: Actual Knowledge and Perspectives. <i>Medical Sciences (Basel, Switzerland)</i> , 2022, 10, 25.	1.3	10
1891	New TRPM8 blockers exert anticancer activity over castration-resistant prostate cancer models. <i>European Journal of Medicinal Chemistry</i> , 2022, 238, 114435.	2.6	8
1892	Non-drug efflux function of ABCC5 promotes enzalutamide resistance in castration-resistant prostate cancer via upregulation of P65/AR-V7. <i>Cell Death Discovery</i> , 2022, 8, 241.	2.0	2
1893	A novel inhibitor of AR $\alpha$ and AR $\delta$ induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer. <i>Acta Pharmaceutica Sinica B</i> , 2022, , .	5.7	1
1894	Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. <i>European Journal of Cancer</i> , 2022, 170, 296-304.	1.3	14
1895	Development of novel androgen receptor antagonists based on the structure of darolutamide. <i>Biorganic Chemistry</i> , 2022, 124, 105829.	2.0	2
1896	MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets. <i>Nature Communications</i> , 2022, 13, 2559.	5.8	56
1897	Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer. <i>Current Oncology Reports</i> , 2022, 24, 1287-1298.	1.8	4
1898	Diagnosis and treatment of metastatic prostate cancer. , 2022, , 23-47.		0
1899	Multiple roles of circulating tumor cells and exosomes in cancer metastasis. , 2022, , 7-21.		0
1901	Topological dynamics of an intrinsically disordered N-terminal domain of the human androgen receptor. <i>Protein Science</i> , 2022, 31, .	3.1	11
1902	The Androgen Receptor Variant AR $\nu$ 33 Increased Enzalutamide-Resistance in Prostate Cancer &lt;i>via</i> a Unique Trans-Splicing Mechanism. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1903	Prognostic Implications of Portal Venous Circulating Tumor Cells in Resectable Pancreatic Cancer. <i>Biomedicines</i> , 2022, 10, 1289.	1.4	6

#	ARTICLE	IF	CITATIONS
1904	Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer. <i>Prostate</i> , 2022, 82, .	1.2	6
1905	Future directions for precision oncology in prostate cancer. <i>Prostate</i> , 2022, 82, .	1.2	2
1907	Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo. <i>Cancer Drug Resistance (Alhambra, Calif )</i> , 2022, 5, 667-90.	0.9	8
1909	Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
1910	Proteogenomic, Epigenetic, and Clinical Implications of Recurrent Aberrant Splice Variants in Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2022, 82, 354-362.	0.9	13
1911	Regulatory genes in the androgen production, uptake and conversion (APUC) pathway in advanced prostate cancer. <i>Endocrine Oncology</i> , 2022, 2, R51-R64.	0.1	1
1912	Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	40
1913	Serum prolactin level as a predictive factor for abiraterone response in patients with metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2022, 82, 1284-1292.	1.2	2
1914	Emerging Proteins in CRPC: Functional Roles and Clinical Implications. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1915	Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges. <i>British Journal of Cancer</i> , 2022, 127, 1394-1402.	2.9	25
1916	The androgen receptor messenger RNA: what do we know?. <i>RNA Biology</i> , 2022, 19, 819-828.	1.5	4
1917	Chronologically modified androgen receptor in recurrent castration-resistant prostate cancer and its therapeutic targeting. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	12
1918	Inhibition of N-Acetyltransferase 10 Suppresses the Progression of Prostate Cancer through Regulation of DNA Replication. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6573.	1.8	8
1920	Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Controlled Trial-Based Network Meta-Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-20.	0.6	0
1921	The Extracellular Matrix Stiffening: A Trigger of Prostate Cancer Progression and Castration Resistance?. <i>Cancers</i> , 2022, 14, 2887.	1.7	13
1923	An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective. <i>BMC Health Services Research</i> , 2022, 22, .	0.9	0
1924	Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice. , 2022, 39, .		5
1925	Sex Differences in Taxane Toxicities. <i>Cancers</i> , 2022, 14, 3325.	1.7	4

#	ARTICLE	IF	CITATIONS
1926	Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	69
1927	Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
1928	Role of ubiquitin specific proteases in the immune microenvironment of prostate cancer: A new direction. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1929	Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies. <i>JCO Precision Oncology</i> , 2022, , .	1.5	10
1930	Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3979-3989.	3.2	8
1931	Therapeutic Strategies to Target the Androgen Receptor. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 8772-8797.	2.9	18
1932	Genomic Sequencing Should Be Part of the Standard of Care for Most Urologic Cancers: For. <i>European Urology Focus</i> , 2022, , .	1.6	2
1933	<i>Aspalathus linearis</i> suppresses cell survival and proliferation of enzalutamide-resistant prostate cancer cells via inhibition of c-Myc and stability of androgen receptor. <i>PLoS ONE</i> , 2022, 17, e0270803.	1.1	2
1934	AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer. <i>ELife</i> , 0, 11, .	2.8	10
1935	Emerging Biomarker-Guided Therapies in Prostate Cancer. <i>Current Oncology</i> , 2022, 29, 5054-5076.	0.9	10
1936	Synthesis and biological evaluation of niclosamide PROTACs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 72, 128870.	1.0	4
1937	The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer. <i>Biomedicines</i> , 2022, 10, 1778.	1.4	10
1938	Immune Evasion and Drug Resistance Mediated by USP22 in Cancer: Novel Targets and Mechanisms. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
1940	Androgen receptor signaling and spatial chromatin organization in castration-resistant prostate cancer. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
1941	Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404). <i>Journal of Clinical Oncology</i> , 2022, 40, 4240-4249.	0.8	20
1942	Single-Circulating Tumor Cell Whole Genome Amplification to Unravel Cancer Heterogeneity and Actionable Biomarkers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8386.	1.8	10
1943	Case Report: 18F-PSMA PET/CT Scan in Castration Resistant Prostate Cancer With Aggressive Neuroendocrine Differentiation. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1944	Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation-based therapy. <i>Cancer Communications</i> , 2022, 42, 683-688.	3.7	0



#	ARTICLE	IF	CITATIONS
1945	The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organsâ€”Part B: Prostate and Urinary Tract Tumors. <i>European Urology</i> , 2022, 82, 469-482.	0.9	71
1947	Developing New Treatment Options for Castration-Resistant Prostate Cancer and Recurrent Disease. <i>Biomedicines</i> , 2022, 10, 1872.	1.4	6
1948	Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1594-1607.	1.9	5
1949	Overcoming Obstacles in Liquid Biopsy Developments for Prostate Cancer. <i>OncoTargets and Therapy</i> , 0, Volume 15, 897-912.	1.0	2
1951	Androgen receptor splicing variant 7 ( <scp>ARv7</scp> ) promotes <scp>DNA</scp> damage response in prostate cancer cells. <i>FASEB Journal</i> , 2022, 36, .	0.2	5
1952	Upâ€”regulation of secretory leukocyte protease inhibitor in human samples might have a potential role of predicting prostate cancer recurrence and progression after surgery and hormonal therapy. <i>Cancer Medicine</i> , 0, , .	1.3	1
1953	Targeting the radiation-induced ARv7-mediated circNHS/miR-512-5p/XRCC5 signaling with Quercetin increases prostate cancer radiosensitivity. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	6
1954	Factors influencing survival in metastatic castration-resistant prostate cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 1061-1079.	1.1	2
1955	The clinical efficacy and limitations of dutasteride-regulated abiraterone metabolism in abiraterone-resistant patients: a prospective single-arm clinical trial in Chinese patients. <i>Translational Andrology and Urology</i> , 2022, 11, 1169-1176.	0.6	0
1956	The Prognostic Value of Liquid Biopsies for Benefit of Salvage Radiotherapy in Relapsed Oligometastatic Prostate Cancer. <i>Cancers</i> , 2022, 14, 4095.	1.7	0
1958	How splicing confers treatment resistance in prostate cancer. <i>ELife</i> , 0, 11, .	2.8	4
1959	Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial. <i>European Journal of Cancer</i> , 2022, 173, 317-326.	1.3	3
1960	CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	6
1961	Combinatorial approaches of nanotherapeutics for inflammatory pathway targeted therapy of prostate cancer. <i>Drug Resistance Updates</i> , 2022, 64, 100865.	6.5	4
1962	Drugging the Undruggable: Targeting the N-Terminal Domain of Nuclear Hormone Receptors. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 311-326.	0.8	1
1963	AR Structural Variants and Prostate Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 195-211.	0.8	2
1964	Discovery of Novel Thiohydantoin Derivatives as Full Antagonists and Efficient Degradors of Androgen Receptor. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1965	Biotechnology for diagnosis, prognosis, and monitoring cancer. , 2022, , 49-69.		0

#	ARTICLE	IF	CITATIONS
1966	Gankyrin-Mediated Interaction between Cancer Cells and Tumor-Associated Macrophages Facilitates Prostate Cancer Progression and Androgen Deprivation Therapy Resistance. SSRN Electronic Journal, 0, , .	0.4	0
1967	Impacts of androgen deprivation therapy on the risks and outcomes of SARS-CoV-2 infection in patients with prostate cancer. Asian Journal of Andrology, 2023, 25, 366-374.	0.8	2
1968	A comprehensive view of the prostate cancer metastasis and role of androgen receptor splice variants. , 2022, , 149-165.		0
1969	Changes in prostate-specific antigen kinetics during androgen-deprivation therapy as a predictor of response to abiraterone in chemonaÃve patients with metastatic castration-resistant prostate cancer. Investigative and Clinical Urology, 2022, 63, 546.	1.0	1
1971	Targeted Protein Degradation to Overcome Resistance in Cancer Therapies: PROTAC and N-Degron Pathway. Biomedicines, 2022, 10, 2100.	1.4	5
1972	The androgen receptor couples promoter recruitment of RNA processing factors to regulation of alternative polyadenylation at the 3' end of transcripts. Nucleic Acids Research, 2022, 50, 9780-9796.	6.5	2
1973	Androgen receptor in breast cancer: The â€œ5Wâ€•questions. Frontiers in Endocrinology, 0, 13, .	1.5	10
1974	High dose androgen suppresses natural killer cytotoxicity of castration-resistant prostate cancer cells via altering AR/circFKBP5/miRNA-513a-5p/PD-L1 signals. Cell Death and Disease, 2022, 13, .	2.7	7
1975	Antagonizing CD105 and androgen receptor to target stromal-epithelial interactions for clinical benefit. Molecular Therapy, 2023, 31, 78-89.	3.7	2
1976	Choice of antibody is critical for specific and sensitive detection of androgen receptor splice variant-7 in circulating tumor cells. Scientific Reports, 2022, 12, .	1.6	1
1977	Discovery of Highly Potent Daphnane Diterpenoids Uncovers Importin-Î²1 as a Druggable Vulnerability in Castration-Resistant Prostate Cancer. Journal of the American Chemical Society, 2022, 144, 17522-17532.	6.6	16
1978	Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs. Research and Reports in Urology, 0, Volume 14, 339-350.	0.6	8
1979	Bone Health Management in the Continuum of Prostate Cancer Disease. Cancers, 2022, 14, 4305.	1.7	5
1980	Celastrol recruits UBE3A to recognize and degrade the DNA binding domain of steroid receptors. Oncogene, 2022, 41, 4754-4767.	2.6	3
1981	Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer. Medical Science Monitor, 0, 28, .	0.5	1
1982	Development and Analytical Validation of a 6-Plex Reverse Transcription Droplet Digital PCR Assay for the Absolute Quantification of Prostate Cancer Biomarkers in Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Chemistry, 2022, 68, 1323-1335.	1.5	3
1983	Glucocorticoid receptor and androgen receptor-targeting therapy in patients with castration-resistant prostate cancer. Frontiers in Oncology, 0, 12, .	1.3	4
1984	Metformin regulates multiple signaling pathways within castration-resistant human prostate cancer cells. BMC Cancer, 2022, 22, .	1.1	5

#	ARTICLE	IF	CITATIONS
1985	Emerging hormonal agents for the treatment of prostate cancer. Expert Opinion on Emerging Drugs, 2022, 27, 301-309.	1.0	2
1987	Establishment of a <scp>fiveâ€enzalutamideâ€resistanceâ€relatedâ€geneâ€based</scp> classifier for <scp>recurrenceâ€free</scp> survival predicting of prostate cancer. Journal of Cellular and Molecular Medicine, 2022, 26, 5379-5390.	1.6	1
1988	Positive epigenetic regulation loop between AR and NSUN2 promotes prostate cancer progression. Clinical and Translational Medicine, 2022, 12, .	1.7	11
1989	Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches. Molecules, 2022, 27, 5730.	1.7	133
1990	Targeting L-type amino acid transporter 1 in urological malignancy: Current status and future perspective. Journal of Pharmacological Sciences, 2022, 150, 251-258.	1.1	1
1991	CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients. European Journal of Cancer, 2022, 177, 33-44.	1.3	6
1992	Molecular Mechanisms of Castrate-Resistant Prostate Cancer. Urologic Clinics of North America, 2022, 49, 615-626.	0.8	1
1993	Identification of Candidate mRNA Isoforms for Prostate Cancer-Risk SNPs Utilizing Iso-eQTL and sQTL Methods. International Journal of Molecular Sciences, 2022, 23, 12406.	1.8	0
1994	Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC). BMC Urology, 2022, 22, .	0.6	0
1995	The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer. Cancers, 2022, 14, 4877.	1.7	12
1998	Metastatic prostate cancer diagnosed by fineâ€needle aspiration: Contemporary cytopathologic and biomarker assessment with clinical correlates. Cancer Cytopathology, 2023, 131, 117-135.	1.4	3
1999	A COPI-GATA2 axis suppresses AR signaling and prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	5
2000	Dual-Acting Peptides Target EZH2 and AR: A New Paradigm for Effective Treatment of Castration-Resistant Prostate Cancer. Endocrinology, 2022, 164, .	1.4	1
2001	Efficacy of cabazitaxel and androgen splicing variant-7 status in circulating tumor cells in Asian patients with metastatic castration-resistant prostate cancer. Scientific Reports, 2022, 12, .	1.6	4
2002	Repression of <i>SLC22A3</i> by the <scp>ARâ€V7</scp>/<scp>YAP1</scp>/<scp>TAZ</scp> axis in enzalutamideâ€resistant castrationâ€resistant prostate cancer. FEBS Journal, 2023, 290, 1645-1662.	2.2	2
2003	Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer. Npj Precision Oncology, 2022, 6, .	2.3	10
2004	ASCancer Atlas: a comprehensive knowledgebase of alternative splicing in human cancers. Nucleic Acids Research, 2023, 51, D1196-D1204.	6.5	10
2005	Combination of niclosamide and current therapies to overcome resistance for cancer: New frontiers for an old drug. Biomedicine and Pharmacotherapy, 2022, 155, 113789.	2.5	5

#	ARTICLE	IF	CITATIONS
2006	Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study. <i>Lancet Oncology</i> , The, 2022, 23, 1398-1408.	5.1	12
2007	Prostate cancer resistance leads to a global deregulation of translation factors and unconventional translation. <i>NAR Cancer</i> , 2022, 4, .	1.6	2
2008	Detection of YAP1 and AR-V7 mRNA for Prostate Cancer Prognosis Using an ISFET Lab-On-Chip Platform. <i>ACS Sensors</i> , 0, , .	4.0	5
2009	RNA profiling of circulating tumor cells systemically captured from diagnostic leukapheresis products in prostate cancer patients. <i>Materials Today Bio</i> , 2022, 17, 100474.	2.6	3
2010	Optical tweezers for drug discovery. <i>Drug Discovery Today</i> , 2023, 28, 103443.	3.2	2
2011	Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients. <i>World Journal of Urology</i> , 2022, 40, 2939-2946.	1.2	1
2012	Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	4
2013	Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13521.	1.8	4
2014	A Novel Biguanide Derivative, IM176, Induces Prostate Cancer Cell Death via AMPK-mTOR Pathway and Androgen Receptor Signalling Pathway. <i>Prostate International</i> , 2022, , .	1.2	3
2015	Exosomes in Genitourinary Cancers: Emerging Mediators of Drug Resistance and Promising Biomarkers. <i>International Journal of Biological Sciences</i> , 2023, 19, 167-182.	2.6	3
2016	PROTACS: A technology with a gold rush-like atmosphere. <i>European Journal of Medicinal Chemistry</i> , 2023, 247, 115037.	2.6	9
2017	Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling. <i>Cancer Research</i> , 2023, 83, 219-238.	0.4	4
2018	Acetyl-CoA Counteracts the Inhibitory Effect of Antiandrogens on Androgen Receptor Signaling in Prostate Cancer Cells. <i>Cancers</i> , 2022, 14, 5900.	1.7	0
2019	A systematic review of cytoreductive prostatectomy outcomes and complications in oligometastatic disease. <i>Asian Journal of Urology</i> , 2022, , .	0.5	0
2020	Experimental in vitro, exÂvivo and in vivo models in prostate cancer research. <i>Nature Reviews Urology</i> , 2023, 20, 158-178.	1.9	11
2021	Cancer Stemness/Epithelialâ€Mesenchymal Transition Axis Influences Metastasis and Castration Resistance in Prostate Cancer: Potential Therapeutic Target. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14917.	1.8	10
2022	Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis. <i>Current Oncology</i> , 2022, 29, 9511-9524.	0.9	3
2024	Biology, vulnerabilities and clinical applications of circulating tumour cells. <i>Nature Reviews Cancer</i> , 2023, 23, 95-111.	12.8	58

#	ARTICLE	IF	CITATIONS
2025	Prostate fibroblasts enhance androgen receptor splice variant 7 expression in prostate cancer cells. <i>Prostate</i> , 0, , .	1.2	1
2026	A correlative biomarker study and integrative prognostic model in chemotherapy- and metastatic castration-resistant prostate cancer treated with enzalutamide. <i>Prostate</i> , 2023, 83, 376-384.	1.2	3
2027	The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications. <i>Nature Reviews Urology</i> , 2023, 20, 265-278.	1.9	10
2029	Experience of bipolar androgen therapy (BAT) in Argentinian oncology centres. <i>Ecancermedicalscience</i> , 0, 16, .	0.6	1
2030	Idarubicin combats abiraterone and enzalutamide resistance in prostate cells via targeting XPA protein. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	0
2031	A Phase II Trial of Abiraterone With Dutasteride for Second-Generation Antiandrogen- and Chemotherapy- and Patients With Castration-Resistant Prostate Cancer. <i>Journal of Clinical Pharmacology</i> , 2023, 63, 445-454.	1.0	2
2032	Role of Nivolumab in the Modulation of PD-1 and PD-L1 Expression in Papillary and Clear Cell Renal Carcinoma (RCC). <i>Biomedicines</i> , 2022, 10, 3244.	1.4	1
2033	Marine Natural Products with Activities against Prostate Cancer: Recent Discoveries. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1435.	1.8	3
2034	<sc>YAP</sc> antagonizes <sc>TEAD</sc>-mediated <sc>AR</sc> signaling and prostate cancer growth. <i>EMBO Journal</i> , 2023, 42, .	3.5	5
2035	Mechanistic Investigation of the Androgen Receptor DNA-Binding Domain and Modulation via Direct Interactions with DNA Abasic Sites: Understanding the Mechanisms Involved in Castration-Resistant Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1270.	1.8	3
2036	New Marine Fungal Deoxy-14,15-Dehydroisoaustamide Resensitizes Prostate Cancer Cells to Enzalutamide. <i>Marine Drugs</i> , 2023, 21, 54.	2.2	1
2037	RNA splicing dysregulation and the hallmarks of cancer. <i>Nature Reviews Cancer</i> , 2023, 23, 135-155.	12.8	73
2038	RNA modification writers pattern in relation to tumor microenvironment and prognosis in prostate cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
2039	Quantitative <i>In Vivo</i> Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response. <i>Molecular Cancer Research</i> , 2023, 21, 307-315.	1.5	1
2040	Molecular Mechanisms of Noncoding RNA in the Occurrence of Castration-Resistant Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1305.	1.8	2
2041	Clinical and molecular significance of the RNA m6A methyltransferase complex in prostate cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	6
2042	STAT3 signaling in prostate cancer progression and therapy resistance: An oncogenic pathway with diverse functions. <i>Biomedicine and Pharmacotherapy</i> , 2023, 158, 114168.	2.5	3
2043	Targeting the N-terminal domain of the androgen receptor: The effective approach in therapy of CRPC. <i>European Journal of Medicinal Chemistry</i> , 2023, 247, 115077.	2.6	8

#	ARTICLE	IF	CITATIONS
2044	Inhibiting androgen receptor splice variants with cysteine-selective irreversible covalent inhibitors to treat prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	12
2045	Par14 interacts with the androgen receptor, augmenting both its transcriptional activity and prostate cancer proliferation. <i>Cancer Medicine</i> , 0, , .	1.3	2
2046	Expression of high molecular weight cytokeratinâ€”A novel feature of aggressive and innate hormoneâ€”refractory prostatic adenocarcinoma. <i>Prostate</i> , 2023, 83, 462-469.	1.2	2
2047	The Impact of Indoles Activating the Aryl Hydrocarbon Receptor on Androgen Receptor Activity in the 22Rv1 Prostate Cancer Cell Line. <i>International Journal of Molecular Sciences</i> , 2023, 24, 502.	1.8	1
2048	The SMARCD Family of SWI/SNF Accessory Proteins Is Involved in the Transcriptional Regulation of Androgen Receptor-Driven Genes and Plays a Role in Various Essential Processes of Prostate Cancer. <i>Cells</i> , 2023, 12, 124.	1.8	5
2049	Plasma extracellular vesicle circRNA signature and resistance to abiraterone in metastatic castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2023, 128, 1320-1332.	2.9	4
2050	PIK3R1, HRAS and AR Gene Alterations Associated with Sclerosing Polycystic Adenoma of the Parotid Gland. <i>Current Issues in Molecular Biology</i> , 2023, 45, 954-962.	1.0	1
2051	Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer. <i>ELife</i> , 0, 12, .	2.8	6
2052	AR and PI3K/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2046.	1.8	12
2053	The application of RNA sequencing in precision cancer medicine. , 2024, , 46-58.		0
2054	Gankyrin-mediated interaction between cancer cells and tumor-associated macrophages facilitates prostate cancer progression and androgen deprivation therapy resistance. <i>Oncolmmunology</i> , 2023, 12, .	2.1	1
2055	State-Of-The-Art Treatment in Castration-Resistant Prostate Cancer. <i>European Medical Journal Oncology</i> , 0, , 10-105.	0.0	0
2056	Epigenetic mechanism of therapeutic resistance and potential of epigenetic therapeutics in chemorefractory prostate cancer. <i>International Review of Cell and Molecular Biology</i> , 2023, , 173-210.	1.6	0
2057	Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16). <i>Journal of Clinical Oncology</i> , 2023, 41, 3608-3615.	0.8	2
2058	Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models. <i>Pharmacological Research</i> , 2023, 189, 106692.	3.1	0
2059	Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer. <i>Biomarker Research</i> , 2023, 11, .	2.8	0
2060	Enzalutamide combination with Arsenic trioxide suppresses the progression of castration-resistant prostate cancer. <i>Journal of Chemotherapy</i> , 0, , 1-11.	0.7	0
2061	Cancer stem cell in prostate cancer progression, metastasis and therapy resistance. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188887.	3.3	7



#	ARTICLE	IF	CITATIONS
2062	Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective. <i>Oncology Research</i> , 2022, 30, 137-155.	0.6	5
2063	Sequential Androgen Receptor Pathway Inhibitor in Prostate Cancer: Piling-Up The Benefits or a Case for Cross-Resistance?. <i>European Medical Journal Oncology</i> , 0, , 40-47.	0.0	0
2064	Circulating tumor cell quantification during abiraterone plus prednisone therapy may estimate survival in metastatic castration-resistant prostate cancer patients. <i>International Urology and Nephrology</i> , 2023, 55, 883-892.	0.6	0
2065	Mechanisms of Prostate Cancer Cells Survival and Their Therapeutic Targeting. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2939.	1.8	5
2066	Body composition parameters were associated with response to abiraterone acetate and prognosis in patients with metastatic castration-resistant prostate cancer. <i>Cancer Medicine</i> , 2023, 12, 8251-8266.	1.3	1
2067	Dependence on MUC1-C in Progression of Neuroendocrine Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3719.	1.8	5
2068	Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer. <i>Cell Reports Medicine</i> , 2023, 4, 100937.	3.3	11
2069	Monoamine oxidase A: An emerging therapeutic target in prostate cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
2070	Preclinical models of prostate cancer " modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo. <i>Nature Reviews Urology</i> , 2023, 20, 480-493.	1.9	5
2071	The positive relationship between androgen receptor splice variant-7 expression and the risk of castration-resistant prostate cancer: A cumulative analysis. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
2072	Prostate cancer and novel pharmacological treatment options"what"s new for 2022?. <i>Expert Review of Clinical Pharmacology</i> , 2023, 16, 231-244.	1.3	1
2073	hSSB1 (NABP2/OBFC2B) modulates the DNA damage and androgen-induced transcriptional response in prostate cancer. <i>Prostate</i> , 2023, 83, 628-640.	1.2	6
2074	Racial Differences in Androgen Receptor (AR) and AR Splice Variants (AR-SVs) Expression in Treatment-Naïve Androgen-Dependent Prostate Cancer. <i>Biomedicines</i> , 2023, 11, 648.	1.4	1
2075	Discovering New Targets in Triple-Negative Breast Cancer (TNBC): The Androgen Receptor and the Estrogen Receptor $\beta$ . , 2023, , .		0
2076	A compendium of Androgen Receptor Variant 7 target genes and their role in Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
2077	Role of bromodomain and extraterminal (BET) proteins in prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , 2023, 32, 213-228.	1.9	3
2079	Remodeling oncogenic transcriptomes by small molecules targeting NONO. <i>Nature Chemical Biology</i> , 2023, 19, 825-836.	3.9	15
2080	Genomic, epigenomic, and transcriptomic signatures of prostate cancer between African American and European American patients. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	8



#	ARTICLE	IF	CITATIONS
2081	Urolithin A analog inhibits castration-resistant prostate cancer by targeting the androgen receptor and its variant, androgen receptor-variant 7. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
2083	Cancer-Associated Fibroblast: Role in Prostate Cancer Progression to Metastatic Disease and Therapeutic Resistance. <i>Cells</i> , 2023, 12, 802.	1.8	9
2084	Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer. <i>EBioMedicine</i> , 2023, 90, 104500.	2.7	7
2085	LOX-1 Activation by oxLDL Induces AR and AR-V7 Expression via NF- $\kappa$ B and STAT3 Signaling Pathways Reducing Enzalutamide Cytotoxic Effects. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5082.	1.8	4
2086	Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	0
2087	Efficacy and Safety of a 5-Alpha Reductase Inhibitor, Dutasteride, Added to Bacillus Calmette-GuÃ©rin Immunotherapy for Prevention of Recurrence and Progression of Intermediate- and High-Risk Non-Muscle Invasive Bladder Cancer: A Single-Arm, Phase 2 Clinical Trial. <i>Journal of Urological Surgery</i> , 2023, 10, 36-42.	0.2	0
2088	Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 2324-2335.	3.2	7
2089	The epigenetic function of androgen receptor in prostate cancer progression. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	2
2090	A Compendium of AR Splice Variants in Metastatic Castration-Resistant Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6009.	1.8	1
2091	The Transmembrane Protein TM4SF3 Interacts With AR and AR-V7 and is Recruited to AR Target Genes. <i>Endocrinology</i> , 2023, 164, .	1.4	2
2092	Molecular testing of DNA damage response pathways in prostate cancer patients. <i>Current Opinion in Oncology</i> , 2023, 35, 224-230.	1.1	0
2093	Androgen Receptor Upregulates Mucosa-Associated Lymphoid Tissue 1 to Induce NF- $\kappa$ B Activity via Androgen-Dependent and -Independent Pathways in Prostate Carcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6245.	1.8	0
2094	PROTAC <sup>TM</sup> ing oncoproteins: targeted protein degradation for cancer therapy. <i>Molecular Cancer</i> , 2023, 22, .	7.9	18
2095	Lysine-Specific Demethylase 1 Promises to Be a Novel Target in Cancer Drug Resistance: Therapeutic Implications. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 4275-4293.	2.9	7
2097	Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen Therapy. <i>Biomedicines</i> , 2023, 11, 1105.	1.4	0
2098	Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far. <i>OncoTargets and Therapy</i> , 0, Volume 16, 235-247.	1.0	3
2099	Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer. <i>Oncologist</i> , 2023, 28, 465-473.	1.9	3
2100	Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning. <i>Nature Communications</i> , 2023, 14, .	5.8	4

#	ARTICLE	IF	CITATIONS
2101	From classic medicinal chemistry to state-of-the-art interdisciplinary medicine: Recent advances in proteolysis-targeting chimeras technology. , 2023, 1, .		2
2102	ALAN is a computational approach that interprets genomic findings in the context of tumor ecosystems. Communications Biology, 2023, 6, .	2.0	2
2104	Monoamine oxidase A (MAOA): A promising target for prostate cancer therapy. Cancer Letters, 2023, 563, 216188.	3.2	4
2105	Identification of bicalutamide resistance-related genes and prognosis prediction in patients with prostate cancer. Frontiers in Endocrinology, 0, 14, .	1.5	2
2106	The Molecular Biology of Prostate Cancer Stem Cells: From the Past to the Future. International Journal of Molecular Sciences, 2023, 24, 7482.	1.8	1
2107	The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer. British Journal of Cancer, 2023, 128, 2326-2337.	2.9	2
2108	Hormonal therapy. , 2023, , 161-204.		0
2109	MicroRNA-708 emerges as a potential candidate to target undruggable NRAS. PLoS ONE, 2023, 18, e0284744.	1.1	0
2113	Anticancer drugs that modulate hormone action. , 2023, , 101-164.		0
2121	Editorial: Molecular drivers of prostate cancer pathogenesis and therapy resistance. Frontiers in Cell and Developmental Biology, 0, 11, .	1.8	1
2133	Genetic and epigenetic features of neuroendocrine prostate cancer and their emerging applications. International Review of Cell and Molecular Biology, 2024, , 41-66.	1.6	1
2142	Androgen Receptor in Health and Disease. , 2023, , 21-75.		0
2146	The androgen receptor. Vitamins and Hormones, 2023, , .	0.7	2
2156	Transcriptomic Analysis of CTCs. Current Cancer Research, 2023, , 277-299.	0.2	0
2161	Androgen Receptor Signaling: A Central and Evolving Theme in Prostate Cancer Treatment. , 2023, , 1-29.		0
2163	Histone Demethylase KDM3 (JMJD1) in Transcriptional Regulation and Cancer Progression. Advances in Experimental Medicine and Biology, 2023, , 69-86.	0.8	0
2166	Pathology and Staging. , 2023, , 209-227.		0
2169	Molekulare Mechanismen der Resistenzentstehung und pathologische Aspekte der Therapieplanung beim Prostatakarzinom. , 2023, , 7-13.		0

#	ARTICLE	IF	CITATIONS
2171	Therapeutic, diagnostic and prognostic values of TRIM proteins in prostate cancer. Pharmacological Reports, 2023, 75, 1445-1453.	1.5	1
2173	Androgen receptor-dependent mechanisms mediating therapy resistance in prostate cancer. , 2024, , 57-84.		0
2191	A Closer Look at the Androgen Receptor (AR)- positive and AR-negative Metastatic Triple-Negative Breast Cancer: Can We Apply Novel Targeted Therapeutics?. , 2023, , 22-38.		0
2199	Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer. Npj Genomic Medicine, 2024, 9, .	1.7	0
2201	Molecular Pathology of Prostate Cancer. , 2023, , 377-399.		0
2209	Hormone-dependent cancers. , 2024, , 15-27.		0
2218	Editorial: Circulating biomarkers in prostate cancer. Frontiers in Oncology, 0, 14, .	1.3	0
2233	Biological Markers of Therapeutic Response in Prostate Cancer. , 2024, , 221-241.		0